

# EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication

**Andreas Goette (EHRA chair)<sup>1\*</sup>, Jonathan M. Kalman (APHRS co-chair)<sup>2\*</sup>, Luis Aguinaga (SOLAECE co-chair)<sup>3\*</sup>, Joseph Akar<sup>4</sup>, Jose Angel Cabrera<sup>5</sup>, Shih Ann Chen<sup>6</sup>, Sumeet S. Chugh<sup>7</sup>, Domenico Corradi<sup>8</sup>, Andre D'Avila<sup>9</sup>, Dobromir Dobrev<sup>10</sup>, Guilherme Fenelon<sup>11</sup>, Mario Gonzalez<sup>12</sup>, Stephane N. Hatem<sup>13</sup>, Robert Helm<sup>14</sup>, Gerhard Hindricks<sup>15</sup>, Siew Yen Ho<sup>16</sup>, Brian Hoit<sup>17</sup>, Jose Jalife<sup>18</sup>, Young-Hoon Kim<sup>19</sup>, Gregory Y.H. Lip<sup>20</sup>, Chang-Sheng Ma<sup>21</sup>, Gregory M. Marcus<sup>22</sup>, Katherine Murray<sup>23</sup>, Akihiko Nogami<sup>24</sup>, Prashanthan Sanders<sup>25</sup>, William Uribe<sup>26</sup>, David R. Van Wagoner<sup>27</sup>, and Stanley Nattel (HRS co-chair)<sup>28,29\*</sup>**

<sup>1</sup>Departement of Cardiology and Intensive Care Medicine, St. Vincenz-Hospital Paderborn, Working Group: Molecular Electrophysiology, University Hospital Magdeburg, Germany; <sup>2</sup>University of Melbourne, Royal Melbourne Hospital, Melbourne, VIC, Australia; <sup>3</sup>Centro Privado de Cardiología, Tucumán, Argentina; <sup>4</sup>Yale University, New Haven, CT, USA; <sup>5</sup>European University Quirón-Madrid, Madrid, Spain; <sup>6</sup>Veterans General Hospital, Taipei, Taiwan; <sup>7</sup>The Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; <sup>8</sup>University of Parma, Parma, Italy; <sup>9</sup>Mount Sinai School of Medicine, New York, NY, USA; <sup>10</sup>Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany; <sup>11</sup>Federal University of Sao Paulo, Sao Paulo, Brazil; <sup>12</sup>Penn State Heart and Vascular Institute, Penn State University, Hershey, PA, USA; <sup>13</sup>Department of Cardiology, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital; Sorbonne University; INSERM UMR\_S1166; Institute of Cardiometabolism and Nutrition-ICAN, Paris, France; <sup>14</sup>Boston University School of Medicine, Boston Medical Center, Boston, MA, USA; <sup>15</sup>University of Leipzig Heart Center, Leipzig, Germany; <sup>16</sup>Royal Brompton Hospital and Imperial College London, London, UK; <sup>17</sup>UH Case Medical Center, Cleveland, OH, USA; <sup>18</sup>University of Michigan, Ann Arbor, MI, USA; <sup>19</sup>Korea University Medical Center, Seoul, South Korea; <sup>20</sup>University of Birmingham, Birmingham, UK; <sup>21</sup>Anzhen Hospital, Beijing, China; <sup>22</sup>University of California, San Francisco, CA, USA; <sup>23</sup>Vanderbilt University, Nashville, TN, USA; <sup>24</sup>University of Tsukuba, Ibaraki, Japan; <sup>25</sup>Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia; <sup>26</sup>Electrophysiology Department at Centros Especializados de San Vicente Fundación and Clínica CES. Universidad CES, Universidad Pontificia Bolivariana (UPB), Medellín, Colombia; <sup>27</sup>Department of Molecular Cardiology, Cleveland Clinic, Cleveland, OH, USA; <sup>28</sup>Université de Montréal, Montreal Heart Institute Research Center and McGill University, Montreal, Quebec, Canada; and <sup>29</sup>Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany

**Document Reviewers: Osmar A. Centurion (Paraguay), Karl-Heinz Kuck (Germany), Kristen K. Patton (USA), John L. Sapp (Canada), Martin Stiles (New Zealand), Jesper Hastrup Svendsen (Denmark), and Gaurav A. Upadhyay (USA)**

**Review coordinator: Alena Shantsila (UK)**

Online publish-ahead-of-print 8 July 2016

## Table of Contents

Introduction and definition of atrial cardiomyopathy . . . . .	1456	Atrial cardiomyocytes . . . . .	1458
Definition of atrial cardiomyopathy . . . . .	1456	Atrial interstitium . . . . .	1459
Anatomical considerations and atrial muscular architecture . .	1457	Atrial-specific physiological and functional considerations . .	1461
Normal atrial structures . . . . .	1457	Atrial-selective electrophysiological properties . . . . .	1461
Gross morphology . . . . .	1457	Action potential/ion-channel properties . . . . .	1461
Normal atrial myocardium . . . . .	1458	Intercellular coupling properties . . . . .	1461

\* Corresponding authors: Professor Andreas Goette, Chefarzt Medizinische Klinik II, St. Vincenz-Krankenhaus, Paderborn, Am Busdorf 2, 33098 Paderborn. Tel: 05251/861651. Fax: 05251/861652. E-mail address: andreas.goette@vincenz.de.

Professor Jonathan M. Kalman, University of Melbourne, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia. Tel: +61 3 9349 5400 (PA - Sally Diamond). Fax: +61 3 9349 5411. E-mail address: jon.kalman@mh.org.au. Doctor Luis Aguinaga, Presidente Sociedad de Cardiología de Tucumán, Ex-PRESIDENTE DE SOLAECE, Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología, Tel: 54-381-4217676. E-mail address: lsaguinaga@gmail.com. Professor Stanley Nattel, University of Montreal, Montreal Heart Institute Research Center, 5000 Belanger St. E., Montreal, QC, Canada H1T 1C8. Tel: +1 514 376 3330 ext 3990. Fax: +1 514 593 2493. E-mail address: stanley.nattel@icm-mhi.org

Endorsed by EHRA, APHRS, SOLAECE in May 2016, by HRS, AHA, ACC in June 2016.

The article has been co-published with permission in *EP-Europace*, *HeartRhythm* and *Journal of Arrhythmia*. All rights reserved in respect of *HeartRhythm* and *Journal of Arrhythmia*. © The Authors 2016. For *EP-Europace*, © The Author 2016. For permissions please email: journals.permissions@oup.com.

Atrial structural properties	1461
Autonomic ganglia	1462
Left atrium mechanics	1462
Functions of the left atrium	1462
Left atrium booster-pump function	1462
Left atrium reservoir function	1462
Left atrium conduit function	1463
Atrial-selective Ca <sup>2+</sup> handling	1463
Pathology of atrial cardiomyopathies	1463
Lone atrial fibrillation (AF without concomitant conditions)	1463
Isolated atrial amyloidosis	1466
NPPA mutations	1466
Hereditary muscular dystrophies	1466
Atrial cardiomyopathy due to congestive heart failure	1467
Obstructive sleep apnoea	1467
Atrial fibrillation-induced atrial remodelling	1467
Drug-related atrial fibrillation	1468
Myocarditis	1468
Atrial cardiomyopathy associated with genetic repolarization disturbances	1469
Aging	1470
Hypertension	1470
Obesity	1470
Diabetes mellitus	1470
Atrial cardiomyopathy due to valvular heart disease	1471
Mitral stenosis	1471
Mitral regurgitation	1471
Aortic stenosis	1471
Impact of atrial cardiomyopathies on occurrence of atrial fibrillation and atrial arrhythmia	1472
Atrial cardiomyopathies, systemic biomarkers, and atrial thrombogenesis	1473
Atrial cardiomyopathies and systemic biomarkers	1473
Atrial inflammation and inflammatory biomarkers	1473
Systemic inflammatory activation in atrial fibrillation	1473
Intra-atrial sampling studies	1473
Practical implications and use of systemic biomarkers	1473
Prothrombotic indices—coagulation, platelets	1474
Prediction of thrombogenesis	1475
Imaging techniques to detect atrial cardiomyopathies mapping and ablation in atrial cardiomyopathies	1476
Echocardiography	1476
Left atrial function by Doppler echocardiography	1476
New echocardiographic techniques	1476
Cardiac computed tomography	1476
Magnetic resonance imaging of the atrium	1476
Imaging with electroanatomic mapping	1477
Ablation of atrial tachyarrhythmia	1477
Age and atrial fibrillation ablation	1478
Hypertension	1478
Heart failure and atrial fibrillation ablation	1478
Metabolic syndrome and obesity	1478
Impact of diabetes on ablation outcomes	1478
Role of myocarditis	1478
Impact of atrial fibrillation duration on atrial myopathy and atrial fibrillation ablation outcomes	1478
Impact of ongoing atrial fibrillation on electrical and structural remodelling	1478

Impact of catheter ablation on atrial pathology	1479
Conclusion	1479

## Introduction and definition of atrial cardiomyopathy

The atria provide an important contribution to cardiac function.<sup>1,2</sup> Besides their impact on ventricular filling, they serve as a volume reservoir, host pacemaker cells and important parts of the cardiac conduction system (e.g. sinus node, AV node), and secrete natriuretic peptides like atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) that regulate fluid homeostasis. Atrial myocardium is affected by many cardiac and non-cardiac conditions<sup>3</sup> and is, in some respects, more sensitive than ventricular.<sup>4</sup> The atria are activated, besides the three specialized intermodal tracts,<sup>5,6</sup> through working cardiomyocytes, so that any architectural or structural change in the atrial myocardium may cause significant electrophysiological disturbances. In addition, atrial cells (both cardiomyocytes and non-cardiomyocyte elements like fibroblasts, endothelial cells, and neurons) react briskly and extensively to pathological stimuli<sup>3</sup> and are susceptible to a range of genetic influences.<sup>7</sup> Responses include atrial cardiomyocyte hypertrophy and contractile dysfunction, arrhythmogenic changes in cardiomyocyte ion-channel and transporter function, atrial fibroblast proliferation, hyperinnervation, and thrombogenic changes.<sup>2</sup> Thus, atrial pathologies have a substantial impact on cardiac performance, arrhythmia occurrence, and stroke risk.<sup>1,8</sup>

Ventricular cardiomyopathies have been well classified; however, a definition and detailed analysis of 'atrial cardiomyopathy' is lacking from the literature. The purpose of the present consensus report, prepared by a working group with representation from the European Heart Rhythm Association (EHRA), the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and Sociedad Latino Americana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE), was to define atrial cardiomyopathy, to review the relevant literature, and to consider the impact of atrial cardiomyopathies on arrhythmia management and stroke.

## Definition of atrial cardiomyopathy

The working group proposes the following working definition of atrial cardiomyopathy: 'Any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically-relevant manifestations' (Table 1).

Many diseases (like hypertension, heart failure, diabetes, and myocarditis) or conditions (like ageing and endocrine abnormalities) are known to induce or contribute to an atrial cardiomyopathy. However, the induced changes are not necessarily disease-specific and pathological changes often share many similarities.<sup>9,10</sup> The extent of pathological changes may vary over time and atrial location, causing substantial intraindividual and interindividual differences. In addition, while some pathological processes may affect the atria very selectively (e.g. atrial fibrillation-induced remodelling), most cardiomyopathies that affect the atria also involve the ventricles to a greater or lesser extent. There is no presently accepted histopathological classification of atrial pathologies.

Therefore, we have proposed here a working histological/pathophysiological classification scheme for atrial cardiomyopathies (Table 1; Figure 1). We use the acronym EHRAS (for EHRA/HRS/APHRS/SOLAECE), defining four classes: (I) principal cardiomyocyte changes;<sup>11–15</sup> (II) principally fibrotic changes;<sup>10,14,16</sup> (III) combined cardiomyocyte-pathology/fibrosis;<sup>9,11,12</sup> (IV) primarily non-collagen infiltration (with or without cardiomyocyte changes).<sup>17–19</sup> This simple classification may help to convey the primary underlying pathology in various clinical conditions. The EHRAS class may vary over time and may differ at atrial sites in certain patients. Thus, this classification is purely descriptive and in contrast to other classifications (NYHA class, CCS class etc.), there is no progression in severity from EHRAS class I to EHRAS IV (Table 2). The classification may be useful to describe pathological changes in biopsies and to correlate pathologies with results obtained from imaging technologies etc. In the future, this may help to define a tailored therapeutic approach in atrial fibrillation (AF) (Figures 1–3).

**Table 1** Definition of atrial cardiomyopathy

'Any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically-relevant manifestations'.

## Anatomical considerations and atrial muscular architecture

### Normal atrial structures


#### Gross morphology

Each atrium has a morphologically characteristic atrial body and appendage (Figure 4). In the body, there is a venous component with the orifices of the systemic or pulmonary veins (PVs) and a vestibular component that surrounds the atrial outlet.<sup>20</sup> The interatrial septum (IAS) separates the atrial bodies. The venous component of the left atrium (LA) is located posterosuperiorly and receives the PVs at the four corners, forming a prominent atrial dome. The LA is situated more posteriorly and superiorly than the right atrium separated by the obliquity of the plane of the IAS.<sup>21</sup>

The LA appendage (LAA) is smaller than the right atrium appendage (RAA). Narrower and with different shapes has a distinct opening to the atrial body and overlies the left circumflex coronary artery. Its endocardial aspect is lined by a complex network of muscular ridges and membranes.<sup>22,23</sup> Different LAA morphologies have been described, and it appears that LAA morphology correlates with the risk of thrombogenesis.<sup>24</sup>


Bachmann's bundle is a broad epicardial muscular band running along the anterior wall of both atria (Figure 4). The rightward arms extend superiorly towards the sinus node and inferiorly

#### Primarily Cardiomyocyte-dependent (Class I)




- lone AF
- genetic diseases
- diabetes mellitus

#### Primarily Fibroblast-dependent (Class II)



- aging
- cigarette smoking

#### Mixed Cardiomyocyte-Fibroblast-dependent (Class III)



- CHF
- valvular diseases

#### Primarily Non-Collagen Deposits (Class IV)



- isolated atrial amyloidosis
- granulomatosis
- inflammatory infiltrates
- glycosphingolipids

**Figure 1** Histological and pathophysiological classification of atrial cardiomyopathies (EHRA/HRS/APHRS/SOLAECE): EHRAS classification. The EHRAS class may vary over time in the cause of the disease and may differ at various atrial sites. Of note, the nature of the classification is purely descriptive. EHRAS I-IV is *not intended* to describe disease progression from EHRAS I to EHRAS IV.

towards the right atrioventricular groove, while the leftward arms blend with deeper myofibres to pass around the neck of the LAA and reunite posteriorly to join the circumferential vestibule of the

LA. The walls of LA are non-uniform in thickness (1–15 mm) and thicker than the right atrium.<sup>25</sup>

Normal atrial myocardium


Atrial cardiomyocytes

Atrial cardiomyocytes are geometrically complex cylinders that sometimes bifurcate at their ends where they connect with adjacent fibres via band-like ‘intercalated discs’. This contractile syncytium is organized in well-defined bands that establish non-uniform anisotropic propagation of the atrial impulse.<sup>9,11,26</sup> The only clear light-microscopic morphological difference between atrial and ventricular cardiomyocytes is in size.<sup>27</sup> In paraffin-embedded human specimens, the cardiomyocyte transverse diameter is ~12 µm in the LAs vs. 20–22 µm in the ventricles.<sup>11,28</sup> Atrial cardiomyocytes are mainly mononucleated; a minor fraction possess two or more nuclei. The nucleus is usually centrally located, with granular and/or condensed chromatin. The nuclear shape is influenced by fibre contraction, becoming more fusiform with longitudinal cell stretch.<sup>29</sup> Biochemically, atrial cardiomyocytes have greater lipid content than ventricular muscle cells.<sup>30</sup>

Atrial cardiomyocytes share many characteristics with ventricular in terms of nucleus, contractile apparatus, cytoskeleton, and organelles.<sup>27,29,31,32</sup> Unlike ventricular cardiomyocytes, atrial cardiomyocytes do not possess an extensive T-tubule network but they do have prominent sarcoplasmic reticulum (SR) elements known


**Table 2 EHRAS classification of atrial cardiomyopathy**

EHRAS class	Histological characterization
I <sup>11–15,503</sup>	Morphological or molecular changes affecting ‘primarily’ the cardiomyocytes in terms of cell hypertrophy and myocytolysis; no significant pathological tissue fibrosis or other interstitial changes
II <sup>8,12,14,504–506</sup>	Predominantly fibrotic changes; cardiomyocytes show normal appearance
III <sup>9,11,12,217,266</sup>	Combination of cardiomyocyte changes (e.g. cell hypertrophy, myocytolysis) and fibrotic changes
IV <sup>17–19</sup>	Alteration of interstitial matrix without prominent collagen fibre accumulation
IVa	Accumulation of amyloid
IVf	Fatty infiltration
IVi	Inflammatory cells
IVo	Other interstitial alterations



**Figure 2** (A) EHRAS Class I (biopsy): there are severe changes affecting ‘primarily’ the cardiomyocytes in terms of cell hypertrophy and myocytolysis; fibrosis is much less evident than myocyte modifications. (B) EHRAS Class II (biopsy): cardiomyocyte alterations are relatively modest compared with severe fibrotic changes; in this case, interstitial changes are much more prevalent than myocyte ones. (C) EHRAS Class III (biopsy): this is a combination of cardiomyocyte changes and collagen fibre deposition. (D) EHRAS Class IV (autopsy heart): primarily neutrophilic myocarditis.






**Figure 3** EHRAS Class IV (autopsy heart): this image shows a myocardial interstitial with some fibrosis but prominent amyloid (AL type) deposition (left-hand side, congo red staining under regular light microscope; right-hand side, congo red staining under polarized light microscope).

as Z-tubules.<sup>33</sup> Therefore, the atrial sarcolemma does not protrude into the cell, and voltage-operated  $\text{Ca}^{2+}$  channels mainly function at the cell periphery.<sup>34</sup> Atrial cardiomyocytes display specific granules (100–400 nm) situated mainly in the paranuclear area adjacent to the Golgi apparatus, which contain ANP, the BNP, and related peptides.<sup>23,24</sup>

### Atrial interstitium


Atrial interstitium consists of cellular and extracellular components (see Figures 2–5). The cellular elements include fibroblast/myofibroblasts, adipocytes, undifferentiated mesenchymal cells, and isolated inflammatory cells. The atrial wall has a significant number of medium-sized blood vessels, especially in the sub-epicardium. Mature adipose tissue is frequently found in atrial myocardium, especially the epicardium, and often permeates the layers around intramural coronary branches. The number of adipocytes is highly variable and increases with age.<sup>27</sup> The extracellular components consist of collagen fibres, which form most of the myocardial skeleton, proteoglycan particles, lipidic debris, spherical micro-particles, and matrix vesicles.<sup>27</sup>

Collagen fibers, mainly type I, are both normal and essential components (Figures 1–5). Atrial fibrous tissue may be sub-divided into



**Figure 4** Schematic representations and heart dissections to show the arrangement of the myocardial strands in the superficial parts of the walls. (A) The dissection viewed from the anterior aspect display the interatrial muscle Bachmann bundle and its bifurcating branches leftward and rightward. (B) A view of the roof and posterior wall of the left and right atria. The right pulmonary veins (PVs) passes behind the intercaval area. The subepicardial dissection shows the abrupt changes in fibre orientation and the myocardial strands (septopulmonary bundle) in the region between the left and right PVs. The red arrows show multiple muscle bridges connecting the two atria. ICV, inferior caval vein; LAA, left atrial appendage; LSPV, left superior pulmonary vein; MV, mitral valve; RAA, right atrial appendage; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein; SCV, superior caval vein; TV, tricuspid valve (see text for details).





**Figure 5** Normal histology of the left atrium and relevant pathological changes in mitral valve disease-associated atrial fibrillation. (A) Medium-power view of a normal left atrial myocardium which is composed of large bands of homogeneous cardiomyocytes. (B) In the same atrium as in (A), the Van Gieson staining show that collagen fibres (red colour) are primarily seen in the adventitial spaces of blood vessels (arrow). (C) Low-power view of a left atrium from a patient with mitral valve disease-associated atrial fibrillation. Large bands of cardiomyocytes are separated by significant amounts of pathologic fibrous tissue (arrows). (D) In the same atrium as in (C), the Van Gieson staining shows that the pathologic fibrous significantly thickens the perivascular spaces (perivascular fibrosis, arrow) and separates single or small groups of cardiomyocytes (interstitial fibrosis, arrowhead). (E) In atrial fibrillation, a variable number of cardiomyocytes undergo loss of contractile elements starting from the perinuclear area and resulting in so-called myocytolysis. These spaces may be empty (arrow) or filled with glycogen (arrowhead). (F) A higher-power view of myocytolysis with both glycogen rich (arrow) and optically empty (arrowhead) cardiomyocytes. (G) Ultrastructural view of a myolytic cardiomyocyte with significant loss of contractile elements around the nucleus (asterisk). In this empty area, there is very often accumulation of mitochondria (arrowhead) while the adjacent myofibrils display signs of abnormal contraction (arrow). (H) An LA from a patient with atrial fibrillation where the myocardial microcirculation (arrow) is slightly reduced and irregularly distributed. Stainings. (A and C) haematoxylin–eosin staining; (B and D) Van Gieson staining for collagen; (E and F) Periodic acid Schiff staining; (G) ultrastructural image; (H) immunohistochemical analysis with an anti-CD31 antibody. Original magnifications. (A, B, E, and H)  $\times 20$ ; (C and D)  $\times 4$ ; (F)  $\times 40$ ; (G)  $\times 2800$ .

pure interstitial and perivascular (or adventitial). Interstitial collagen fibres represent ~5% of the atrial wall volume. The atrial myocardium is also the site of sparse postganglionic nerve endings (from the 'intrinsic cardiac nervous system'), mostly within discrete fat pads but also among cardiomyocytes.<sup>35</sup>

## Atrial-specific physiological and functional considerations

### Atrial-selective electrophysiological properties

The atria have a number of electrophysiological features that distinguish them from the ventricles and govern their arrhythmia susceptibility.

### Action potential/ion-channel properties

Atrial cardiomyocytes have distinct action potential (AP) properties from ventricular cardiomyocytes, resulting in a large part from distinct ion-channel properties and distribution (Figure 6A).<sup>36,37</sup> Atrial background inward-rectifier  $K^+$  current ( $I_{K1}$ ) is smaller than that of ventricular  $K^+$  current, resulting in a less negative resting potential and more gradual slope of phase-3 repolarization. Atrial cells also


have two  $K^+$ -currents that are absent in ventricle cells: the ultrarapid delayed rectifier current ( $I_{Kur}$ ) and the acetylcholine-regulated  $K^+$ -current ( $I_{KACH}$ ). In addition, there is evidence that atrial  $Na^+$ -current has different properties compared with ventricular current.<sup>38</sup> As well as distinctions between atrial and ventricular APs, different atrial regions may have discrete AP and ion-channel properties.<sup>37,39</sup> These cellular electrophysiological characteristics have implications for antiarrhythmic drug action and design, and may also affect the responses to atrial arrhythmias and disease.<sup>36,37</sup>

### Intercellular coupling properties

The atria have a different pattern of cell-to-cell coupling protein (connexin) distribution compared with ventricular myocardium.<sup>36</sup> Whereas working ventricular cardiomyocytes express connexin-43 exclusively, atrial cardiomyocytes have significant expression of connexin-40 (Figure 6B).<sup>36</sup> Heterogeneities in connexin-40 distribution are common in paroxysmal AF and may play a pathophysiological role,<sup>40</sup> and gene variants affecting connexin-40 sequence and/or transcription predispose to AF occurrence.<sup>41</sup>

### Atrial structural properties

The atria have a very complex 3D structure (Figure 6C) not found in the ventricles. These include interatrial connections limited to



**Figure 6** (A) Comparison of atrial and ventricular action potential properties and underlying ionic currents. Resting potentials ( $-mV$ ) are more negative (averaging  $-80$  to  $-85$   $mV$ ) in ventricular vs. atrial ( $-70$  to  $-75$   $mV$ ) myocytes. (B) Connexin distribution differs between atria and ventricles, with connexin-43 only expressed in ventricular cardiomyocytes (CMs) but atrial CMs having both connexin-40 and connexin-43. (C) Realistic reconstruction of the structure of sheep atria. The right atrium (RA), left atrium (LA), pectinate muscles (PM), Bachmann's bundle (BB) and pulmonary veins (PV) are colour coded. From ref. (43) with permission.



Bachmann's bundle, the septum, and the CS; pectinate muscles, the crista terminalis, and fibres surrounding the coronary sinus in the right atrium; and the PVs with complex fibre orientation around them in the LA. These structural complexities have important potential implications for atrial pathophysiology and management of atrial arrhythmias.<sup>42</sup> Extensive recent work has gone into the realistic mathematical reconstruction of such geometric complexities,<sup>43</sup> and they have been incorporated into analytical approaches designed to implement patient-specific arrhythmia therapies.<sup>44</sup> Cable-like strands of atrial tissue like the pectinate muscles and crista terminalis are organized such that conduction within them is primarily longitudinal, with an 'anisotropy ratio' (longitudinal/transverse conduction velocities) as great as 10, whereas in working ventricular muscle the ratio is typically more between 2 and 4.<sup>45</sup>

## Autonomic ganglia

There are autonomic ganglia on the surface of the heart that are important way-stations for cardiac autonomic control.<sup>46</sup> Moreover, alterations in local cardiac innervation and intracardiac autonomic reflexes play an important role in physiology and arrhythmia control. Most of the cardiac autonomic ganglia are located on the atria, and in particular in the region of the PV ostia. Thus, they are well positioned to affect atrial electrical activity in regions particularly important in AF, and their alteration by therapeutic manoeuvres like PV ablation may contribute to antiarrhythmic efficacy.<sup>42,46,47</sup>

## Left atrium mechanics

The left atrial contribution to overall cardiovascular performance is determined by unique factors. First, left atrial function critically determines left ventricular (LV) filling. Second, chamber-specific structural, electrical and ion remodelling alter left atrial function and arrhythmia susceptibility. Third, atrial function is highly relevant for the therapeutic responses of AF. Fourth, LA volume is an important biomarker that integrates the magnitude and duration of LV diastolic dysfunction. The development of sophisticated, non-invasive indices of LA size, and function might help to clinically exploit the importance of LA function in prognosis and risk stratification.<sup>1,48</sup>

Fibre orientation of the two thin muscular layers (the fascicles of which both originate and terminate at the atrioventricular ring) introduce a complexity that challenges functional analysis. Ultrastructurally, atrial cardiomyocytes are smaller in diameter, have fewer T-tubules, and more abundant Golgi apparatus than ventricular. In addition, rates of contraction and relaxation, conduction velocity, and anisotropy differ, as does the myosin isoform composition and the expression of ion transporters, channels, and gap junctional proteins (see relevant sections).

## Functions of the left atrium

The principal role of the LA is to modulate LV filling and cardiovascular performance by operating as a reservoir for PV return during LV systole, a conduit for PV return during early LV diastole, and as a booster pump that augments LV filling during LV diastole. There is a critical interplay between these atrial functions and ventricular systolic and diastolic performance. Thus, while LA compliance (or its inverse, stiffness), and, to a lesser extent, LA contractility and relaxation are the major determinants of reservoir function during LV systole, LV end-systolic volume and descent of the LV base during systole are

important contributors. Conduit function is also governed by LA compliance and is reciprocally related to reservoir function, but because the mitral valve is open in diastole, conduit function is also closely related to LV compliance (of which relaxation is a major determinant). Atrial booster-pump function reflects the magnitude and timing of atrial contractility, but also depends on venous return (atrial preload), LV end-diastolic pressures (atrial afterload), and LV systolic reserve.

### Left atrium booster-pump function

Left atrium booster-pump function represents the augmented LV-filling resulting from active atrial contraction (minus retrograde blood-ejection into the PVs) and has been estimated by measurements of (i) cardiac output with and without effective atrial systole, (ii) relative LV-filling using spectral Doppler of transmitral, PV, and LA-appendage flow, (iii) LA-shortening and volumetric analysis, and (iv) tissue Doppler and deformation analysis (strain and strain-rate imaging) of the LA-body.<sup>1</sup> Booster-pump function can also be evaluated echocardiographically by estimating the kinetic energy and force generated by LA contraction. The relative importance of the LA contribution to LV filling and cardiac output remain controversial. A load-independent index of LA contraction based on the analysis of instantaneous relation between LA pressure and volume, analogous to LV end-systolic elastance measurements, has been used as a load-independent measure of LA pump function, validated *ex vivo* and in the intact dog (Figure 7).<sup>49</sup> While LA pressure–volume loops can be generated with invasive and semi-invasive means in humans,<sup>50</sup> these methods are cumbersome, time-consuming, and difficult to apply. Measurement of myocardial strain and strain rate, which represent the magnitude and rate of myocardial deformation, assessed using either tissue Doppler velocities (tissue Doppler imaging, TDI) or by 2D echocardiographic (2D speckle-tracking or STE) techniques (Figure 8) provide objective, non-invasive measurements of LA myocardial performance and contractility that overcome these limitations.<sup>1,51</sup>


### Left atrium reservoir function

Nearly half of the LV stroke volume and its associated energy are stored in the LA during LV systole. This energy is subsequently expended during the LV diastole. Reservoir function is governed largely by atrial compliance during ventricular systole, which is measured most rigorously by fitting atrial pressures and dimensions, taken either at the time of mitral valve opening/closure over a range of atrial pressures and volumes or during ventricular diastole, to an exponential equation.<sup>52</sup> Although this method requires atrial dimensions and pressures, the relative reservoir function can be estimated simply with PV Doppler: the proportion of LA inflow during ventricular systole provides an index of the reservoir capacity of the atrium. Reservoir function can also be estimated from LA time–volume relations as either the total ejection fraction or distensibility fraction, calculated as the maximum minus minimum LA volume, normalized to maximal or minimal LA volume, respectively.

Although largely neglected, the LA–appendage is more compliant than the LA–body,<sup>52</sup> so the contribution of the appendage to overall LA compliance is substantial with potential negative implications for routine atrial appendectomy/ligation during mitral valve surgery.

Left atrium strain and strain rates during LV systole predict successful sinus rhythm restoration following DC cardioversion or





**Figure 7** Left atrial pressure–volume loop. (A) Analogue recordings of left atrial pressure and dimensions in the time domain. Vertical lines indicate time of mitral valve opening (A), end of passive atrial emptying and onset of atrial diastasis (B), atrial end-diastole (C), and atrial end-systole (D). a and v represent respective venous pressure waves. (B) Left atrial pressure–volume loop from a single beat illustrating characteristic figure-of-eight configuration. Arrows indicate the direction of loop as a function of time. A loop represents active atrial contraction. V loop represents passive filling and emptying of the LA. MVO, time of mitral valve opening; MVC, approximate time of mitral valve closure; LA, left atrial end-systole; and LAd, left atrial end-diastole. Reproduced from ref. (49) with permission.

AF ablation, and are surrogates of atrial fibrosis and structural remodelling; coupled with an estimate of atrial pressure (e.g. transmitral E/E'), strain has the potential to estimate atrial distensibility non-invasively.<sup>1,53</sup>

### Left atrium conduit function

Left atrium conduit function occurs primarily during ventricular diastole and represents the transport of blood volume that cannot be attributed to either reservoir or booster-pump functions, accounting for approximately one-third of atrial flow.<sup>54</sup> A reciprocal relation exists between LA conduit and reservoir functions; a redistribution between these functions is an important compensatory mechanism that facilitates LV filling with myocardial ischaemia, hypertensive heart disease, and mitral stenosis (MS). Conduit function is estimated by the early diastolic transmitral flow, diastolic PV-flow, and LA strain and strain rate during early diastole.

### Atrial-selective $\text{Ca}^{2+}$ handling

There are major differences in the expression and function of  $\text{Ca}^{2+}$ -handling proteins between atria and ventricles (Figure 9).<sup>55</sup> The atria have reduced cardiomyocyte contraction and relaxation times and shorter  $\text{Ca}^{2+}$ -transient duration.<sup>56–58</sup> In atria, protein levels<sup>57,59</sup> and


activity<sup>57,59</sup> of the SR  $\text{Ca}^{2+}$ -ATPase2a (Serca2a) are two-fold higher, whereas the Serca2a-inhibitor phospholamban (PLB) is less abundant, vs. ventricles.<sup>57,59</sup> Atrial, but not ventricular, Serca2a is also regulated by sarcolipin (SLN) and SLN ablation increases atrial SR  $\text{Ca}^{2+}$ -uptake and contractility.<sup>60</sup> L-type  $\text{Ca}^{2+}$ -current<sup>61</sup> is similar in both chambers, whereas protein levels of ryanodine receptor type-2, calsequestrin, triadin, junction and  $\text{Na}^{2+}$ – $\text{Ca}^{2+}$  exchanger are lower in atria than in ventricles.<sup>59,62,63</sup> In contrast to ventricular myocardium, T-tubules are less abundant in atrial cardiomyocytes.<sup>64</sup> In addition, atrial cardiomyocytes possess much more  $\text{Ca}^{2+}$ -buffering mitochondria than ventricular cardiomyocytes.<sup>56</sup> As a consequence, the atrial  $\text{Ca}^{2+}$  wave starts in the myocyte periphery and then propagates to the centre of the myocyte, activating additional  $\text{Ca}^{2+}$ -releasing sites in the SR.<sup>55</sup>

## Pathology of atrial cardiomyopathies

### Lone atrial fibrillation (atrial fibrillation without concomitant conditions)

'Lone' atrial fibrillation (LAF) is diagnosed when no apparent explanation or underlying comorbidity can be identified.<sup>65,66</sup> Over the last





**Figure 9** Excitation–contraction coupling in atria vs. ventricles. Schematic representation of the cell structure and major  $\text{Ca}^{2+}$  handling proteins, along with related currents and ion transporters (A). Illustration of action potential (top),  $\text{Ca}^{2+}$  transient (middle) and confocal linescan image of intracellular  $\text{Ca}^{2+}$  wave propagation towards cell centre (bottom) in a ventricular (left) vs. atrial (right) cardiomyocyte (B). Arrows indicate differences in expression and/or function of  $\text{Ca}^{2+}$  handling proteins in atrial vs. ventricular cardiomyocytes.  $I_{\text{Na}}$ ,  $\text{Na}^+$  current; FKBP12.6, FK506-binding protein 12.6; JPH2, Junctophilin-2; MyBP-C, Myosin binding protein C; TnI, Troponin-I; for further abbreviations, see text.

EHRAS class III changes and 2 showed EHRAS class II. Stiles *et al.*<sup>74</sup> found bi-atrial structural change, conduction abnormalities, and sinus node dysfunction in paroxysmal LAF patients. Skolidis *et al.*<sup>75</sup> demonstrated atrial perfusion abnormalities and coronary flow reserve impairment. Much more recently,

morphometric assessment of atrial biopsies from the LA posterior wall of persistent or long-lasting persistent LAF patients demonstrated cardiomyocyte hypertrophy, myolytic damage, interstitial fibrosis, and reduced connexin-43 expression vs. controls.<sup>76</sup>



Isolated atrial amyloidosis

The accumulation of insoluble, misfolded proteins is linked to an increasing number of age-related degenerative diseases.<sup>77</sup> Amyloidosis represent the deposition of insoluble, fibrillar proteins in a cross  $\beta$ -sheet structure that characteristically binds dyes such as Congo red. The most common form of age-related or senile amyloidosis is limited to the atrium, a condition known as isolated atrial amyloidosis (IAA).<sup>17,78</sup> The incidence of atrial amyloidosis increases with age, exceeding 90% in the ninth decade.<sup>79</sup> Isolated atrial amyloidosis is also linked to structural heart disease. In atrial biopsies from 167 patients undergoing cardiac surgery, 23 of 26 amyloid-positive specimens were from patients with rheumatic heart disease (RHD), while the remaining 3 came from patients with atrial septal defects.<sup>80</sup> The overall incidence of 16% was greater than that was seen in control atrial autopsy specimens from trauma victims (3%). Histologically, IAA is classified as EHRAS IVa (Figure 3; Table 2).

Atrial natriuretic peptide is a fibrillogenic protein that forms IAA.<sup>81</sup> Amyloid deposits are immunoreactive for ANP in most patients,<sup>17</sup> while transthyretin, a transport protein implicated in systemic senile amyloidosis, was also identified in 10%<sup>4</sup> (NT-pro-ANP has been identified in other studies<sup>82</sup>). As with fibrosis, amyloidosis can cause local conduction block and P-wave duration is increased in IAA. Atrial amyloid is found more commonly in patients with AF vs. sinus rhythm (Figure 3). Both AF and IAA increased with advancing age and female sex, but the relationship between the two is independent of age and gender.<sup>83,84</sup> Isolated atrial amyloidosis is detected in 80% of PV sleeves of elderly patients.<sup>84</sup>

For organ-specific amyloidosis such as Alzheimer’s disease, there is no detectable correlation between quantity of fibrillar deposits and disease advancement.<sup>85</sup> Rather, disease phenotype correlates most closely with accumulation of soluble, prefibrillar protein aggregates.<sup>86</sup> Preamyloid oligomers (PAOs) are cytotoxic to cardiomyocytes.<sup>87</sup> They do not bind Congo red and thus are not visible by standard amyloid staining methods. Using a conformation-specific antibody, PAOs often co-localizing with ANP were detected in atrial samples of 74 of 92 patients without AF undergoing cardiac surgery.<sup>88</sup> The preamyloid oligomer content was independently associated with hypertension. Additional studies are needed to further confirm this association and whether PAOs are increased in AF.

NPPA mutations

Atrial natriuretic peptide is released from the atria in response to atrial stretch or volume expansion, and produces natriuresis, diuresis, and vasodilation.<sup>89</sup> It also interacts with other endogenous systems, inhibiting the renin–angiotensin-II–aldosterone and sympathetic nervous systems, and regulates ion currents.<sup>90,91</sup> Atrial natriuretic peptide-knockout mice develop cardiac hypertrophy and exaggerated responses to hypertrophic stress.<sup>92</sup> The gene encoding the precursor protein for ANP, *NPPA*, encodes prepro-ANP, a 151 amino acid protein that includes a signal peptide cleaved off to form pro-ANP,<sup>93</sup> which is stored in dense granules in the atria. Released pro-ANP undergoes proteolytic processing to generate N-terminal pro-ANP and ANP, 98 and 28 amino acids in length, respectively. N-terminal pro-ANP is cleaved into three hormones with biological activity similar to ANP: long-acting natriuretic hormone (LANH), vessel dilator peptide, and kaliuretic hormone.

Genetic studies have linked abnormal ANP production to familial atrial tachyrrhythmias and atrial cardiomyopathy. In a large family with Holt–Oram syndrome, a missense mutation in T-box transcription factor 5 (*Tbx5*) resulted in an atypical phenotype with early-onset AF and the overexpression of multiple genes, including *NPPA*.<sup>94</sup> In a large family with multiple members having early-onset LAF, a 2-bp deletion was identified that abolishes the ANP stop codon, producing a mature protein containing the usual 28 amino acids plus an anomalous C-terminus of 12 additional residues.<sup>95</sup> The mutant ANP peptide is present in affected family members at plasma concentrations 5–10 times higher than wild-type ANP. Studies of the electrophysiological effects of ANP have been inconsistent.<sup>96</sup>

Additional *NPPA* variants (S64R and A117V) have also been linked to AF.<sup>97,98</sup> The S64R variant occurs in vessel dilator peptide rather than ANP. A truncated peptide containing this mutation increased  $I_{Ks}$  several fold, an effect predicted to shorten action potential duration (APD),<sup>97</sup> but the variant has also been identified in unaffected elderly individuals without AF,<sup>96</sup> and its functional pathological significance remains uncertain.

More recently, an autosomal-recessive atrial cardiomyopathy was described in patients harbouring an *NPPA* mutation (Arg150Gln) predicted to be damaging to protein structure.<sup>99</sup> The phenotype is characterized by biatrial enlargement, initially associated with atrial tachyarrhythmias such as AF and atrial flutter.<sup>100</sup> Biatrial enlargement progresses to partial and ultimately severe atrial standstill, associated with progressive decreases in atrial voltage and extensive atrial scarring. Whether atrial structural changes are primary, or secondary to atrial enlargement, is unknown. Loss of the antihypertrophic effects of ANP may cause the massive atrial enlargement seen in these patients.

Hereditary muscular dystrophies

A common finding in many inherited muscular dystrophies is cardiac involvement, related to myocyte degeneration with fatty or fibrotic replacement (Table 3).<sup>101–103</sup> In some cases, this can be the presenting or predominant clinical manifestation. Multiple complexes and pathways are involved in the maintenance of myocyte integrity,

Table 3 Hereditary muscular dystrophies with cardiac involvement

Muscular dystrophy	Protein/gene	Primary cardiac disease
Duchenne	dystrophin	DCM
Becker	dystrophin	DCM
Myotonic dystrophy, type 1	DMPK	CSD
Emery-Dreifuss	Emerin	CSD
	Lamin A/C	(DCM)
Limb-Girdle	Lamin A/C	CSD
	Sarcoglycans	CM
	others	
Facioscapulohumeral	Dux 4	CSD (rare)

DCM, dilated cardiomyopathy; CSD, conduction system disease; DMPK, myotonic dystrophy protein kinase.

and a defective or absent protein component can lead to progressive cell death. The large dystrophin–glycoprotein complex links the myocyte cytoskeleton to the extracellular basement membrane. For diseases of dystrophin, sarcoglycans, and other complex-related proteins, the most prominent manifestation is a dilated cardiomyopathy due to diffuse myocyte involvement, with arrhythmias and conduction abnormalities secondary to LV dysfunction.<sup>101–105</sup> Specific atrial involvement can lead to sinus node disease and/or atrial arrhythmias with associated thromboembolic events.<sup>106,107</sup> Myotonic dystrophy type I is the most common muscular dystrophy presenting in adults.<sup>108</sup> Up to 15% develop atrial arrhythmias during a 10-year follow-up.<sup>109</sup> The presence of conduction defects and atrial arrhythmias are independent risk factors for sudden death.<sup>103,110</sup> In Emery-Dreifuss and Limb-Girdle type IB disease, widespread atrial fibrosis can lead to atrial standstill.<sup>101</sup> In Emery-Dreifuss, AF and atrial flutter with slow ventricular responses and asystolic pauses can be observed, coupled with the occurrence of thromboembolism and stroke.<sup>111</sup> In facioscapulohumeral muscular dystrophy, arrhythmias are rare, with the most common being supraventricular tachycardia.<sup>112</sup> Histologically, the tissue composition may vary substantially, including all EHRAS classes (see Table 2).

## Atrial cardiomyopathy due to congestive heart failure

Congestive heart failure (CHF) is a common cause (contributing condition) of AF.<sup>3</sup> The CHF-induced atrial phenotype is complex. A particularly important component is atrial fibrosis, which in experimental models occurs earlier in the course of CHF, and to a much greater extent, than in the ventricles, at least in part because of atrial-ventricular fibroblast–phenotype differences.<sup>4</sup> Congestive heart failure-related fibrosis slowly, if at all, and the AF-promoting substrate predominantly tracks fibrosis rather than other components of atrial remodelling like ion-current or connexin changes. Unlike the case for AF-induced remodelling, the atrial ion-current changes in CHF do not abbreviate APD or cause overall conduction slowing,<sup>113,114</sup> so they do not contribute directly to arrhythmogenesis. On the other hand, CHF atria are prone to triggered activity due to abnormal  $\text{Ca}^{2+}$  handling.<sup>115</sup> The principle underlying abnormality appears to be increased cellular  $\text{Ca}^{2+}$  load. While the underlying mechanisms are not completely clear, they likely include phospholamban hyperphosphorylation (which increases SR  $\text{Ca}^{2+}$  uptake) and AP prolongation (which increases  $\text{Ca}^{2+}$  loading by enhancing the period during which L-type  $\text{Ca}^{2+}$  channels are open). The final phenotypic product of the CHF-induced  $\text{Ca}^{2+}$ -handling abnormalities is focal ectopic activity due to aberrant diastolic  $\text{Ca}^{2+}$ -release events from the SR, similar to abnormalities seen with paroxysmal and long-standing persistent AF.<sup>116</sup>

Congestive heart failure also causes atrial hypocontractility, despite increased cytosolic  $\text{Ca}^{2+}$  transient, indicating reduced contractile sensitivity to intracellular  $\text{Ca}^{2+}$ , possibly because of reduced expression of total and phosphorylated myosin-binding protein C.<sup>115</sup> This hypocontractility may be important in contributing to the increased likelihood of thromboembolic events in AF patients who also have CHF. Of the atrial changes that occur in CHF, many are also seen in the ventricle. However, the highly atrial-selective fibrosis may contribute to atrial cardiomyopathy in

the absence of clear signs of disturbed ventricular function, particularly in patients with prior CHF events who later become well-compensated under therapy or after resolution of the underlying cause. Collagen depositions are prominent in CHF, leading most commonly to EHRAS Class II and III properties. However, EHRAS Class IVi and IVf may also be found in certain areas of the atria (see Table 2).

## Obstructive sleep apnoea

Obstructive sleep apnoea (OSA) is known to impair cardiac function and predispose to AF.<sup>117–119</sup> Obstructive sleep apnoea prolongs atrial conduction times, slows atrial conduction, reduces atrial-electrogram voltages and increases electrogram complexity.<sup>117,118</sup> Signal-averaged P-wave duration is increased by OSA, and decreases significantly with continuous positive airway pressure treatment.<sup>120</sup> In a rat model, repeated obstructive apnoea over a 4-week period increases AF vulnerability and slows atrial conduction by altering connexin-43 expression and inducing atrial fibrosis.<sup>121</sup>

## Atrial fibrillation-induced atrial remodelling

Atrial fibrillation itself induces atrial remodelling that contributes to the maintenance, progression, and stabilization of AF.<sup>41,116</sup> The high atrial rate causes cellular  $\text{Ca}^{2+}$  loading. This induces a decrease in  $I_{\text{Ca,L}}$  due to down-regulation of the underlying Cav1.2 subunits, and an increase in constitutively active  $I_{\text{K,Ach}}$ .<sup>41,116,122,123</sup> MiR-328 up-regulation with consequent repression of Cav1.2-translation and  $\text{Ca}^{2+}$ -dependent calpain activation, causing proteolytic breakdown of L-type  $\text{Ca}^{2+}$  channels.<sup>41,116</sup> The rate-dependent up-regulation of  $I_{\text{K1}}$  results from a  $\text{Ca}^{2+}$ /calcineurin/NFAT-mediated down-regulation of the inhibitory miR-26, removing translational-inhibition of Kir2.1.<sup>41,116</sup> Increased  $I_{\text{K1}}$  stabilizes AF by abbreviating and hyperpolarizing atrial cardiomyocyte Aps.<sup>41</sup> Small-conductance  $\text{Ca}^{2+}$ -activated  $\text{K}^{+}$  (SK) currents ( $I_{\text{SK}}$ ) also play a role in AF.<sup>41,116</sup> Computational modelling shows that increased total inward-rectifier  $\text{K}^{+}$  current in chronic atrial fibrillation (cAF) is the major contributor to the stabilization of re-entrant circuits by shortening APD and hyperpolarizing the resting membrane potential.<sup>41,116</sup>

Atrial tachycardia remodelling reduces  $\text{Ca}^{2+}$ -transient amplitude by a variety of mechanisms, contributing to atrial contractile dysfunction.<sup>41,116,124</sup> Reduced atrial contractility causes atrial ‘stunning’ that may be involved in thromboembolic complications.

Long-term atrial tachycardia remodelling causes conduction slowing in several animal models, at least partly due to  $I_{\text{Na}}$  down-regulation.<sup>122</sup> Heterogeneously distributed gap-junction uncoupling due to connexin remodelling likely contributes to atrial conduction slowing.<sup>41,116</sup> Heterogeneity in connexin-40 distribution correlates with AF stability in goats with repetitive burst-pacing-induced AF.<sup>125</sup> Connexin-40 expression decreases in the PVs of dogs with AF-related remodelling, possibly due to tachycardia-induced connexin-degradation by calpains.<sup>41,116</sup>

Long-term atrial tachycardia/AF may itself cause atrial fibrosis that contributes to long-term persistence.<sup>126</sup> Rapid atrial firing promotes fibroblast differentiation to collagen-secreting myofibroblasts through autocrine and paracrine mechanisms.<sup>32</sup> Atrial tachycardia-induced NFAT-mediated decreases in fibroblast

miR-26 may also contribute to structural remodelling. Atrial fibroblasts have non-selective cation channels of the transient receptor potential (TRP) family that carry  $\text{Ca}^{2+}$  into the cell; the increased cell- $\text{Ca}^{2+}$  then triggers increased collagen production. Since miR-26 represses TRPC3 gene expression, miR-26 reductions increase TRPC3 expression, promoting fibroblast  $\text{Ca}^{2+}$  entry that causes proliferation/myofibroblast differentiation.<sup>127</sup> TRPM7 may similarly contribute to fibrotic changes in AF.<sup>128</sup>

APD shortening in cAF patients also results from increased inward-rectifier  $\text{K}^+$  currents,<sup>129</sup> both  $I_{K1}$  and a constitutive form of  $I_{K_{\text{ACh}}}$ .<sup>41,116</sup> Agonist-activated  $I_{K_{\text{ACh}}}$  is decreased in right atrium of AF patients because of a reduction in underlying Kir3.1 and Kir3.4 subunits,<sup>129</sup> whereas agonist-independent current is increased.<sup>41,116</sup>

Atrial cardiomyocytes from patients with long-standing persistent AF show spontaneous diastolic SR  $\text{Ca}^{2+}$ -release events (SCaEs) and delayed after depolarizations (DADs).<sup>130</sup> CaMKII-dependent RyR2 hyperphosphorylation underlies the SR  $\text{Ca}^{2+}$  leak and SCaEs.<sup>32,106,130</sup> Protein kinase A-dependent RyR2 hyperphosphorylation also occurs,<sup>130</sup> likely promoting the dissociation of the inhibitory FKBP12.6 subunit from the RyR2 channel. Larger inward NCX current may also contribute to the stronger propensity for DADs.<sup>130</sup>

Although initial work pointed to unchanged  $I_{\text{Na}}$  or mRNA expression of the Nav1.5  $\alpha$ -subunit in AF patients, recent studies reported reduced peak  $I_{\text{Na}}$ .<sup>41,116</sup> There is also evidence for increased  $I_{\text{Na,late}}$ , although its functional consequences are less clear. Altered mRNA and protein levels of connexin-40/-43 may also contribute to re-entry-promoting conduction abnormalities in cAF patients. Reduced connexin-40 expression together with lateralization to the transverse cell membrane may cause heterogeneous conduction.<sup>41,116</sup>

Overall, ion-channel changes contribute to AF stabilization and early recurrence after cardioversion.  $\text{Ca}^{2+}$ -handling abnormalities are involved in atrial ectopy, and atrial fibrosis is important in the progression of long-term persistent AF to resistant forms. Atrial fibrillation-induced atrial myopathy has changes that depend on AF duration. Very short-term AF produces no ultrastructural alterations, while AF lasting several weeks causes EHRAS I alterations.<sup>13</sup> Long-term persistent AF produces EHRAS III changes.<sup>126</sup>

## Drug-related atrial fibrillation

A large number of drug classes have been associated with the induction of AF either in patients without heart disease or in individuals with pre-existing cardiac disorders (Table 4),<sup>131</sup> but drug-induced AF (DIAF) has received less attention than that it might deserve. The overall incidence of DIAF is still unknown for several reasons: (a) the evidence associating specific drugs with AF has largely been based on anecdotal reports, with very few controlled prospective clinical trials, (b) DIAF is often paroxysmal and documentation may be difficult/poor, (c) while DIAF is easily recognized if it occurs just after i.v. drug administrations (e.g. adenosine or dobutamine), AF episodes can be missed if they appear after multiple exposures (e.g. chemotherapy), (d) patients often receive multiple drugs, making the specific culprit agent difficult to identify, (e) with non-cardiovascular drugs, DIAF is often diagnosed by non-cardiologists, often with an imprecise description of the arrhythmic event and

clinical history.<sup>132</sup> Multiple mechanisms have been suggested to explain the pathogenesis of DIAF: (a) direct atrial electrophysiological effects like abbreviated refractoriness, slowed conduction, or triggered activity due to  $\text{Ca}^{2+}$  loading, (b) changes in autonomic tone, (c) myocardial ischaemia, (d) direct myocardial damage and other mechanisms such as release of pro-inflammatory cytokines, oxidative stress, hypotension, and electrolyte disturbances.<sup>131,132</sup>

In the majority of cases, DIAF is a benign self-limited disorder. However, DIAF may be clinically serious in polymedicated patients with underlying comorbidities.<sup>132</sup> Discontinuation of the causative drug(s) usually leads to cardioversion in few minutes or hours. When AF persists, treatment is similar to that of non-DIAF patients.<sup>133,134</sup> Because of the wide range of mechanisms by which drugs cause AF, the histological changes associated with DIAF may vary substantially from EHRAS class I–IV (see Table 2 for reference). Future studies are warranted to assess specific effects of various drugs on atrial tissue.

## Myocarditis

Myocarditis refers to an inflammatory disease of the heart, which occurs as a result of exposure to external triggers (e.g. infectious agents, toxins, or drugs) or internal ones like autoimmune disorders.<sup>135,136</sup>

The incidence is difficult to ascertain since it depends on the diagnostic criteria. A likely estimate is 8 to 10 per 100 000 population, representing the third leading cause of sudden death after hypertrophic cardiomyopathy and coronary artery disease.<sup>137</sup> In autopsy series, the prevalence of myocarditis varies from 2% to 42% in young adults with sudden death.<sup>138,139</sup> Biopsy demonstrates an inflammatory infiltrate in 9–16% of patients with unexplained non-ischaemic dilated cardiomyopathy.<sup>140,141</sup>

Myocarditis is defined by the 'Dallas criteria' as the presence of a myocardial inflammatory infiltrate with necrosis and/or degeneration of adjacent cardiomyocytes of non-ischaemic nature.<sup>142</sup> According to the type of inflammatory cell, myocarditis may be subdivided into lymphocytic, eosinophilic, polymorphic, giant-cell myocarditis, and cardiac sarcoidosis.<sup>136</sup>

Atrial fibrillation is frequently part of the clinical presentation of myocarditis. In 245 patients with clinically suspected myocarditis, AF occurred in about 30%.<sup>143</sup> Myocarditis with lone atrial involvement is rarely diagnosed.<sup>144–146</sup> This may reflect the fact that atrial myocardium is not methodically sampled either at autopsy or in routine endomyocardial biopsy. In most such cases, AF dominated the clinical picture, suggesting a role for architectural remodelling that interferes with atrial conduction.<sup>9,147</sup> Giant-cell myocarditis is a distinct—and probably autoimmune—myocarditis characterized by diffuse infiltration by lymphocytes and numerous multinucleated giant-cells, frequent eosinophils, cardiomyocyte necrosis and, ultimately, fibrosis. The natural course is often fulminant and mortality is high if untreated. An isolated atrial variant of giant-cell myocarditis was first reported in 1964.<sup>148</sup> Since then, only a few cases have been described in the English language literature. The atrial variant appears to have a more favourable course compared with the classical form.<sup>149</sup> The atrial giant-cell myocarditis may represent a distinct entity, potentially attributable to atrium-specific auto-antigens.<sup>150</sup> EHRAS Class IVi is observed in patients with atrial myocarditis. As myocarditis persists and enters a chronic phase, characteristics may change to EHRAS Class III (see Table 2).



**Table 4** Drugs reported to induce atrial fibrillation

Drug group	Drugs	Mechanism
<i>Bisphosphonates</i>	Alendronate, zoledronic acid	
<i>Cardiovascular</i>		
Inotropics	Dopamine, dobutamine, dopexamine, arbutamine, enoximone, milrinone, levosimendan	Adrenergic stimulation
Vasodilators	Isosorbide, losartan, flosequinan	Hypotension with probable adrenergic reflex
Cholinergics	Acetylcholine	Vagal stimulation
Diuretics	Thiazides	Hypokaliemia
<i>Respiratory System</i>		
Sympathomimetics	Pseudoephedrine, albuterol, oricprenaline, salbutamol, salmeterol	Adrenergic stimulation
Xanthines	Aminophylline, theophylline	Adrenergic stimulation
<i>Central Nervous System</i>		
Anticholinergics	Atropine	Adrenergic stimulation
Anticonvulsants	Lacosamide, paliperidone	
Antidepressants	Fluoxetine, tranylcypromine, trazodone	Direct cardiodepressant effect, sympathetic tone
Antimigraine	Ondasetron, sumatriptan	coronary spasm
Antipsychotics	Clozapine, loxapine, olanzapine	Direct cardiodepressant effect, sympathetic tone
Cholinergics	Physostigmine, donepezil	Vagal stimulation
Dopamine agonists	Apomorphine	Vagal activity
<i>Chemotherapeutics</i>		Cardiac injury, coronary vasospasm, hypertension, reactive oxygen species, changes in mitochondrial calcium transport, electrolyte disturbances, inflammation
Alylating agents	Cisplatin, cyclophosphamide, ifosfamide, melphalan	
Anthracyclines	Doxorubicin, mitoxantrone	
Anti-metabolites	Capecitabine, 5-fluorouracil, gemcitabine	
Antimicrotubule agents	Docetaxel, paclitaxel	
Tyrosine kinase inhibitors	cetuximab, sorafenib, sunitinib	
Topoisomerase inhibitors	amsacrine, etoposide	
Monoclonal antibodies	alemtuzumab, bevacizumab, rituximab, trastuzumab	
Cytokines and immunomodulators	azathioprine, interferon-gamma, interleukin-2, lenalidomide	
<i>Genitourinary System</i>		
Drugs for erectile dysfunction	sildenafil, tadalafil, vardenafil	Hypotension with adrenergic reflex
Tocolytic drugs	$\beta_2$ -adrenoceptor agonists (hexoprenalin, terbutaline), magnesium sulphate	
<i>Hormones</i>		
Anabolic-androgenic steroids		Structural changes, changes in autonomic activity

## Atrial cardiomyopathy associated with genetic repolarization disturbances

Atrial standstill, a severe form of atrial cardiomyopathy, is associated with combined heterozygous mutations of SCN5A and Connexin-40 genes.<sup>151</sup> Gain-of-function mutations in K<sup>+</sup>-channel subunits (e.g. KCNQ1, KCNH2, KCND3, and KCNE5) or loss-of-function mutations in KCN5A have been identified in AF patients.<sup>152</sup> Thus, either gain or loss of K<sup>+</sup>-channel function can cause AF, indicating that repolarization requires optimal tuning and deficits

in either direction can be arrhythmogenic. Recently, early repolarization or J-wave syndrome has been associated with AF although, in middle-aged subjects, early repolarization in inferior leads did not predict AF.<sup>153</sup> A gain-of-function mutation in KCNJ8, encoding the cardiac Kir 6.1 (KATP) channel, is associated with both increased AF susceptibility and early repolarization.<sup>154</sup> There is an established association between atrial arrhythmias and primary ventricular arrhythmia syndromes, which was first reported among conditions that manifest with obvious structural abnormalities.<sup>155</sup> Atrial

fibrillation is relatively common in hypertrophic cardiomyopathy (prevalence ~20%).<sup>156</sup> In arrhythmogenic right ventricular cardiomyopathy, an even higher proportion (up to 40%) of patients may manifest AF.<sup>157</sup> The association with AF also extends to primary arrhythmia syndromes without obvious structural heart disease. Supraventricular tachycardias, primarily AF/AFL, have been reported in Brugada syndrome.<sup>158,159</sup> Among long QT syndrome (LQTS) patients, prolongation of action potentials leading to atrial fibrillation has been suggested to be an atrial form of 'torsades de pointes'.<sup>152</sup> A subtle form of 'cardiomyopathy' that includes increased left atrial volumes occurs in ~12% of LQTS patients.<sup>160</sup> The reports available mostly implicate genetic variants in Na<sup>+</sup>-channel genes.<sup>161</sup> Patients with early-onset lone AF have a high prevalence of LQTS-associated SCN5A variants.<sup>162</sup> A mouse model of LQT3 is prone to atrial arrhythmias due to EADs.<sup>163</sup> There are sporadic reports of atrial arrhythmias in patients with CPVT.<sup>164</sup> Taken together, the associations between AF and sudden death syndromes likely reflect common mechanisms between atrial and ventricular arrhythmogenesis.

## Ageing

In elderly dogs, premature impulses show markedly slowed conduction, associated with a doubling of fibrous-tissue content APD prolongation and spatial heterogeneity in repolarization.<sup>165,166</sup> Clinical mapping studies have also demonstrated similar findings of conduction abnormalities, prolonged refractoriness, reduced myocardial voltage, and a greater number of double potentials and fractionated electrograms.<sup>167,168</sup> Perhaps as a result of these atrial changes, alteration of wavefront propagation velocities has been described with an inverse correlation to age.<sup>169</sup> Histologically, fibrotic changes are the most obvious alteration (EHRAS Class II; see Table 2).

## Hypertension

Hypertension accounts for at least one in five incident AF cases.<sup>170</sup> In hypertensive subjects, both left atrial enlargement and P-wave changes are predictive of AF occurrence.<sup>171,172</sup>

In small animal models, mimicking hypertension by partial aortic clamping induces LA hypertrophy, fibrosis, connexin-43 down-regulation and slow/inhomogeneous conduction.<sup>173</sup> Prenatal corticosteroid exposure-induced hypertension in sheep causes atrial conduction abnormalities, wavelength shortening, and increased AF.<sup>174</sup> Lau et al. utilized a one-kidney one-clip model to investigate the impact of short- and long-term hypertension on the evolution of an atrial cardiomyopathy.<sup>175,176</sup> Utilization of this model intrinsically is more reflective of a disordered renin–angiotensin axis. Short-term hypertension progressively enlarged the LA, reduced LA emptying fraction, prolonged atrial refractoriness, slowed conduction, and caused LA interstitial fibrosis and inflammatory cell infiltration.<sup>175,176</sup> In patients with established hypertension and LV hypertrophy, there is global and regional conduction slowing associated with fractionated electrograms and double potentials along the crista terminalis, along with an increase in low-voltage areas.<sup>177</sup>

Importantly, population studies show increased AF risk even with 'pre-hypertension' (systolic blood pressure 130–139 mmHg).<sup>178</sup> The abnormal atrial substrate is reversible, with studies demonstrating improved electrical and structural parameters and reduced AF burden following treatment with renin–angiotensin–aldosterone system blockers.<sup>179–181</sup> In patients with resistant hypertension

and improved blood pressure following renal denervation, there was a global improvement in atrial conduction and reduced complex fractionated activity. Histologically, pressure overload induces hypertrophy of atrial myocytes (EHRAS Class I). Collagen deposition may also occur (EHRAS II–III) with more severe hypertension causing LV hypertrophy and diastolic dysfunction (see Table 2).

## Obesity

Several population-based studies have demonstrated a robust relationship between obesity and AF.<sup>182–184</sup> A recent meta-analysis estimates a 3.5–5.3% excess risk of AF for every one unit of body mass index increase.<sup>185</sup>

Left atrium dilation and dysfunction are known consequences of the cardiomyopathy due to obesity.<sup>186</sup> In a sheep model of obesity, progressive weight gain over 8 months was associated with increased atrial volume, pressure, and pericardial fat volume along with atrial interstitial fibrosis, inflammation, and myocardial lipidosis.<sup>187</sup> This was associated with decreased conduction velocity, increased heterogeneity of conduction and a greater inducibility of atrial fibrillation. With more sustained obesity, animals not only demonstrate progressive atrial changes but also in areas adjacent to pericardial fat there is infiltration of the atrial myocardium by fat cells.<sup>188</sup>

Obese patients have higher left atrial volume and pressure with lower left atrial strain associated with shorter refractoriness in the LA and the PVs.<sup>189</sup> A detailed evaluation of atrial changes associated with human obesity showed an increase in the left atrial epicardial fat, a global reduction in atrial conduction velocity, increased fractionation, and preserved overall voltage but greater low-voltage areas.<sup>190</sup> The low-voltage areas were observed in regions adjacent to epicardial fat depots.

Pericardial fat volume has been shown to be associated with AF incidence, severity, and adversely effects ablation outcome.<sup>191,192</sup> Epicardial adiposity is associated with altered 3D atrial architecture, adipocyte infiltration into the myocardium, and atrial fibrosis that may contribute to conduction heterogeneity that promotes AF.<sup>193–195</sup>

In the ovine model of chronic obesity, weight reduction is associated with reduction in total body fat, atrial dilatation, and interstitial fibrosis together with improved hemodynamics, atrial connexin-43 expression and conduction properties that result in reduced vulnerability to AF.<sup>196</sup> In humans, aggressive management of weight and associated risk factors is associated with favourable changes in pericardial fat volume, atrial size, myocardial mass as well as electrophysiological and electroanatomical changes along with reduced AF inducibility and burden.<sup>197</sup> Furthermore, weight loss in morbidly obese subjects is associated with reduced epicardial fat.<sup>198</sup> Weight reduction in obese individuals can result in regression of LV hypertrophy, reduction in left atrial size and reduction in AF burden/severity.<sup>199–201</sup> Histologically, fatty infiltrates (EHRAS Class IVf) as well as collagen depositions are present (EHRAS III; see Table 2).

## Diabetes mellitus

Diabetes is an independent risk factor for development and progression of AF.<sup>202</sup> In a rat model of diabetes mellitus, atrial tissue fibrosis deposit is associated with decreased conduction velocity and

greater AF inducibility.<sup>203</sup> Patients with abnormal glucose metabolism have larger left atrial size, lower left atrial voltage, and longer left atrial activation time compared with controls.<sup>204</sup> Insulin resistance is associated with increased left atrial size and structural heterogeneity.<sup>205,206</sup>

Mitochondrial function is impaired, leading to oxidative stress, in diabetic atria.<sup>207</sup> Oxidative stress and activation of the advanced glycation end-product (AGE)-AGE-receptor (RAGE) system mediates atrial interstitial fibrosis up-regulation of circulating tissue growth factors and pro-inflammatory responses.<sup>207,208</sup> In addition, prolonged hyperglycaemic stress leads to accumulation of AGE-RAGE and nitric oxide inactivation, leading to endothelial dysfunction and myocardial inflammation.<sup>209</sup>

Hyperglycaemia and AGE–RAGE ligand interactions lead to decreased phosphorylation of connexin-43, potentially impairing intercellular coupling.<sup>210</sup> Advanced glycation is also related to alterations in myocardial calcium handling and hence contractility.<sup>211</sup> These findings could explain the electrophysiological alterations that serve as a central mechanism of the vulnerability to AF in diabetes.<sup>212</sup>

Aggressive treatment of diabetes and adequate glycemic control may prevent or delay the occurrence of AF, despite little direct evidence of the effects of anti-diabetic drugs on AF. Peroxisome proliferator-activated gamma receptor agonists may offer protection against AF beyond glycemic control, due to their anti-inflammatory, antioxidant, and anti-fibrotic effects.<sup>213</sup> However, caution should be taken in extrapolating these experimental findings to patients with diabetic cardiomyopathy. Histologically, changes in the atrial myocytes are the initial findings without significant fibrosis (EHRAS I). Later on the disease tissue appearance may change to EHRAS Class III and EHRAS Class IV (see Table 2).

## Atrial cardiomyopathy due to valvular heart disease

Mitral valve disease (MVD) and aortic stenosis (AS) have been associated with atrial structural remodelling and a propensity for AF. Although secondary atrial cardiomyopathy is most often associated with age, hypertension, and heart failure in developed countries, RHD is responsible for over 40% of AF in the developing world.<sup>214</sup>

### Mitral stenosis

In atria from 24 patients with isolated MS and normal sinus rhythm undergoing mitral valvuloplasty, John *et al.*<sup>215</sup> reported unchanged or an increased effective refractory period (ERP), widespread and site-specific conduction delay, myocyte loss and patchy electrical scar, suggesting that structural changes and their electrophysiological consequences precede the development of AF. Factors associated with these structural changes include direct myocardial effects (pathognomonic inflammatory Ashoff bodies), ultrastructural changes, atrial fibrosis, immunoactive cytokines, and matrix metalloproteinase remodelling (decreased MMP-1 and MMP-3).<sup>215–217</sup> Reverse atrial remodelling (an immediate reduction in LA pressure and volume and an improvement in biatrial voltage; and further increases in RA voltage 6 months later) was demonstrated in 21 patients with isolated MS undergoing commissurotomy.<sup>218</sup> In contrast, atrial remodelling did not reverse in patients with lone AF undergoing successful AF ablation; indeed, substrate abnormalities progressed

(decreased voltage and increased regional refractoriness) over the subsequent 6–14 months.<sup>219</sup>

Atrial enlargement and fibrosis are important determinants for the development and maintenance of AF. Increases in collagen I and collagen III (the latter which increase in cultured fibroblasts exposed to mechanical stretch)<sup>220</sup> were seen in patients with AF and MVD, but only type I was seen in patients with lone AF.<sup>221</sup> Cellular decoupling and myocyte isolation, tissue anisotropy, and conduction inhomogeneities were considered the substrate for local re-entry and arrhythmia.

### Mitral regurgitation

Verheule *et al.*<sup>222</sup> found changes in atrial tissue structure and ultrastructure 1 month after creating severe mitral regurgitation (MR) by partial mitral valve avulsion. Effective refractory periods were increased homogeneously and sustained AF (>1 h) was inducible in 10 of 19 MR dogs; in this model, there were no differences in either atrial conduction pattern or velocities. Interstitial fibrosis, chronic inflammation, and cellular glycogen accumulation were noted in the dilated left atria, but myocyte hypertrophy, myolysis, and necrosis were absent. In contrast, myocyte hypertrophy, dedifferentiation, and degeneration and fibrosis are described in pigs with surgically created chronic MR<sup>223</sup> and patients with MR.<sup>12,224</sup>

High-density oligonucleotide microarrays, enrichment analysis, and a differential proteomics approach were used to characterize the molecular regulatory mechanisms and biological processes involved in the atrial myopathy that is seen in pigs with moderate to severe chronic (6 and 12 months) MR.<sup>225</sup> Renin-angiotensin-system and peroxisome proliferator-activated receptor signalling pathways and genes involved in the regulation of apoptosis, autophagy, oxidative stress, cell growth, and carbohydrate metabolism were differentially regulated.<sup>225</sup> MLC2V (a marker of cardiac hypertrophy and important in the regulation of myocyte contractility) had the highest fold change in the MR pigs. Increased activity of a membrane-bound containing NADPH oxidase in atrial myocytes, which correlated with the degree of cellular hypertrophy and myolysis, was demonstrated in patients with isolated severe MR. The authors suggest that atrial stretch-induced NADPH oxidase activation and intracellular oxidative stress contributes to apoptosis, atrial contractile dysfunction, and atrial dilatation.<sup>226</sup>

Correction of MR reverses many features of atrial remodelling and corrects functional abnormalities. Early LA reverse remodelling (45% reduction of mean LA maximal volume) and increased active atrial emptying was found in the early (30 day) postoperative period in 43 patients undergoing mitral valve surgery (successful repair or replacement) for chronic organic MR<sup>227</sup> and a similar improvement at 6 months was reported by Dardas *et al.*<sup>228</sup> Histologically, EHRAS Class III is the most prominent finding in MVD, although the histological appearance of the tissue may vary substantially over time and interindividually and, therefore, all EHRAS classes may be found in the tissue (see Figure 1; Table 2).

### Aortic stenosis

Although AS is associated with chronic AF,<sup>229</sup> animal models of AS and atrial remodelling are lacking. Kim *et al.*<sup>173</sup> studied atrial electrical remodelling in excised perfused hearts in a rat model of increased afterload simulating AS (ascending aortic banding), which produced LVH without systemic hypertension, heart failure,



or neurohormonal activation. Banded hearts showed marked LA hypertrophy and fibrosis at 14 and 20 weeks post-operatively. The incidence and duration of pacing-induced AF was increased at 20 weeks and was associated with decreased mean vectorial conduction velocity and inhomogeneity of conduction, decreased expression of connexin-43, but without changes in ERP. Importantly, atrial remodelling was not present at 8 weeks, when the greatest degree of LVH was present.<sup>173</sup>

Left atrium volumes are higher in patients with AS compared with controls and decrease significantly after valvuloplasty.<sup>230</sup> Plasma natriuretic peptide (ANP) levels are higher in symptomatic than asymptomatic patients with AS<sup>231</sup> and N-ANP levels predict atrial remodelling and late (2 month) post-operative AF after surgery for AS.<sup>232</sup>

Taken together, these data support the notion that substrate-based AF is a consequence of the abnormal haemodynamics and atrial remodelling that accompany valvular heart disease. In this instance, atrial remodelling is the consequence of multiple biological processes that create structural and ultrastructural abnormalities and a change in conduction (as opposed to refractoriness) that favours the development and maintenance of AF. Histologically, EH-RAS Class III is the most prominent finding, although the histological appearance of the tissue may vary substantially over time and inter-individually (see *Figures 1–3; Table 2*). Atrial pathology often also affects specialized conduction system tissues like the sinus and AV nodes. However, these changes are beyond the scope of the present consensus report, which focuses on atrial cardiomyocytes and tissue.

## Impact of atrial cardiomyopathies on occurrence of atrial fibrillation and atrial arrhythmia

Controversy about the mechanism of AF has been alive for over 100 years, yet given the continued increase in worldwide burden of AF,<sup>233</sup> ongoing investigation will drive improved treatment and prevention. Currently, there are two opposing sides in the debate about re-entrant mechanisms in AF. On one side are those who promote variants of the original idea of Gordon Moe that fibrillation, whether atrial or ventricular, results from the continued random propagation of multiple independent electric waves that move independently throughout the atria.<sup>234,235</sup> On the other side are those who adhere to the theory that fibrillation is a consequence of the continued activity of a few vortices (rotors) that spin at high frequencies, generating 'fibrillatory conduction'.<sup>236,237</sup> In either case, arrhythmia maintenance is favoured by abbreviated APD/refractory period.<sup>13,238,239</sup> Another pre-requisite of the multiple wavelet hypothesis is that there should be slow conduction, which is not the case for rotors. According to rotor theory, slowing of conduction is established dynamically by the curvature of the rotating wave front, which is steepest near the rotation centre, at which refractory period is briefest and conduction velocity is slowest.<sup>240</sup> Which of the above two mechanisms prevails in human AF has not been fully established, yet.<sup>241</sup>

Regardless of the mechanism that maintains it, AF leads to high-frequency atrial excitation, which if sustained, results in ion-channel remodelling that further abbreviates the APD and refractory period

to boost its stabilization. Such AF-induced electrical remodelling is reversible in the short term (minutes, hours, or days), but less so when lasting months or years. For a detailed discussion of AF-induced remodelling, see chapter 3. How these changes contribute to AF perpetuation in the long term has not been fully determined.

In a recent study using a sheep model of persistent AF induced by intermittent atrial tachypacing there was a progressive spontaneous increase in the dominant frequency (DF) of AF activation after the first detected AF episode.<sup>240,242</sup> The results suggested that, unlike the tachypacing induced electrical remodelling that can occur over minutes or hours, there existed a protracted, slowly progressing electrical and structural remodelling secondary to AF that sustains for days or weeks.<sup>240,242</sup> In addition, a consistent left-vs.-right atrial DF difference correlated with the presence of rotors, DF gradients, and outward propagation from the posterior LA during sustained AF in the explanted, Langendorff-perfused sheep hearts,<sup>242</sup> and an underlying basis is seen in humans.<sup>243</sup> The DF of non-sustained AF increases progressively at a rate ( $dDF/dt$ ) that accurately predicts the transition from episodic, non-sustained AF to persistent, long-lasting AF.<sup>126</sup> Although fibrosis developed progressively,<sup>126</sup> it is unknown what role if any fibrosis played in rotor acceleration or stabilization. Other studies using different animal models have also demonstrated that long-term atrial tachypacing results in atrial fibrosis,<sup>244</sup> with concomitant release of cytokines that are known to modify atrial electrical function.<sup>245</sup> In the sheep model, atrial structural changes leading to PLA enlargement likely made rotors less likely to collide with anatomic boundaries, thus contributing to their stabilization and AF persistence.<sup>242,246</sup>

Distinct stresses of the atrial myocardium could contribute to the transformation of atrial cardiomyopathy into an arrhythmogenic substrate for AF. For instance, mechanical stress is a major regulator of cardiac electrical properties. The two atria are particularly sensitive to changes in mechanical coupling due to their 'reservoir' position and their function of 'pressure sensor' with a specific endocrine role, i.e. the secretion of natriuretic peptides. Many mechanosensors are expressed in the atrial myocardium and contribute to the interplay between membrane electrical properties, mechanical stresses, and myocardial wall deformation.<sup>247</sup> Recently, it has been reported that shear stress of atrial cardiomyocytes regulates the surface expression of voltage-gated potassium channels via the stimulation of the integrins that link myocytes to the extracellular matrix.<sup>248,249</sup> During atrial haemodynamic overload, the mechanosensor signalling pathways, are constitutively activated, such that myocytes are no longer able to respond to shear stress. This process results in the acceleration of atrial repolarization and could contribute to AF vulnerability.<sup>249</sup>

Oxidative stress is also thought to be important in AF-induced atrial remodelling leading to cardiomyopathy and AF perpetuation.<sup>250</sup> However, the manner in which reactive oxygen species (ROS) mediate atrial ionic remodelling is inadequately understood. NOX2/4 activity increases in fibrillating atria and is a potential source of ROS in AF. Mitochondrial ROS is potentially another important source of oxidative stress; mitochondrial dysfunction has been demonstrated in AF. It remains to be determined whether atrial oxidative stress directly affects atrial APD and refractoriness and thus contributes to rotor acceleration and stability in AF. Several

sarcolemmal ionic currents are directly or indirectly modulated by ROS,<sup>251</sup> but the relevance of these mechanisms to human AF has not been demonstrated.

Sustained AF activates the release of pro-inflammatory cytokines and hormones related to cardiovascular disease and tissue injury, including angiotensin-II (Ang-II), tumour necrosis factor (TNF)- $\alpha$ , interleukin (IL)-6, and IL-8.<sup>252</sup> Pro-inflammatory stimuli such as NOX-derived ROS, growth factors, and other hormones has been demonstrated to have a role in Ang-II function.<sup>253</sup> However, the precise molecular modifications of the putative signalling targets of ROS after Ang-II stimulation are yet to be identified. Knowing which NOXs are activated by Ang-II in the normal atria may help generate better interventions aimed at preventing AF associated with Ang-II activation. Ang-II is a well-known trigger of fibroblast activation and differentiation into myofibroblasts, which are key factors in the generation of fibrosis. Pro-inflammatory cytokines also promote ion-channel dysfunction, which together with myocyte apoptosis and extracellular matrix remodelling predisposes patients to AF.

Recently, atrial adipose tissue has emerged as a potential player in the pathophysiology of AF.<sup>3,254</sup> In addition to its paracrine effects,<sup>192</sup> adipose tissue can infiltrate the subepicardium of the atrial myocardium and become fibrotic<sup>255</sup> contributing to the functional dissociation of electrical activity between epicardial layer and the endocardial bundle network, favouring wavebreak, and rotor formation. Lone AF or rapid atrial pacing promotes adipogenesis through the regulation of genes specific to metabolic adaptation. Therefore, it is possible that the accumulation and infiltration of adipose tissue reflects metabolic stress secondary to excessive work of the atrial myocardium.<sup>191</sup> Furthermore, adipose tissue can induce fibrosis and alter gene-expression patterns.<sup>195,256</sup>

## Atrial cardiomyopathies, systemic biomarkers, and atrial thrombogenesis

### Atrial cardiomyopathies and systemic biomarkers

#### Atrial inflammation and inflammatory biomarkers

Infiltration of neutrophils, macrophages, and lymphocytes accompanies surgical injury or pericarditis, promoting the development of atrial fibrosis, resulting in heterogeneous and slowed conduction, a risk factor for re-entrant arrhythmia.<sup>257–261</sup> This provides a mechanistic link between inflammatory activation and atrial arrhythmogenesis. Anti-inflammatory interventions such as prednisone are effective in preventing neutrophil infiltration in sterile pericarditis and in suppressing pacing-inducible atrial flutter,<sup>262</sup> and steroid pretreatment has been found to reduce the incidence of postoperative AF in an appropriately powered randomized, clinical trial.<sup>263</sup> An ongoing trial studies the effect of colchicine (NCT 001128427).

In a mouse model of persistent hypertension, Ang-II infusion promotes increased atrial abundance of myeloperoxidase (MPO, a neutrophil and macrophage oxidant-generating enzyme) and promotes atrial fibrosis.<sup>261</sup> In MPO knockout mice, the profibrotic response to A-II infusion was eliminated. Angiotensin II and endothelin-1 are linked to inflammatory and proarrhythmic

atrial remodelling.<sup>2,264–266</sup> This evidence suggests that inflammatory cell infiltration has an important role in promoting the creation of a substrate for AF, as a result of conduction heterogeneity and slowing, both in the setting of cardiac surgery and beyond.

#### Systemic inflammatory activation in atrial fibrillation

In addition to haemodynamic stress-induced cellular inflammation of the atria, a cross-sectional study demonstrated that AF was associated with higher plasma levels of C-reactive protein (CRP), a sensitive but non-specific biomarker of systemic inflammation produced by the liver.<sup>267</sup> A follow-up secondary analysis of the participants Cardiovascular Health Study participants further revealed that elevated CRP predicted incident AF.<sup>268</sup>

Subsequent studies have demonstrated relationships between several different serologic markers of inflammation and AF, including IL-6,<sup>269</sup> TNF- $\alpha$ ,<sup>270</sup> aldosterone<sup>271</sup> and simple white blood cell counts.<sup>272</sup> Analyses of multiple inflammatory biomarkers within the same study have suggested that IL-6 and osteoprotegerin<sup>273</sup> may be especially important. The relationship between IL-6 and AF may be mediated by left atrial enlargement.<sup>269</sup>

While evidence that inflammatory markers presage the development of AF has been replicated,<sup>268,274</sup> there are also multiple studies to demonstrate that atrial arrhythmias likely contribute to inflammation: specifically, cardioversion of AF<sup>275</sup> as well as ablation of either AF<sup>276</sup> or atrial flutter<sup>277</sup> has resulted in a decrease in inflammation. Indeed, Marcus *et al.* demonstrated that the rhythm at the time of the blood draw (AF vs. sinus) was an important determinant in detecting an elevated CRP or IL-6 level.<sup>278</sup> Taken together, these data suggest that the relationship between inflammation and AF may be bidirectional and progressive.


#### Intra-atrial sampling studies

As the enhanced risk of stroke in the setting of AF has been attributed to status of blood flow and in particular thromboemboli originating in the left atrial appendage, there has been an interest in determining whether peripheral blood can adequately reflect the hypercoagulability that may be present locally within the atria (see Figure 10).<sup>279</sup> The first intra-atrial sampling study failed to identify evidence of statistically significant differences between several markers of hypercoagulability in right and left atrial vs. femoral vein and arterial samples among persistent AF patients with MS;<sup>280</sup> of note, the same markers revealed statistically significant differences when compared with normal controls without AF.<sup>279</sup> In contrast, a subsequent study demonstrated that platelet activation acutely increased in coronary sinus blood in AF, while systemic platelet activation (obtained from the femoral vein) revealed no such change.<sup>281</sup>

A similar approach to multi-site sampling has also been applied to better understand the relationship between inflammation and AF. Liuba *et al.* found higher levels of IL-8 in the femoral vein, right atrium, and coronary sinus than the left and right upper PVs among eight permanent AF patients (without any such differences 10 paroxysmal AF patients or 10 controls).<sup>280</sup>

#### Practical implications and use of systemic biomarkers

Systemic biomarkers have been used to predict development of AF and/or its complications (Table 5). Various studies have examined the role of inflammatory indices, natriuretic peptides, injury markers,



**Figure 10** Concept of ‘endocardial remodelling’ in fibrillating atria. In accordance to Virchow’s triad hypercoagulability, flow abnormalities, and endothelial changes must co-exist to induce thrombogenesis at the atrial endocardium. Molecular studies have revealed substantial endocardial changes in left atrial tissue samples. Prothrombotic factors (vWF, adhesion molecules like VCAM-1, P-selectin etc; green) are expressed at the surface of endothelial cells causing an increased adhesiveness of platelets and leucocytes to the atrial endocardium. This initiates atrial thrombogenesis at the atrial endocardium. Several clinical factors like diabetes mellitus, heart failure ageing etc. (CHA<sub>2</sub>DS<sub>2</sub>VASc Parameters) increase molecular alterations (oxidative stress pathways etc.) within myocytes and endothelial cells, and thereby, increase the expression of prothrombotic factors. These alterations are not directly related to the presence or absence of atrial fibrillation in the surface ECG, and therefore, help to explain, why thrombogenesis is increased even during episodes of sinus rhythm.

etc. in predicting incident AF, especially in the post-surgery setting. Many of these biomarkers are non-specific, and high levels may reflect infection or sepsis, an acute phase reaction, etc.<sup>282,283,284</sup>

Adding BNP and CRP to a prediction score derived from CHARGE-AF (which included data from the Atherosclerosis Risk in Communities Study (ARIC), Cardiovascular Health Study (CHS), the Framingham Heart Study, the Age, Gene/Environment Susceptibility Reykjavik Study (AGES), and the Rotterdam Study) and utilizing age, race, height, weight, systolic and diastolic blood pressure, current smoking, use of antihypertensive medication, diabetes, history of myocardial infarction and history of heart failure<sup>285</sup> improved the statistical model.<sup>286</sup> Once again, the addition of CRP did not meaningfully improve the model.

In another study evaluating the relationship of extracellular matrix modulators (matrix metalloproteinases, MMPs, and their tissue inhibitors, TIMPs) and AF risk, only elevated MMP9 levels were significantly associated with AF risk.<sup>287</sup> Proteases having desintegrin and metalloprotease activities (ADAM) are related to atrial dilatation and thereby influence mechanical performance of the atria.<sup>288</sup>

The clinical benefit of considering biomarkers associated with AF is questionable unless there is clear evidence of a direct benefit in AF risk prediction and management- this has not been achieved to date.

## Prothrombotic indices—coagulation, platelets

Over 150 years ago, Virchow proposed a triad of abnormalities that contributed to thrombus formation (thrombogenesis), that is,

abnormalities of vessel wall, abnormal blood flow and abnormal blood constituents (Figure 10). In the setting of AF, abnormalities of vessel walls are evident by the association of thromboembolism with structural heart disease (eg. mitral valve stenosis) and complex aortic plaque, as well as endothelial damage/dysfunction, whether recognized by biomarkers (eg. von Willebrand factor (vWF), tissue plasminogen activator, tPA), immunohistochemistry studies of the left atrial wall, electron microscopy, or by functional studies (eg. flow mediated dilatation).<sup>289</sup> Abnormal blood flow in AF can be visualized by spontaneous echocontrast in the LA, as well as low left atrial appendage Doppler velocities. Abnormal blood constituents in AF are evident from abnormalities of coagulation, platelets, fibrinolysis, inflammation, extracellular matrix turnover, etc. that are all directly or indirectly associated with thrombogenesis, or a predisposition to the latter. While abnormalities of platelets are often evident in AF, they may be more reflective of associated vascular disease or comorbidities than of AF per se.<sup>290,291</sup> Indeed, thrombus obtained in AF is largely fibrin-rich (‘red clot’) compared with arterial thrombus, which is largely platelet-rich (‘white clot’), providing a mechanistic explanation for the role of anticoagulation therapy, rather than antiplatelet therapy for AF-related thromboembolism.<sup>291,292</sup>

The concept of AF being a prothrombotic or hypercoagulable state was first proposed in 1995.<sup>293</sup> Many prothrombotic indices in AF have been related to subsequent stroke and thromboembolism, whether in non-anticoagulated or anticoagulated subjects (Figure 10). Initial studies showed that coagulation-related factors, such as fibrin D-dimer (an index of fibrin turnover and



**Table 5** Coagulations markers in atrial fibrillation

Study	AF group(s)	Control group(s)	Significant abnormalities found in AF (increase in coagulation markers)*
Gustafsson (1990) <sup>507</sup>	20 (with stroke) 20 (without stroke)	40 (normal without stroke) 20 (with stroke)	D-dimers, vWF irrespectively of history of stroke
Kumagai (1990) <sup>508</sup>	73	73	D-dimers
Asakura (1992) <sup>509</sup>	83	(normal)	PF1+2, TATIII complex
Sohara (1994) <sup>510</sup>	13 (paroxysmal)	(normal)	TATIII complex (no difference in D-dimers),
Lip (1995) <sup>511</sup>	87	158	D-dimers, vWF
Lip (1996) <sup>512</sup>	51	26 (healthy)	D-dimers
Kahn (1997) <sup>513</sup>	50 (without prior stroke) 25 (with prior stroke)	31 (without prior stroke) 11 (with prior stroke)	Fibrinogen in AF without stroke vs. controls without stroke (no difference was seen between groups with prior stroke)
Heppell (1997) <sup>514</sup>	19 with thrombus in LA 90 without thrombus in LA	not applicable	D-dimers, vWF, TATIII complex if LA thrombus
Shinohara (1998) <sup>515</sup>	45 (non-valvular)	not applicable	D-dimers, TATIII complex in patients with low vs. high LAA velocity
Feinberg (SPAF III) (1999) <sup>516</sup>	1531	not applicable	No association of PF1+2 with thromboembolism
Mondillo (2000) <sup>517</sup>	45	35 (healthy)	D-dimers, vWF, s-thrombomodulin
Fukuchi (2001) <sup>518</sup>	16	27 (cardiac without AF)	vWF in LA appendage tissue
Conway (2002) <sup>296</sup>	1321		vWF in high-risk group for stroke
Kamath (2002) <sup>519</sup>	93	50 (normal)	D-dimers
Vene (2003) <sup>520</sup>	113		D-dimers in patients having cardiovascular events vs. no event
Nakamura (2003) <sup>521</sup>	LA appendage tissue of 7 non-valvular	4 non-cardiac death	vWF, TF
Conway (2003) <sup>297</sup>	994	not applicable	vWF not associated of with risk of stroke, vWF independently associated with vascular events
Kamath (2003) <sup>522</sup>	31 (acute onset) 93 (permanent)	31 (healthy)	Haematocrit raised in acute AF D-dimers in permanent AF (but not in acute AF)
Sakurai (2004) <sup>523</sup>	28 (AFL)	27	D-dimers if impaired LAA function
Inoue (2004) <sup>524</sup>	246 (non-valvular)	111	D-dimers in patients having risk factors, PF1+2 (NS)
Kumagai (2004) <sup>525</sup>	16 (post mortem)		vWF and protein in patients with enlarged atrium
Marin (2004) <sup>526</sup>	24 (acute onset) 24 (chronic)	24 (CAD patients in sinus rhythm) 24 (healthy)	D-dimers, vWF, s-thrombomodulin (no longer different after cardioversion)
Nozawa (2004) <sup>527</sup>	509	111 (healthy)	D-dimers, PF1+2 (NS)
Freestone (2005) <sup>528</sup>	59	40 (healthy)	vWF
Nozawa (2006) <sup>295</sup>	509 (non-valvular)		D-dimers (but not PF1+2) predictive for thromboembolic events
Ohara (2007) <sup>294</sup>	591 (non-valvular)	129	D-dimers, PF1+2, platelet factor 4, $\beta$ -thromboglobulin D-dimers, PF1+2 (correlated with presence of risk factors for stroke)

AF, atrial fibrillation; AFL, atrial flutter; CAD, coronary artery disease; LA, left atrial; LAA, left atrial appendage; NS, non-significant; vWF, von Willebrand factor; PF1+2, prothrombin fragment 1 + 2; TATIII, thrombin-antithrombin III; TF, tissue factor; s-thrombomodulin, soluble-thrombomodulin; \*Significantly different in AF group, unless otherwise indicated.

thrombogenesis) were related to stroke risk strata as well as an adverse prognosis from thromboembolism, whether or not patients were anticoagulated.<sup>294–297</sup> In contrast, there was no prognostic advantage of platelet indices.<sup>295,298,299</sup>

### Prediction of thrombogenesis

Addition of vWf refines clinical risk stratification in AF, first shown in the non-anticoagulated or suboptimally anticoagulated patients from the SPAF study.<sup>300</sup> More recently, vWf has been related to thromboembolism as well as bleeding risks in anticoagulated AF patients.<sup>301</sup> Ancillary studies from large Phase 3 anticoagulation trials

have reported prognostic implications for increased levels of D-dimer, troponin, natriuretic peptides, and novel biomarkers (e.g. GDF15).<sup>302–304</sup> Many of these studies have been performed in selected clinical trial cohorts, and the prognostic role in risk stratification requires prospective testing in unselected large 'real-world' cohorts with a broad range of stroke risk and renal function. As in the case of AF prediction, evidence for the additive value of biomarkers for stroke risk prediction from large prospective non-anticoagulated 'real-world' cohorts is limited.<sup>305</sup> Endocardial thrombogenic alterations in diseased atria, which appear to be related to oxidative stress, appear to contribute to clot formation,

particularly in the left atrial appendage.<sup>306–310</sup> Thus, the impact and the relation between EHRA Classes and the extent of endocardial thrombogenic alterations have to be assessed in future studies. Interestingly, duration of AF does not correlate with the extent of observed endocardial changes.<sup>309</sup>

## Imaging techniques to detect atrial cardiomyopathies mapping and ablation in atrial cardiomyopathies

It is well established that an enlarged LA is associated with adverse cardiovascular outcomes.<sup>311–316</sup> In the absence of MVD, an increase in LA size most commonly reflects increased wall tension as a result of increased LA pressure,<sup>317–320</sup> as well as impairment in LA function secondary to atrial myopathy.<sup>321,322</sup> A clear relationship exists between an enlarged LA and the incidence of atrial fibrillation and stroke,<sup>323–332</sup> risk for overall mortality after myocardial infarction,<sup>321,322,333,334</sup> risk for death and hospitalization in patients with dilated cardiomyopathy,<sup>335–344</sup> and major cardiac events or death in patients with diabetes mellitus.<sup>345</sup> Left atrium enlargement is a marker of both the severity and chronicity of diastolic dysfunction and magnitude of LA pressure elevation.<sup>317–320</sup> A recent consensus report on multi-modality imaging for AF patients summarizes the current status of atrial imaging in more detail.<sup>346</sup>

### Echocardiography

Echocardiography is the imaging modality of choice for screening and serially following patients with diseases involving the LA morphology and function.<sup>347</sup>

For assessment of atrial size, most widely reported is the linear dimension in the parasternal long-axis view using M-mode or 2 delayed enhancement (DE).<sup>324–339,345,347–349</sup> However, due to the complex 3D nature of the atrium and the non-uniform nature of atrial remodelling, this measurement frequently does not provide an accurate picture of LA size.<sup>350–354</sup> Thus, when assessing LA size and remodelling, the measurement of LA volume is a more powerful prognostic indicator in a variety of cardiac disease states.<sup>329,331,333–339,345,347–360</sup> Two-dimensional echocardiographic LA volumes are typically smaller than those reported from computed tomography or cardiac magnetic resonance imaging (CMR).<sup>361–365</sup> Left atrium volume from 2D images is best measured using the disk summation algorithm because it includes fewer geometric assumptions.<sup>366,367</sup> The advent of 3-D ECHO has improved the accuracy of ECHO volume measurements which correlate well with cardiac computed tomography<sup>368,369</sup> and magnetic resonance imaging.<sup>370,371</sup> Compared with 2D assessment of LA volume, 3DE also has superior prognostic prediction.<sup>372,373</sup>

The recommended upper normal indexed LA volume is 34 mL/m<sup>2</sup> for both genders which fits well with a risk-based approach for determination of cut-off between a normal and an enlarged LA.<sup>323,357–359</sup>

### Left atrial function by Doppler echocardiography

Left atrium function can be assessed by pulsed-wave Doppler measurements of late (mitral A) diastolic filling. Multiple studies have used this parameter as an index of LA function assessment, but it

is affected by age and loading conditions.<sup>317,374–382</sup> The PV atrial reversal velocity has also been used as a measurement of LA function.<sup>317,377,379–382</sup> In the presence of reduced LV compliance and elevated filling pressures, atrial contraction results in significant flow reversal into the PVs.<sup>80,81</sup> Studies have also demonstrated that Doppler tissue imaging can be used as an accurate marker of atrial function.<sup>383,384</sup>

### New echocardiographic techniques

Two-dimensional speckle-tracking echo has been used as a more sensitive marker to detect early functional remodelling before anatomical alterations occur.<sup>385–400</sup>

Strain (S) and strain rate (SR) imaging provide data on myocardial deformation by estimating spatial gradients in myocardial velocities.<sup>385,388,392,393,401–405</sup> This technique has been used as a surrogate of LA structural remodelling and fibrosis.<sup>388–393</sup> Interestingly, LA dysfunction with changes in strain and strain rate has been observed in patients with amyloidosis in the absence of other echocardiographic features of cardiac involvement.<sup>402</sup> Abnormalities in atrial strain have been observed in diverse conditions, including AF, valvular pathology, heart failure, hypertension, diabetes, and cardiomyopathies.<sup>388,389,396–400</sup> Population-based studies have demonstrated the prognostic value of LA strain analysis for long-term outcome.<sup>388,394</sup>

Less research and fewer clinical outcomes data are available on the quantification of RA size. Right atrial volumes are also underestimated with 2D echocardiographic techniques compared with 3DE.<sup>343,406,407</sup>

### Cardiac computed tomography

Cardiac CT may be used for accurate assessment of atrial volumes. Volumetric data from cardiac computed tomography (CCT) are comparable to data generated by CMR and 3D echocardiographic imaging and is superior to 2D echocardiography.<sup>371</sup> The LA volume prior to catheter ablation and the presence of asymmetry of chamber geometry predicts the likelihood of maintaining sinus rhythm post-procedure.<sup>408</sup> As the LA enlarges, the shape of the LA roof initially becomes flat and then becomes coved, and this progression may correlate with development of non-PV substrate in patients undergoing AF ablation.<sup>409</sup>

CCT may also be used to screen for thrombus prior to AF ablation. The diagnostic accuracy of CT has been studied by multiple groups, with a systematic review of 19 studies and 2955 patients reporting a sensitivity and specificity of 96 and 92%, respectively, translating to a positive predictive value of 41% and a negative predictive value of 99%.<sup>410</sup> Diagnostic accuracy increased to 99%, with 100% specificity, when delayed imaging was performed. An advantage of using CT imaging to exclude thrombus is that CCT is frequently performed prior to AF ablation for integration into the electroanatomic mapping systems routinely used during AF ablation procedures. CCT can also provide accurate information about PV anatomy and variants and correlates well with CMR in that regard.<sup>411</sup>

### Magnetic resonance imaging of the atrium

Over recent years CMR has been used in clinical and research settings to provide gold standard volumetric assessments of chamber

structure and function. Drawbacks are that CMR is expensive and has more limited availability than echocardiography. Recently, contrast-enhanced CMR with gadolinium has been used as a technique to detect atrial fibrosis.<sup>412</sup> Although these methods are still in relatively early stages and have not been extensively reproduced, the ability to identify early degrees of atrial structural change would no doubt enhance our ability to detect varying degrees of remodeling that may not be as clear from volumetric or functional assessment. In addition to late-gadolinium-enhanced (LGE) CMR to detect replacement fibrosis, post-contrast T1 mapping<sup>413,414</sup> has been used to quantify diffuse interstitial fibrosis. Both techniques have been correlated with bipolar voltage measured during invasive mapping.<sup>412</sup> However, these techniques require specialized post-imaging processing. While they are commonly used for ventricular imaging, they have not been widely employed for atrial imaging because of the technical challenges in achieving adequate image resolution in the thin-walled atrium.<sup>415</sup>

Using a systematic scoring system for the extent of delayed enhancement, a recently-published multicentre study has related the extent of LGE CMR detected fibrosis to the outcome of AF ablation.<sup>416</sup> The risk of recurrent AF increased from 15% for stage I fibrosis (<10% of the atrial wall) to 69% for stage IV fibrosis ( $\geq 30\%$  of the atrial wall). The authors suggested that CMR quantification of fibrosis may play a role in the appropriate selection of patients most likely to benefit from AF ablation. Late-gadolinium-enhanced CMR has also been used to predict development of sinus node dysfunction,<sup>417</sup> stroke risk,<sup>418</sup> and progression of atrial fibrillation from paroxysmal to persistent.<sup>419</sup> However, various studies have highlighted the need to further improve the methods of accurately identifying replacement fibrosis and to improve reproducibility of data analysis before LGE CMR can be considered a routine clinical tool.<sup>420,421</sup>

Recently, a number of studies have used CMR DE late gadolinium enhancement (LGE) in order to non-invasively characterize the extent and distribution of scarring present following AF ablation.<sup>422–424</sup> Several studies observed that patients with more extensive scar at 3 months (or greater percentage scar around the PV circumference) had a lower AF recurrence rate.<sup>423,425</sup> Another study showed a correlation between measured contact force at the time of ablation, and the extent of CMR determined scar development.<sup>426</sup> Other studies have shown a concordance between scar around the PVs and low-voltage regions on invasive electroanatomic mapping (EAM).<sup>427,428</sup> Isolation of PVs at repeat procedures could be achieved guided by the imported MR image to identify the gaps.<sup>427,428</sup> However, other studies found no association between CMR scar gaps and mapped PV reconnection sites. A study in 50 paroxysmal AF patients undergoing either wide area or ostial ablation found that the proportion of patients in whom CMR could correctly identify the distribution of ablation lesions varied from as low as 28% to 54% depending on the technique used.<sup>429</sup> These authors concluded that LGE imaging of atrial scar was not yet sufficiently accurate to reliably identify ablation lesions or to determine their distribution. Whether CMR will have the resolution to detect such focal regions where scar is incomplete remains uncertain. Of note, Harrison *et al.* used an animal model to correlate lesion size on CMR with lesion volume at pathology. The correlation depended critically on the definition of pixel intensity used to define scar with small changes in definition leading to large changes in estimated scar volume.<sup>415</sup>

## Imaging with electroanatomic mapping

Electroanatomic mapping systems have become the standard for invasive substrate characterization of atrial cardiomyopathies. Using various technologies, these systems allow for rapid characterization and reproduction of atrial anatomy with 3-D display rendering. Anatomic variations in PV anatomy, including common ostium or additional veins, may be identified. Visualization software allows for accurate measurements of atrial distances<sup>430</sup> and gross volumetric data but assessment of venous diameter may be suboptimal owing to venous susceptibility to distortion. Anatomic imaging of the atria may be enhanced with the co-registration of DICOM images from previously acquired cardiac MRI or CT or with the use of real-time contrast angiography or intracardiac echocardiogram.

While EAM allows for anatomic reproduction of the atria, it also enables the assessment of the atrial substrate through the geographic display of unipolar and bipolar signal amplitude data, as well as other signal characteristics, on rendered atrial surfaces. Regions of low-voltage, electrical silence, fractionation, or double potentials are reputed to correlate with underlying atrial fibrosis, surgical patches, or scar. In the same way, electrical activation of the atrium may be imaged allowing for assessment of regional changes in conduction velocity<sup>431</sup> that may be proarrhythmic and support the perpetuation of atrial fibrillation. The use of EAM for activation mapping of atrial arrhythmia will be discussed in the subsequent section on ablation techniques.

Electroanatomic mapping has been used to image the electroanatomic substrate of atrial cardiomyopathy associated with sinus node disease,<sup>432</sup> rheumatic MS,<sup>215</sup> atrial septal defect,<sup>218,431</sup> CHF,<sup>433</sup> obstructive sleep apnoea,<sup>117</sup> and ageing.<sup>167</sup> It has been a powerful research tool that has enhanced our understanding of the atrial substrate in patients with paroxysmal and persistent atrial fibrillation and<sup>74,434</sup> those who have failed initial PV antrum isolation.<sup>435</sup>

Unlike cardiac MR, CT, or echocardiography, EAM requires invasive catheterization and mapping. However, despite recent advances in MRI techniques that allow for imaging atrial scar, EAM imaging arguably has a great clinical feasibility and superior ability to image and to define the atrial substrate that leads to the development of atrial fibrillation. A recent consensus report on multimodality imaging for AF patients is a useful detailed reference.<sup>346</sup>

## Ablation of atrial tachyarrhythmia

Numerous single-centre, randomized studies and larger multicentre observational registries have demonstrated the superiority of AF ablation over drug therapy for maintenance of sinus rhythm. However, late recurrences are common and associated with more advanced atrial substrate associated with structural heart disease.<sup>436–446</sup>

It is in this context that it is important to consider the various types of underlying atrial cardiomyopathy and how they may affect ablation outcomes. This is timely, as it has recently been observed that lone AF is a rapidly disappearing entity as we recognize conditions such as sleep apnoea, obesity, endurance exercise etc. previously not suspected of being causally associated with atrial fibrillation.<sup>447</sup> In addition, emerging data suggest that treating these underlying causes may be central to improving long-term ablation outcomes.<sup>199,200,448,449</sup> In addition, LA ablation procedures may alter atrial size, structure, and mechanical atrial function. Catheter



ablation may thus influence ongoing pathologies and atrial thrombogenesis.<sup>450,451</sup>

Mapping studies have demonstrated a common electrophysiological endpoint for a range of such conditions affecting the atrium either primarily or secondarily, many of which have been shown to be associated with atrial remodelling characterized by conduction slowing and myocardial voltage reduction suggesting fibrosis.<sup>117,167,177,433,452,453</sup> Magnetic resonance imaging techniques attempting to characterize the extent of myocardial fibrosis have demonstrated that this appears to be the strongest independent predictor of AF recurrence after ablation.<sup>416,454</sup> Whether the EHRA classification has value for informing catheter ablation in human atria remains to be determined.

## Age and atrial fibrillation ablation

Increasing age has been shown to be associated with increasing atrial fibrosis in both basic and clinical studies.<sup>167,455</sup> Numerous studies have evaluated ablation outcomes in ageing patients (variously defined as >65 through to >80).<sup>444,445,456–462</sup> Observational studies have consistently reported high multiple procedure success rates at 12 months of up to 80% in older patients. Conflicting data exist regarding outcomes in comparative studies with one study demonstrating a reduced success rate in patients over 65 years while another study showed similar efficacy in patients over the age of 80 years to the younger cohort.<sup>461,463</sup>

## Hypertension

Hypertension is another well-recognized risk factor for development of atrial fibrillation. Mapping studies have demonstrated the presence of a more advanced atrial substrate in hypertensive patients compared with controls.<sup>177,464</sup> Hypertension has been shown to be a risk factor for recurrence of AF after AF ablation in numerous studies on univariate analysis, but it is less clear whether this is independent of factors such as atrial size. Recent preliminary studies have suggested that aggressive treatment of hypertension improves post-ablation outcomes.<sup>200,464,465</sup>

## Heart failure and atrial fibrillation ablation

Contractile dysfunction has similarly been associated with advanced atrial remodelling and predisposition to atrial fibrillation both in basic and in clinical studies.<sup>113,433</sup> Numerous studies have evaluated the efficacy of catheter ablation of both paroxysmal and persistent atrial fibrillation with significant impairment of systolic function.<sup>437,466–473</sup> The weight of evidence is that sinus rhythm can be successfully achieved in 50–80% of patients although repeat procedures are common and follow-up periods are usually not more than 12 months. Successful ablation has been associated with significant improvements in ejection fraction and reduction in atrial size in the majority of studies.<sup>470,474</sup>

## Metabolic syndrome and obesity

A number of studies have evaluated the impact of the metabolic syndrome on catheter ablation outcomes in atrial fibrillation patients.<sup>475–480</sup> Although the data are mixed, the weight of studies and a systematic review<sup>477</sup> suggest a higher risk of AF recurrence. In the ARREST AF study, patients with BMI over 27 undergoing AF ablation had a much lower risk of recurrence if weight loss

was achieved and maintained.<sup>200</sup> Observational studies have demonstrated a significantly lower risk of recurrent AF in patients with treated compared with untreated OSA.<sup>481</sup>

## Impact of diabetes on ablation outcomes

Several studies have documented an increased recurrence rate of atrial fibrillation after an ablation procedure in patients with diabetes mellitus.<sup>204,475,482</sup> An abnormal atrial substrate and non-PV triggers have been shown to underlie this worse outcome.

## Role of myocarditis

Markers of inflammation such as CRP and IL-6 have been linked to risk of AF.<sup>267,483–485</sup> Recently, giant-cell myocarditis involving only the atria has been shown to result in atrial fibrillation with enlarged atria.<sup>149</sup> Patients with apparently lone atrial fibrillation frequently demonstrate histological findings consistent with an atrial myocarditis,<sup>486</sup> and those with past myocarditis may have atrial electrical scar, conduction abnormalities, or atrial standstill.<sup>146,487–489</sup> Baseline CRP levels have been associated with the risk of recurrent AF after catheter ablation.<sup>278</sup> Recently, colchicine has been used to prevent atrial fibrillation recurrence after PV isolation.<sup>490</sup> It is also possible that AF in itself can result in inflammation and the development of an 'atrial myocarditis'.<sup>491</sup>

## Impact of atrial fibrillation duration on atrial myopathy and atrial fibrillation ablation outcomes

Longitudinal studies in AF patients have demonstrated clinical progression of AF over time in a significant proportion with risk strongly associated with drivers such as increasing age, structural heart disease, and hypertension.<sup>492</sup> Chronic AF results in structural change with a recent study showing that in proportion to AF burden, atrial remodelling may progress significantly even over a time period as short as 1 year.

Numerous studies have demonstrated that atrial size and occasionally mechanical function may improve following ablation,<sup>493</sup> but at least one invasive study showed no improvement in atrial electrophysiology 6 months after successful ablation.<sup>219</sup> Overwhelmingly, studies evaluating long-term outcomes after ablation of persistent atrial fibrillation have demonstrated lower rates of procedural reversion to sinus rhythm and higher late recurrence rates reflecting more advanced atrial substrate.

## Impact of ongoing atrial fibrillation on electrical and structural remodelling

It is now well known that in the presence of an appropriate heterogeneous AF substrate, a focal trigger can result in sustained high-frequency re-entrant AF drivers, named rotors. The waves that emerge from these rotors undergo spatially distributed fragmentation and so give rise to fibrillatory conduction. When high-frequency atrial activation is maintained for at least 24 h, ion-channel remodelling changes the electrophysiologic substrate, promoting perpetuation of re-entry and increasing the activity of triggers, further contributing to AF permanence.<sup>494</sup> Atrial fibrillation itself leads to remodelling, causing electrophysiological (electrical), contractile, and structural changes.<sup>495,496</sup> Although AF can typically be reversed

in its early stages, it becomes more difficult to eliminate over time due to such remodelling.<sup>238,497</sup> Dominant-frequency analysis points to an evolution of mechanisms in AF patients, with PV sources becoming less predominant as AF becomes more persistent and atrial remodelling progresses.<sup>498</sup> The data suggest that in patients with long-standing persistent AF, atrial remodelling augments the number of AF drivers and shifts their location away from the PV/ostial region.

## Impact of catheter ablation on atrial pathology

Several studies have examined LA size before and after catheter ablation and have demonstrated a 10–20% decrease in the dimensions of the LA after catheter ablation of AF.<sup>499,500</sup> Although the precise mechanism of this decrease in size is not known, it appears consistent with reverse remodelling. It has been suggested that earlier aggressive intervention to maintain sinus rhythm, including AF ablation if needed, may aid to prevent ‘chronicization’ of AF and improve long-term outcomes.<sup>501</sup> A large-scale multicentre trial is presently testing this idea.<sup>502</sup>

The true impact of atrial cardiomyopathies on the success of catheter ablation has not been elucidated. Nevertheless, it is very likely that atrial pathology affects energy delivery to tissue and specific forms of cardiomyopathy may differentially affect ablation procedures. However, the true impact and interaction of various energy sources with different atrial pathologies need to be studied.

## Conclusion

Atrial cardiomyopathies as defined in this consensus paper have a significant impact on atrial function and arrhythmogenesis. The EHRAS classification (EHRAS Class I–IV) is a first attempt to characterize atrial pathologies into discrete cohorts. Because disease-related histological changes in atrial tissue are often poorly characterized, not necessarily specific and vary considerably over time their classification is challenging. Further studies are needed to implement and validate the EHRAS classification and to assess its value in guiding clinical understanding and management of AF. Nevertheless, a more precise, defined classification of atrial pathologies may contribute to establishing an individualized approach to AF therapy, which might improve therapeutic outcomes.

## Supplementary material

Supplementary material is available at *Europace* online.

**Conflict of interest:** A detailed list of disclosures of financial relations is provided as Supplementary material online.

## References

- Hoit BD. Left atrial size and function: role in prognosis. *J Am Coll Cardiol* 2014;**63**: 493–505.
- Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. *Physiol Rev* 2011;**91**:265–325.
- Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. *Circ Res* 2014;**114**:1453–68.
- Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. *Circulation* 2008;**117**:1630–41.
- Davies MJ, Pomerance A. Pathology of atrial fibrillation in man. *Br Heart J* 1972;**34**: 520–5.
- Sims BA. Pathogenesis of atrial arrhythmias. *Br Heart J* 1972;**34**:336–40.
- Tucker NR, Ellinor PT. Emerging directions in the genetics of atrial fibrillation. *Circ Res* 2014;**114**:1469–82.
- Goette A, Bukowska A, Dobrev D, Pfeifferberger J, Morawietz H, Strugala D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. *Eur Heart J* 2009;**30**:1411–20.
- Corradi D. Atrial fibrillation from the pathologist's perspective. *Cardiovasc Pathol* 2014;**23**:71–84.
- Corradi D, Callegari S, Maestri R, Benussi S, Alfieri O. Structural remodeling in atrial fibrillation. *Nat Clin Pract Cardiovasc Med* 2008;**5**:782–96.
- Corradi D, Callegari S, Benussi S, Maestri R, Pastori P, Nascimbene S et al. Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. *Hum Pathol* 2005;**36**:1080–9.
- Corradi D, Callegari S, Maestri R, Ferrara D, Mangieri D, Alinovi R et al. Differential structural remodeling of the left-atrial posterior wall in patients affected by mitral regurgitation with or without persistent atrial fibrillation: a morphological and molecular study. *J Cardiovasc Electrophysiol* 2012;**23**:271–9.
- Ausma J, Wjiffels M, Thone F, Wouters L, Allesie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. *Circulation* 1997;**96**:3157–63.
- Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation* 1997;**96**:1180–4.
- Ausma J, Wjiffels M, van Eys G, Koide M, Ramaekers F, Allesie M et al. Dedifferentiation of atrial cardiomyocytes as a result of chronic atrial fibrillation. *Am J Pathol* 1997;**151**:985–97.
- Corradi D, Callegari S, Benussi S, Nascimbene S, Pastori P, Calvi S et al. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. *Virchows Arch* 2004;**445**:498–505.
- Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. *Circulation* 2002;**106**:2091–7.
- Kushnir A, Restaino SW, Yuzefpolskaya M. Giant cell arteritis as a cause of myocarditis and atrial fibrillation. *Circ Heart Fail* 2016;**9**:e002778.
- Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, te Riele AS et al. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Heart Rhythm* 2013;**10**:1661–8.
- Cabrera JA, Sanchez-Quintana D. Cardiac anatomy: what the electrophysiologist needs to know. *Heart* 2013;**99**:417–31.
- Ho SY, Cabrera JA, Sanchez-Quintana D. Left atrial anatomy revisited. *Circ Arrhythm Electrophysiol* 2012;**5**:220–8.
- Sanchez-Quintana D, Anderson RH, Cabrera JA, Climent V, Martin R, Farre J et al. The terminal crest: morphological features relevant to electrophysiology. *Heart* 2002;**88**:406–11.
- Cabrera JA, Ho SY, Climent V, Sanchez-Quintana D. The architecture of the left lateral atrial wall: a particular anatomic region with implications for ablation of atrial fibrillation. *Eur Heart J* 2008;**29**:356–62.
- Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. *J Am Coll Cardiol* 2012;**60**:531–8.
- Ho SY, Anderson RH, Sanchez-Quintana D. Atrial structure and fibres: morphologic bases of atrial conduction. *Cardiovasc Res* 2002;**54**:325–36.
- Spach MS, Kootsey JM. The nature of electrical propagation in cardiac muscle. *Am J Physiol* 1983;**244**:H3–22.
- Veinot J, Ghadially F, Walley V. Light microscopy and ultrastructure of the blood vessels and heart. In: Silver M, Gotlieb A, Schoen F, eds. *Cardiovascular Pathology*. New York: Churchill Livingstone; 2001. p30–53.
- Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. *Circulation* 1994;**89**:151–63.
- Lannigan RA, Zaki SA. Ultrastructure of the myocardium of the atrial appendage. *Br Heart J* 1966;**28**:796–807.
- Armiger LC, Seelye RN, Morrison MA, Holliss DG. Comparative biochemistry and fine structure of atrial and ventricular myocardium during autolysis in vitro. *Basic Res Cardiol* 1984;**79**:218–29.
- Corradi D, Maestri R, Macchi E, Callegari S. The atria: from morphology to function. *J Cardiovasc Electrophysiol* 2011;**22**:223–35.
- Kitzman DW, Edwards WD. Age-related changes in the anatomy of the normal human heart. *J Gerontol* 1990;**45**:M33–9.
- Yamasaki Y, Furuya Y, Araki K, Matsuura K, Kobayashi M, Ogata T. Ultra-high-resolution scanning electron microscopy of the sarcoplasmic reticulum of the rat atrial myocardial cells. *Anat Rec* 1997;**248**:70–5.

34. Mackenzie L, Roderick HL, Berridge MJ, Conway SJ, Bootman MD. The spatial pattern of atrial cardiomyocyte calcium signalling modulates contraction. *J Cell Sci* 2004;**117**:6327–37.
35. Sanchez-Quintana D, Lopez-Minguez JR, Macias Y, Cabrera JA, Saremi F. Left atrial anatomy relevant to catheter ablation. *Cardiol Res Pract* 2014;**2014**:289720.
36. Ehrlich JR, Biliczki P, Hohnloser SH, Nattel S. Atrial-selective approaches for the treatment of atrial fibrillation. *J Am Coll Cardiol* 2008;**51**:787–92.
37. Schram G, Pourrier M, Melnyk P, Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. *Circ Res* 2002;**90**:939–50.
38. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. *Circulation* 2007;**116**:1449–57.
39. Feng J, Yue L, Wang Z, Nattel S. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. *Circ Res* 1998;**83**:541–51.
40. Gemel J, Levy AE, Simon AR, Bennett KB, Ai X, Akhter S et al. Connexin40 abnormalities and atrial fibrillation in the human heart. *J Mol Cell Cardiol* 2014;**76**:159–68.
41. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest* 2011;**121**:2955–68.
42. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. *Circulation* 2011;**124**:2264–74.
43. Butters TD, Aslanidi OV, Zhao J, Smail B, Zhang H. A novel computational sheep atria model for the study of atrial fibrillation. *Interface Focus* 2013;**3**:20120067.
44. McDowell KS, Zahid S, Vadakkumpadan F, Blauer J, MacLeod RS, Trayanova NA. Virtual electrophysiological study of atrial fibrillation in fibrotic remodeling. *PLoS One* 2015;**10**:e0117110.
45. Saffitz JE, Kanter HL, Green KG, Tolley TK, Beyer EC. Tissue-specific determinants of anisotropic conduction velocity in canine atrial and ventricular myocardium. *Circ Res* 1994;**74**:1065–70.
46. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. *Circ Res* 2014;**114**:1500–15.
47. Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A et al. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. *Circulation* 2008;**117**:470–7.
48. Nattel S, Shiroshita-Takeshita A, Cardin S, Pelletier P. Mechanisms of atrial remodeling and clinical relevance. *Curr Opin Cardiol* 2005;**20**:21–5.
49. Hoit BD, Shao Y, Gabel M, Walsh RA. In vivo assessment of left atrial contractile performance in normal and pathological conditions using a time-varying elastance model. *Circulation* 1994;**89**:1829–38.
50. Pagel PS, Kehl F, Gare M, Hettrick DA, Kersten JR, Wartier DC. Mechanical function of the left atrium: new insights based on analysis of pressure-volume relations and Doppler echocardiography. *Anesthesiology* 2003;**98**:975–94.
51. Vieira MJ, Teixeira R, Goncalves L, Gersh BJ. Left atrial mechanics: echocardiographic assessment and clinical implications. *J Am Soc Echocardiogr* 2014;**27**:463–78.
52. Hoit BD, Walsh RA. Regional atrial distensibility. *Am J Physiol* 1992;**262**:H1356–60.
53. Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovsky EG, Vijayakumar S et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. *Circ Cardiovasc Imaging* 2010;**3**:231–9.
54. Hitch DC, Nolan SP. Descriptive analysis of instantaneous left atrial volume—with special reference to left atrial function. *J Surg Res* 1981;**30**:110–20.
55. Bootman MD, Higazi DR, Coombes S, Roderick HL. Calcium signalling during excitation-contraction coupling in mammalian atrial myocytes. *J Cell Sci* 2006;**119**:3915–25.
56. Tanaami T, Ishida H, Seguchi H, Hirota Y, Kadono T, Genka C et al. Difference in propagation of  $Ca^{2+}$  release in atrial and ventricular myocytes. *Jpn J Physiol* 2005;**55**:81–91.
57. Boknik P, Unkel C, Kirchhefer U, Kleideiter U, Klein-Wiele O, Knapp J et al. Regional expression of phospholamban in the human heart. *Cardiovasc Res* 1999;**43**:67–76.
58. Maier LS, Barckhausen P, Weisser J, Aleksic I, Baryalei M, Pieske B.  $Ca^{2+}$  handling in isolated human atrial myocardium. *Am J Physiol Heart Circ Physiol* 2000;**279**:H952–8.
59. Luss I, Boknik P, Jones LR, Kirchhefer U, Knapp J, Linck B et al. Expression of cardiac calcium regulatory proteins in atrium v ventricle in different species. *J Mol Cell Cardiol* 1999;**31**:1299–314.
60. Babu GJ, Bhupathy P, Timofeyev V, Petrashevskaya NN, Reiser PJ, Chiamvimonvat N et al. Ablation of sarcolipin enhances sarcoplasmic reticulum calcium transport and atrial contractility. *Proc Natl Acad Sci USA* 2007;**104**:17867–72.
61. Li GR, Nattel S. Properties of human atrial ICa at physiological temperatures and relevance to action potential. *Am J Physiol* 1997;**272**:H227–35.
62. Cote K, Proteau S, Teijeira J, Rousseau E. Characterization of the sarcoplasmic reticulum  $k^{+}$  and  $Ca^{2+}$ -release channel-ryanodine receptor-in human atrial cells. *J Mol Cell Cardiol* 2000;**32**:2051–63.
63. Wang J, Schwinger RH, Frank K, Muller-Ehmsen J, Martin-Vasallo P, Pressley TA et al. Regional expression of sodium pump subunits isoforms and  $Na^{+}$ - $Ca^{2+}$  exchanger in the human heart. *J Clin Invest* 1996;**98**:1650–8.
64. Richards MA, Clarke JD, Saravanan P, Voigt N, Dobrev D, Eisner DA et al. Transverse tubules are a common feature in large mammalian atrial myocytes including human. *Am J Physiol Heart Circ Physiol* 2011;**301**:H1996–2005.
65. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Illstrup DM et al. The natural history of lone atrial fibrillation. A population-based study over three decades. *N Engl J Med* 1987;**317**:669–74.
66. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2011;**123**:e269–367.
67. Potpara TS, Lip GY. Lone atrial fibrillation: what is known and what is to come. *Int J Clin Pract* 2011;**65**:446–57.
68. Potpara TS, Lip GY. Lone atrial fibrillation—an overview. *Int J Clin Pract* 2014;**68**:418–33.
69. Weijs B, Pisters R, Nieuwlaar R, Breithardt G, Le Heuzey JY, Vardas PE et al. Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. *Europace* 2012;**14**:184–90.
70. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. *Circulation* 1990;**82**:792–7.
71. Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. *Chest* 2012;**141**:339–47.
72. Osranek M, Bursi F, Bailey KR, Grossardt BR, Brown RD Jr, Kopecky SL et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. *Eur Heart J* 2005;**26**:2556–61.
73. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. *Circulation* 2007;**115**:3050–6.
74. Stiles MK, John B, Wong CX, Kuklik P, Brooks AG, Lau DH et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the “second factor”. *J Am Coll Cardiol* 2009;**53**:1182–91.
75. Skaliadis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. *J Am Coll Cardiol* 2008;**51**:2053–7.
76. Corradi D, Callegari S, Manotti L, Ferrara D, Goldoni M, Alinovi R et al. Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. *Heart Rhythm* 2014;**11**:1250–8.
77. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction. *N Engl J Med* 2013;**368**:1755.
78. Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. *Cardiovasc Pathol* 2006;**15**:287–90.
79. Steiner I. The prevalence of isolated atrial amyloid. *J Pathol* 1987;**153**:395–8.
80. Looi LM. Isolated atrial amyloidosis: a clinicopathologic study indicating increased prevalence in chronic heart disease. *Hum Pathol* 1993;**24**:602–7.
81. Johansson B, Wernstedt C, Westermark P. Atrial natriuretic peptide deposited as atrial amyloid fibrils. *Biochem Biophys Res Commun* 1987;**148**:1087–92.
82. Louros NN, Ionomidou VA, Tsiolaki PL, Chrysina ED, Baltatzis GE, Patsouris ES et al. An N-terminal pro-atrial natriuretic peptide (NT-proANP) ‘aggregation-prone’ segment involved in isolated atrial amyloidosis. *FEBS Lett* 2014;**588**:52–7.
83. Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. *Eur Heart J* 2004;**25**:1237–41.
84. Steiner I, Hajkova P, Kvasnicka J, Kholova I. Myocardial sleeves of pulmonary veins and atrial fibrillation: a postmortem histopathological study of 100 subjects. *Virchows Arch* 2006;**449**:88–95.
85. Knowles TP, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. *Nat Rev Mol Cell Biol* 2014;**15**:384–96.
86. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction—Alzheimer’s disease of the heart? *N Engl J Med* 2013;**368**:455–64.
87. McLendon PM, Robbins J. Desmin-related cardiomyopathy: an unfolding story. *Am J Physiol Heart Circ Physiol* 2011;**301**:H1220–8.
88. Sidorova TN, Mace LC, Wells KS, Yermaltitskaya LV, Su PF, Shyr Y et al. Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology? *J Am Heart Assoc* 2014;**3**:e001384.



89. Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. *Eur Heart J* 2014;**35**:419–25.
90. Hua R, MacLeod SL, Polina I, Moghtadaei M, Jansen HJ, Bogachev O *et al*. Effects of wild-type and mutant forms of atrial natriuretic peptide on atrial electrophysiology and arrhythmogenesis. *Circ Arrhythm Electrophysiol* 2015;**8**:1240–54.
91. Moghtadaei M, Polina I, Rose RA. Electrophysiological effects of natriuretic peptides in the heart are mediated by multiple receptor subtypes. *Prog Biophys Mol Biol* 2016;**120**:37–49.
92. Gardner DG, Chen S, Glenn DJ, Grigsby CL. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. *Hypertension* 2007;**49**:419–26.
93. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. *IUBMB Life* 2002;**53**:153–9.
94. Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun A *et al*. A gain-of-function TBX5 mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. *Circ Res* 2008;**102**:1433–42.
95. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ *et al*. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. *N Engl J Med* 2008;**359**:158–65.
96. Perrin MJ, Gollob MH. The role of atrial natriuretic peptide in modulating cardiac electrophysiology. *Heart Rhythm* 2012;**9**:610–5.
97. Abraham RL, Yang T, Blair M, Roden DM, Darbar D. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. *J Mol Cell Cardiol* 2010;**48**:181–190.
98. Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S *et al*. Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. *J Am Coll Cardiol* 2012;**60**:1173–81.
99. Disertori M, Quintarelli S, Grasso M, Pilotto A, Narula N, Favalli V *et al*. Autosomal recessive atrial dilated cardiomyopathy with standstill evolution associated with mutation of Natriuretic Peptide Precursor A. *Circ Cardiovasc Genet* 2013;**6**:27–36.
100. Disertori M, Mase M, Marini M, Mazzola S, Cristoforetti A, Del Greco M *et al*. Electroanatomic mapping and late gadolinium enhancement MRI in a genetic model of arrhythmogenic atrial cardiomyopathy. *J Cardiovasc Electrophysiol* 2014;**25**:964–70.
101. Wallace GQ, McNally EM. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. *Annu Rev Physiol* 2009;**71**:37–57.
102. Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG. Hereditary muscular dystrophies and the heart. *Neuromuscul Disord* 2010;**20**:479–92.
103. Groh WJ. Arrhythmias in the muscular dystrophies. *Heart Rhythm* 2012;**9**:1890–5.
104. Diegoli M, Grasso M, Favalli V, Serio A, Gambarin FI, Klersy C *et al*. Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects. *J Am Coll Cardiol* 2011;**58**:925–34.
105. Townsend D, Yasuda S, McNally E, Metzger JM. Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. *FASEB J* 2011;**25**:3106–14.
106. Finsterer J, Stollberger C. Stroke in myopathies. *Cerebrovasc Dis* 2010;**29**:6–13.
107. Finsterer J, Stollberger C. Atrial fibrillation/flutter in myopathies. *Int J Cardiol* 2008;**128**:304–10.
108. Petri H, Vissing J, Witting N, Bundgaard H, Kober L. Cardiac manifestations of myotonic dystrophy type 1. *Int J Cardiol* 2012;**160**:82–8.
109. Bhakta D, Shen C, Kron J, Epstein AE, Pascuzzi RM, Groh WJ. Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population. *J Cardiovasc Electrophysiol* 2011;**22**:1369–75.
110. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Cialfoni E *et al*. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. *N Engl J Med* 2008;**358**:2688–97.
111. Boriani G, Gallina M, Merlini L, Bonne G, Toniolo D, Amati S *et al*. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study. *Stroke* 2003;**34**:901–8.
112. Trevisan CP, Pastorello E, Armani M, Angelini C, Nante G, Tomelleri G *et al*. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. *Eur Neurol* 2006;**56**:1–5.
113. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation* 1999;**100**:87–95.
114. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A *et al*. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. *Circulation* 2000;**101**:2631–8.
115. Yeh YH, Wakili R, Qi XY, Chartier D, Boknik P, Kaab S *et al*. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. *Circ Arrhythm Electrophysiol* 2008;**1**:93–102.
116. Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. *Circ Res* 2014;**114**:1483–99.
117. Dimitri H, Ng M, Brooks AG, Kuklik P, Stiles MK, Lau DH *et al*. Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. *Heart Rhythm* 2012;**9**:321–7.
118. Maeno K, Kasai T, Kasagi S, Kawana F, Ishiwata S, Ohno M *et al*. Relationship between atrial conduction delay and obstructive sleep apnea. *Heart Vessels* 2013;**28**:639–45.
119. Chami HA, Devereux RB, Gottdiener JS, Mehra R, Roman MJ, Benjamin EJ *et al*. Left ventricular morphology and systolic function in sleep-disordered breathing: the Sleep Heart Health Study. *Circulation* 2008;**117**:2599–607.
120. Maeno K, Kasagi S, Ueda A, Kawana F, Ishiwata S, Ohno M *et al*. Effects of obstructive sleep apnea and its treatment on signal-averaged P-wave duration in men. *Circ Arrhythm Electrophysiol* 2013;**6**:287–93.
121. Iwasaki YK, Kato T, Xiong F, Shi YF, Naud P, Maguy A *et al*. Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. *J Am Coll Cardiol* 2014;**64**:2013–23.
122. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. *Circ Res* 1997;**81**:512–25.
123. Qi XY, Yeh YH, Xiao L, Burstein B, Maguy A, Chartier D *et al*. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. *Circ Res* 2008;**103**:845–54.
124. Lenaerts I, Bito V, Heinzel FR, Driesen RB, Holemans P, D'Hooge J *et al*. Ultrastructural and functional remodeling of the coupling between  $Ca^{2+}$  influx and sarcoplasmic reticulum  $Ca^{2+}$  release in right atrial myocytes from experimental persistent atrial fibrillation. *Circ Res* 2009;**105**:876–85.
125. van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allesie MA *et al*. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. *Cardiovasc Res* 2000;**46**:476–86.
126. Martins RP, Kaur K, Hwang E, Ramirez RJ, Willis BC, Filgueiras-Rama D *et al*. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. *Circulation* 2014;**129**:1472–82.
127. Harada M, Luo X, Qi XY, Tadevosyan A, Maguy A, Ordog B *et al*. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. *Circulation* 2012;**126**:2051–64.
128. Du J, Xie J, Zhang Z, Tsujikawa H, Fusco D, Silverman D *et al*. TRPM7-mediated  $Ca^{2+}$  signals confer fibrogenesis in human atrial fibrillation. *Circ Res* 2010;**106**:992–1003.
129. Dobrev D, Graf E, Wettwer E, Himmel HM, Hala O, Doerfel C *et al*. Molecular basis of downregulation of G-protein-coupled inward rectifying  $K(+) current (I(K_{ACH})$  in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced  $I(K_{ACH})$  and muscarinic receptor-mediated shortening of action potentials. *Circulation* 2001;**104**:2551–7.
130. Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I *et al*. Enhanced sarcoplasmic reticulum  $Ca^{2+}$  leak and increased  $Na^{+}$ - $Ca^{2+}$  exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation* 2012;**125**:2059–70.
131. van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH. Drug-induced atrial fibrillation. *J Am Coll Cardiol* 2004;**44**:2117–24.
132. Tamargo J, Caballero R, Delpon E. Drug-induced atrial fibrillation: does it matter? *Discov Med* 2012;**14**:295–9.
133. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA *et al*. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *J Am Coll Cardiol* 2011;**57**:e101–98.
134. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH *et al*. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;**33**:2719–47.
135. Cooper L, Knowlton K. Myocarditis. In: Mann D, Bonow R, Zipes D, Libby P, Braunwald E, eds. *Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine*. 10th ed. Philadelphia, PA: Elsevier; 2015. p1589–602.
136. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB *et al*. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013;**34**:2636–48, 2648a–2648d.

137. Chandra N, Bastiaenen R, Papadakis M, Sharma S. Sudden cardiac death in young athletes: practical challenges and diagnostic dilemmas. *J Am Coll Cardiol* 2013;**61**: 1027–40.
138. Gore I, Saphir O. Myocarditis; a classification of 1402 cases. *Am Heart J* 1947;**34**: 827–30.
139. Basso C, Calabrese F, Corrado D, Thiene G. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings. *Cardiovasc Res* 2001;**50**:290–300.
140. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. *N Engl J Med* 1995;**333**:269–75.
141. Felker GM, Hu W, Hare JM, Hruban RH, Baughman KL, Kasper EK. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. *Medicine* 1999;**78**:270–83.
142. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. *Cardiovasc Pathol* 2012;**21**:245–74.
143. Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. *Circulation* 2005;**111**:887–93.
144. Frustaci A, Cameli S, Zeppilli P. Biopsy evidence of atrial myocarditis in an athlete developing transient sinoatrial disease. *Chest* 1995;**108**:1460–2.
145. Habara M, Fujieda H, Nakamura Y. Images in cardiology. Atrial myocarditis: a possible cause of idiopathic enlargement of bilateral atria. *Heart* 2006;**92**:842.
146. Fromer M, Genton C, Schlaepfer J, Goy JJ, Kappenberger L. Is there an isolated arrhythmogenic right atrial myocarditis? *Eur Heart J* 1990;**11**:566–71.
147. Hoyano M, Ito M, Kimura S, Tanaka K, Okamura K, Komura S et al. Inducibility of atrial fibrillation depends not on inflammation but on atrial structural remodeling in rat experimental autoimmune myocarditis. *Cardiovasc Pathol* 2010;**19**:e149–57.
148. McCrea PC, Childers RW. Two unusual cases of giant cell myocarditis associated with mitral stenosis and with Wegener's syndrome. *Br Heart J* 1964;**26**:490–8.
149. Larsen BT, Maleszewski JJ, Edwards WD, Cooper LT Jr, Sobonya RE, Thompson VE et al. Atrial giant cell myocarditis: a distinctive clinicopathologic entity. *Circulation* 2013;**127**:39–47.
150. Basso C, Thiene G. When giant cell myocarditis affects only the atria. *Circulation* 2013;**127**:8–9.
151. Groenewegen WA, Firouzi M, Bezzina CR, Vliex S, van Langen IM, Sandkuijl L et al. A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. *Circ Res* 2003;**92**:14–22.
152. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. *J Cardiovasc Electrophysiol* 2003;**14**:1027–33.
153. Junttila MJ, Tikkanen JT, Kenttä T, Anttonen O, Aro AL, Porthan K et al. Early repolarization as a predictor of arrhythmic and nonarrhythmic cardiac events in middle-aged subjects. *Heart Rhythm* 2014;**11**:1701–6.
154. Delaney JT, Muhammad R, Blair MA, Kor K, Fish FA, Roden DM et al. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. *Europace* 2012;**14**:1428–32.
155. Glancy DL, O'Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. *Br Heart J* 1970;**32**:652–9.
156. Olivetto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation* 2001;**104**:2517–24.
157. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. *Am J Cardiol* 2010;**106**:720–2.
158. Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T et al. Brugada syndrome and supraventricular tachyarrhythmias: a novel association? *J Cardiovasc Electrophysiol* 2001;**12**:680–5.
159. Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E et al. Atrial fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, management, and correlation with prognosis. *Heart Rhythm* 2014;**11**: 259–65.
160. Haugaa KH, Johnson JN, Bos JM, Phillips BL, Eidem BW, Ackerman MJ. Subclinical cardiomyopathy and long QT syndrome: an echocardiographic observation. *Conduit Heart Dis* 2013;**8**:352–9.
161. Olesen MS, Holst AG, Svendsen JH, Haunso S, Tfelt-Hansen J. SCN1Bb R214Q found in 3 patients: 1 with Brugada syndrome and 2 with lone atrial fibrillation. *Heart Rhythm* 2012;**9**:770–3.
162. Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB et al. High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. *Circ Cardiovasc Genet* 2012;**5**:450–9.
163. Lemoine MD, Duverger JE, Naud P, Chartier D, Qi XY, Comtois P et al. Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. *Cardiovasc Res* 2011;**92**:67–74.
164. Sumitomo N, Sakurada H, Taniguchi K, Matsumura M, Abe O, Miyashita M et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. *Circ J* 2007;**71**:1606–9.
165. Anyukhovsky EP, Sosunov EA, Chandra P, Rosen TS, Boyden PA, Danilo P Jr et al. Age-associated changes in electrophysiologic remodeling: a potential contributor to initiation of atrial fibrillation. *Cardiovasc Res* 2005;**66**:353–63.
166. Anyukhovsky EP, Sosunov EA, Plotnikov A, Gainullin RZ, Jhang JS, Marboe CC et al. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. *Cardiovasc Res* 2002;**54**:462–9.
167. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. *J Am Coll Cardiol* 2004;**44**:109–16.
168. Roberts-Thomson KC, Kistler PM, Sanders P, Morton JB, Haqqani HM, Stevenson I et al. Fractionated atrial electrograms during sinus rhythm: relationship to age, voltage, and conduction velocity. *Heart Rhythm* 2009;**6**:587–91.
169. Kojodjojo P, Kanagaratnam P, Markides V, Davies DW, Peters N. Age-related changes in human left and right atrial conduction. *J Cardiovasc Electrophysiol* 2006;**17**:120–7.
170. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011;**123**:1501–8.
171. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: predictors and outcome. *Hypertension* 2003;**41**: 218–23.
172. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. *Am Heart J* 2000;**139**:814–9.
173. Kim SJ, Choisy SC, Barman P, Zhang H, Hancox JC, Jones SA et al. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. *Circ Arrhythm Electrophysiol* 2011;**4**:761–9.
174. Kistler PM, Sanders P, Dodic M, Spence SJ, Samuel CS, Zhao C et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. *Eur Heart J* 2006;**27**:3045–56.
175. Lau DH, Mackenzie L, Kelly DJ, Psaltis PJ, Brooks AG, Worthington M et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. *Heart Rhythm* 2010;**7**:1282–90.
176. Lau DH, Mackenzie L, Kelly DJ, Psaltis PJ, Worthington M, Rajendram A et al. Short-term hypertension is associated with the development of atrial fibrillation substrate: a study in an ovine hypertensive model. *Heart Rhythm* 2010;**7**:396–404.
177. Medi C, Kalman JM, Spence SJ, Teh AV, Lee G, Bader I et al. Atrial electrical and structural changes associated with longstanding hypertension in humans: implications for the substrate for atrial fibrillation. *J Cardiovasc Electrophysiol* 2011;**22**: 1317–24.
178. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. *Circulation* 2009;**119**:2146–52.
179. Kimura S, Ito M, Tomita M, Hoyano M, Obata H, Ding L et al. Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. *Hypertens Res* 2011;**34**:584–91.
180. Matsuyama N, Tsutsumi T, Kubota N, Nakajima T, Suzuki H, Takeyama Y. Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats. *Hypertens Res* 2009;**32**: 721–6.
181. Fogari R, Zoppi A, Maffioli P, Mugellini A, Preti P, Perrone T et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. *Clin Cardiol* 2012;**35**:359–64.
182. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). *J Am Coll Cardiol* 2010;**55**:2319–27.
183. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. *J Am Coll Cardiol* 2007;**49**:565–71.
184. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS et al. Obesity and the risk of new-onset atrial fibrillation. *JAMA* 2004;**292**:2471–7.
185. Wong CX, Sun M, Mahajan R, Pathak RK, Middeldorp ME, Twomey D et al. Obesity and the risk of incident, post-operative and post ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. *JACC Clin Electrophysiol* 2015;**1**: 139–52.

186. Di Salvo G, Pacileo G, Del Giudice EM, Natale F, Limongelli G, Verrengia M *et al.* Atrial myocardial deformation properties in obese nonhypertensive children. *J Am Soc Echocardiogr* 2008;**21**:151–6.
187. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M *et al.* Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. *Heart Rhythm* 2013;**10**:90–100.
188. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood J *et al.* Electrophysiological, electroanatomical and structural remodeling of the atria as a consequence of sustained obesity. *J Am Coll Cardiol* 2015;**66**:1–11.
189. Munger TM, Dong YX, Masaki M, Oh JK, Mankad SV, Borlaug BA *et al.* Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. *J Am Coll Cardiol* 2012;**60**:851–60.
190. Mahajan R, Nelson A, Wong CX, Williams K, Teo K, Twomey D *et al.* Epicardial fat depots and atrial remodeling in obese patients with atrial fibrillation: evidence for a direct pathogenic role. *Heart Rhythm* 2015;**12**:S81–2.
191. Wong CX, Abed HS, Molaei P, Nelson AJ, Brooks AG, Sharma G *et al.* Pericardial fat is associated with atrial fibrillation severity and ablation outcome. *J Am Coll Cardiol* 2011;**57**:1745–51.
192. Al Chekakie MO, Welles CC, Metoyer R, Ibrahim A, Shapira AR, Cytron J *et al.* Pericardial fat is independently associated with human atrial fibrillation. *J Am Coll Cardiol* 2010;**56**:784–8.
193. Maesen B, Zeemering S, Afonso C, Eckstein J, Burton RA, van Hunnik A *et al.* Re-arrangement of atrial bundle architecture and consequent changes in anisotropy of conduction constitute the 3-dimensional substrate for atrial fibrillation. *Circ Arrhythm Electrophysiol* 2013;**6**:967–75.
194. Eckstein J, Zeemering S, Linz D, Maesen B, Verheule S, van Hunnik A *et al.* Transmural conduction is the predominant mechanism of breakthrough during atrial fibrillation: evidence from simultaneous endo-epicardial high-density activation mapping. *Circ Arrhythm Electrophysiol* 2013;**6**:334–41.
195. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F *et al.* Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokinases. *Eur Heart J* 2015;**36**:795–805a.
196. Mahajan R, Brooks AG, Shipp NJ, Thanigaimani S, Alasady M, Roberts-Thomson KC *et al.* Epicardial and endocardial differences in electrophysiological remodeling of atria due to obesity and weight reduction. *Heart Rhythm* 2013;**10**:401.
197. Pathak RK, Middeldorp ME, Meredith M, Stolcman S, Willoughby SG, Mahajan R *et al.* Aggressive Risk factor REduction STudy: implications for the substrate for Atrial Fibrillation (ARREST-AF Substrate Study). *Heart Rhythm* 2015;**12**:S57–96.
198. Gaborit B, Jacquier A, Kober F, Abdesselam I, Cuisset T, Boullu-Ciocca S *et al.* Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. *J Am Coll Cardiol* 2012;**60**:1381–9.
199. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX *et al.* Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). *J Am Coll Cardiol* 2015;**65**:2159–69.
200. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D *et al.* Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol* 2014;**64**:2222–31.
201. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME *et al.* Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA* 2013;**310**:2050–60.
202. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol* 2011;**108**:56–62.
203. Kato T, Yamashita T, Sekiguchi A, Sagara K, Takamura M, Takata S *et al.* What are arrhythmogenic substrates in diabetic rat atria? *J Cardiovasc Electrophysiol* 2006;**17**:890–4.
204. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF *et al.* Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. *Am J Cardiol* 2010;**106**:1615–20.
205. Shigematsu Y, Norimatsu S, Ogimoto A, Ohtsuka T, Okayama H, Higaki J. The influence of insulin resistance and obesity on left atrial size in Japanese hypertensive patients. *Hypertens Res* 2009;**32**:500–4.
206. Celentano A, Vaccaro O, Tammaro P, Galderisi M, Crivaro M, Oliviero M *et al.* Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. *Am J Cardiol* 1995;**76**:1173–6.
207. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neuffer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. *J Am Coll Cardiol* 2009;**54**:1891–8.
208. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M *et al.* AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. *J Cardiovasc Electrophysiol* 2008;**19**:415–20.
209. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. *Circ Res* 2001;**89**:684–91.
210. Mitaskova M, Lin H, Soukup T, Imanaga I, Tribulova N. Diabetes and thyroid hormones affect connexin-43 and PKC-epsilon expression in rat heart atria. *Physiol Res* 2009;**58**:211–7.
211. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC *et al.* A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. *Circ Res* 2003;**92**:785–92.
212. Watanabe M, Yokoshiki H, Mitsuyama H, Mizukami K, Ono T, Tsutsui H. Conduction and refractory disorders in the diabetic atrium. *Am J Physiol Heart Circ Physiol* 2012;**303**:H86–95.
213. Shimano M, Tsuji Y, Inden Y, Kitamura K, Uchikawa T, Harata S *et al.* Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. *Heart Rhythm* 2008;**5**:451–9.
214. Selzer A, Cohn KE. Natural history of mitral stenosis: a review. *Circulation* 1972;**45**:878–90.
215. John B, Stiles MK, Kuklik P, Chandy ST, Young GD, Mackenzie L *et al.* Electrical remodelling of the left and right atria due to rheumatic mitral stenosis. *Eur Heart J* 2008;**29**:2234–43.
216. Thiedemann KU, Ferrans VJ. Left atrial ultrastructure in mitral valvular disease. *Am J Pathol* 1977;**89**:575–604.
217. Anne W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P *et al.* Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. *Cardiovasc Res* 2005;**67**:655–66.
218. John B, Stiles MK, Kuklik P, Brooks AG, Chandy ST, Kalman JM *et al.* Reverse remodeling of the atria after treatment of chronic stretch in humans: implications for the atrial fibrillation substrate. *J Am Coll Cardiol* 2010;**55**:1217–26.
219. Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ *et al.* Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. *Heart Rhythm* 2012;**9**:473–80.
220. Carver W, Nagpal ML, Nachtigal M, Borg TK, Terracio L. Collagen expression in mechanically stimulated cardiac fibroblasts. *Circ Res* 1991;**69**:116–22.
221. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G *et al.* Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. *Heart* 2004;**90**:400–5.
222. Verheule S, Wilson E, Everett T IV, Shanbhag S, Golden C, Olgin J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. *Circulation* 2003;**107**:2615–22.
223. Chang JP, Tsai TH, Chen YL, Wang YH, Ho WC, Yu GH *et al.* Left atrial enlargement induced by pure mitral regurgitation: time frame in a new swine model. *Eur Surg Res* 2010;**45**:98–104.
224. Chen MC, Chang JP, Huang SC, Chang HW, Chen CJ, Yang CH *et al.* Dedifferentiation of atrial cardiomyocytes in cardiac valve disease: unrelated to atrial fibrillation. *Cardiovasc Pathol* 2008;**17**:156–65.
225. Chen MC, Chang JP, Chang TH, Hsu SD, Huang HD, Ho WC *et al.* Unraveling regulatory mechanisms of atrial remodeling of mitral regurgitation pigs by gene expression profiling analysis: role of type I angiotensin II receptor antagonist. *Transl Res* 2015;**165**:599–620.
226. Chang JP, Chen MC, Liu WH, Yang CH, Chen CJ, Chen YL *et al.* Atrial myocardial Nox2 containing NADPH oxidase activity contribution to oxidative stress in mitral regurgitation: potential mechanism for atrial remodeling. *Cardiovasc Pathol* 2011;**20**:99–106.
227. Le Bihan DC, Della Tognia DJ, Barretto RB, Assef JE, Machado LR, Ramos AI *et al.* Early improvement in left atrial remodeling and function after mitral valve repair or replacement in organic symptomatic mitral regurgitation assessed by three-dimensional echocardiography. *Echocardiography* 2015;**32**:1122–30.
228. Dardas PS, Pitsis AA, Tsikaderis DD, Mezilis NE, Geleris PN, Boudoulas HK. Left atrial volumes, function and work before and after mitral valve repair in chronic mitral regurgitation. *J Heart Valve Dis* 2004;**13**:27–32.
229. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M *et al.* Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. *Am Heart J* 2005;**149**:489–96.
230. Triposkiadis F, Pitsavos C, Boudoulas H, Trikas A, Kallikazaros I, Stefanadis C *et al.* Left atrial volume and function in valvular aortic stenosis. *J Heart Valve Dis* 1993;**2**:104–13.
231. Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM *et al.* Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. *Circulation* 2003;**107**:1884–90.



232. Yilmaz MB, Erbay AR, Balci M, Guray Y, Cihan G, Guray U et al. Atrial natriuretic peptide predicts impaired atrial remodeling and occurrence of late postoperative atrial fibrillation after surgery for symptomatic aortic stenosis. *Cardiology* 2006; **105**:207–12.
233. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation* 2014; **129**:837–47.
234. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. *Am Heart J* 1959; **58**:59–70.
235. Allesie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL et al. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. *Circ Arrhythm Electrophysiol* 2010; **3**:606–15.
236. Pandit SV, Jalife J. Rotors and the dynamics of cardiac fibrillation. *Circ Res* 2013; **112**: 849–62.
237. Jalife J. Deja vu in the theories of atrial fibrillation dynamics. *Cardiovasc Res* 2011; **89**:766–75.
238. Wijffels MC, Kirchhof CJ, Dorland R, Allesie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* 1995; **92**: 1954–68.
239. Workman AJ, Kane KA, Rankin AC. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. *Cardiovasc Res* 2001; **52**:226–35.
240. Jalife J, Berenfeld O, Skanes A, Mandapati R. Mechanisms of atrial fibrillation: mother rotors or multiple daughter wavelets, or both? *J Cardiovasc Electrophysiol* 1998; **9**:S2–12.
241. Narayan SM, Baykaner T, Clopton P, Schricker A, Lalani GG, Krummen DE et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation). *J Am Coll Cardiol* 2014; **63**:1761–8.
242. Narayan SM, Krummen DE, Donsky A, Swarup V, Miller JM. Precise rotor elimination without concomitant pulmonary vein isolation for the successful elimination of paroxysmal atrial fibrillation (PRECISE-PAF). *Heart Rhythm* 2013; **10**:LBCT4.
243. Voigt N, Trausch A, Knaut M, Matschke K, Varro A, Van Wagoner DR et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. *Circ Arrhythm Electrophysiol* 2010; **3**: 472–80.
244. He X, Gao X, Peng L, Wang S, Zhu Y, Ma H et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. *Circ Res* 2011; **108**:164–75.
245. Kaur K, Zarzoso M, Ponce-Balbuena D, Guerrero-Serna G, Hou L, Musa H et al. TGF-beta1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. *PLoS One* 2013; **8**:e55391.
246. Filgueiras-Rama D, Price NF, Martins RP, Yamazaki M, Avula UM, Kaur K et al. Long-term frequency gradients during persistent atrial fibrillation in sheep are associated with stable sources in the left atrium. *Circ Arrhythm Electrophysiol* 2012; **5**: 1160–7.
247. Hu H, Sachs F. Stretch-activated ion channels in the heart. *J Mol Cell Cardiol* 1997; **29**:1511–23.
248. Kim D. Novel cation-selective mechanosensitive ion channel in the atrial cell membrane. *Circ Res* 1993; **72**:225–31.
249. Rafizadeh S, Zhang Z, Woltz RL, Kim HJ, Myers RE, Lu L et al. Functional interaction with filamin A and intracellular  $Ca^{2+}$  enhance the surface membrane expression of a small-conductance  $Ca^{2+}$ -activated  $K^{+}$  (SK2) channel. *Proc Natl Acad Sci USA* 2014; **111**:9989–94.
250. Reilly SN, Jayaram R, Nahar K, Antoniadis C, Verheule S, Channon KM et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. *Circulation* 2011; **124**:1107–17.
251. Shimano M, Shibata R, Inden Y, Yoshida N, Uchikawa T, Tsuji Y et al. Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. *Heart Rhythm* 2009; **6**:935–40.
252. Wagner S, Rokita AG, Anderson ME, Maier LS. Redox regulation of sodium and calcium handling. *Antioxid Redox Signal* 2013; **18**:1063–77.
253. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. *J Am Coll Cardiol* 2012; **60**:2263–70.
254. Dikalov SI, Nazarewicz RR. Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. *Antioxid Redox Signal* 2013; **19**:1085–94.
255. Haemers P, Hamdi H, Guedj K, Suffee N, Farahmand P, Popovic N et al. Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the sub-epicardium of human and sheep atria. *Eur Heart J* 2015; doi: 10.1093/eurheartj/ehv625.
256. Chilukoti RK, Giese A, Malenke W, Homuth G, Bukowska A, Goette A et al. Atrial fibrillation and rapid acute pacing regulate adipocyte/adipocyte-related gene expression in the atria. *Int J Cardiol* 2015; **187**:604–13.
257. Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. *J Am Coll Cardiol* 2006; **48**:2315–23.
258. Page PL, Plumb VJ, Okumura K, Waldo AL. A new animal model of atrial flutter. *J Am Coll Cardiol* 1986; **8**:872–9.
259. Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. *Am J Cardiol* 2004; **93**:1176–8.
260. Ishii Y, Schuessler RB, Gaynor SL, Yamada K, Fu AS, Boineau JP et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. *Circulation* 2005; **111**:2881–8.
261. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. *Nat Med* 2010; **16**:470–4.
262. Goldstein RN, Ryu K, Khrestian C, van Wagoner DR, Waldo AL. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. *J Cardiovasc Electrophysiol* 2008; **19**:74–81.
263. Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. *JAMA* 2007; **297**:1562–7.
264. Mayyas F, Niebauer M, Zurick A, Barnard J, Gillinov AM, Chung MK et al. Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. *Circ Arrhythm Electrophysiol* 2010; **3**:369–79.
265. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. *Circulation* 2000; **101**:2678–81.
266. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. *J Am Coll Cardiol* 2000; **35**:1669–77.
267. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. *Circulation* 2001; **104**:2886–91.
268. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. *Circulation* 2003; **108**:3006–10.
269. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. *Am Heart J* 2008; **155**:303–9.
270. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM et al. Role of inflammation and oxidative stress in atrial fibrillation. *Heart Rhythm* 2010; **7**:438–44.
271. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. *Am J Cardiol* 2001; **88**:906–9, A908.
272. Rienstra M, Sun JX, Magnani JW, Sinner MF, Lubitz SA, Sullivan LM et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). *Am J Cardiol* 2012; **109**:533–7.
273. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. *Am J Cardiol* 2009; **104**:92–6.
274. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. *Lancet* 2009; **373**:739–45.
275. Kallergis EM, Manios EG, Kanoupakis EM, Mavrikis HE, Kolyvaki SG, Lyrarakis GM et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. *Heart* 2008; **94**:200–4.
276. Rotter M, Jais P, Vergnes MC, Nurden P, Takahashi Y, Sanders P et al. Decline in C-reactive protein after successful ablation of long-lasting persistent atrial fibrillation. *J Am Coll Cardiol* 2006; **47**:1231–3.
277. Marcus GM, Smith LM, Glidden DV, Wilson E, McCabe JM, Whiteman D et al. Markers of inflammation before and after curative ablation of atrial flutter. *Heart Rhythm* 2008; **5**:215–21.
278. Marcus GM, Smith LM, Ordoas K, Scheinman MM, Kim AM, Badhwar N et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. *Heart Rhythm* 2010; **7**:149–54.
279. Li-Saw-Hee FL, Blann AD, Goldsmith I, Lip GY. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. *Am J Cardiol* 1999; **83**:1206–9.
280. Liuba I, Ahlroth H, Jonasson L, Englund A, Jonsson A, Safstrom K et al. Source of inflammatory markers in patients with atrial fibrillation. *Europace* 2008; **10**: 848–53.

281. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. *J Am Coll Cardiol* 2008;**51**:1790–3.
282. Marcus GM. Predicting incident atrial fibrillation: an important step toward primary prevention. *Arch Intern Med* 2010;**170**:1874–5.
283. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB *et al*. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. *Circulation* 2010;**121**:200–7.
284. Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK *et al*. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. *Ann Intern Med* 2013;**159**:721–8.
285. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB *et al*. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. *J Am Heart Assoc* 2013;**2**:e000102.
286. Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N *et al*. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. *Europace* 2014;**16**:1426–33.
287. Huxley RR, Lopez FL, MacLehose RF, Eckfeldt JH, Couper D, Leidecker-Foster C *et al*. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study. *PLoS One* 2013;**8**:e59052.
288. Arndt M, Lendeckel U, Rocken C, Nepple K, Wolke C, Spiess A *et al*. Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. *Circulation* 2002;**105**:720–5.
289. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet* 2009;**373**:155–66.
290. Choudhury A, Chung I, Blann AD, Lip GY. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. *Chest* 2007;**131**:809–15.
291. Tan KT, Lip GY. Atrial fibrillation: should we target platelets or the coagulation pathway? *Card Electrophysiol Rev* 2003;**7**:370–1.
292. Wysokinski WE, Owen WG, Fass DN, Patrzalek DD, Murphy L, McBane RD II. Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. *J Thromb Haemost* 2004;**2**:1637–44.
293. Lip GY. Does atrial fibrillation confer a hypercoagulable state? *Lancet* 1995;**346**:1313–4.
294. Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K *et al*. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. *Int J Cardiol* 2008;**126**:316–21.
295. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD *et al*. D-dimer level influences thromboembolic events in patients with atrial fibrillation. *Int J Cardiol* 2006;**109**:59–65.
296. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. *Circulation* 2002;**106**:1962–7.
297. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. *Circulation* 2003;**107**:3141–5.
298. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. *Stroke* 2007;**38**:1229–37.
299. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. *J Am Coll Cardiol* 2004;**43**:2075–82.
300. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. *Stroke* 2006;**37**:2294–300.
301. Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, Valdes M *et al*. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. *J Am Coll Cardiol* 2011;**57**:2496–504.
302. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M *et al*. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Circulation* 2014;**130**:1847–58.
303. Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R *et al*. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation—observations from the ARISTOTLE trial. *J Thromb Haemost* 2014;**12**:1401–12.
304. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D *et al*. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. *J Am Coll Cardiol* 2014;**63**:52–61.
305. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? *Eur Heart J* 2013;**34**:1041–9.
306. Bukowska A, Zacharias I, Weinert S, Skopp K, Hartmann C, Huth C *et al*. Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. *Eur J Pharmacol* 2013;**718**:114–23.
307. Goette A, Hammwöhner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D *et al*. The impact of rapid atrial pacing on ADMA and endothelial NOS. *Int J Cardiol* 2012;**154**:141–6.
308. Bukowska A, Rocken C, Erxleben M, Rohl FW, Hammwöhner M, Huth C *et al*. Atrial expression of endothelial nitric oxide synthase in patients with and without atrial fibrillation. *Cardiovasc Pathol* 2010;**19**:e51–60.
309. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwöhner M, Strugala D *et al*. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. *Circulation* 2008;**117**:732–42.
310. Hammwöhner M, Ittenson A, Dierkes J, Bukowska A, Klein HU, Lendeckel U *et al*. Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. *Exp Biol Med* 2007;**232**:581–9.
311. Bouzas-Mosquera A, Brouillon FJ, Alvarez-Garcia N, Mendez E, Peteiro J, Gandara-Sambade T *et al*. Left atrial size and risk for all-cause mortality and ischemic stroke. *CMAJ* 2011;**183**:E657–64.
312. Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET *et al*. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). *Am Heart J* 2006;**151**:412–8.
313. Lancellotti P, Donal E, Magne J, Moonen M, O'Connor K, Daubert JC *et al*. Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay. *Heart* 2010;**96**:1364–71.
314. Le Tourneau T, Messika-Zeitoun D, Russo A, Deltant D, Topilsky Y, Mahoney DW *et al*. Impact of left atrial volume on clinical outcome in organic mitral regurgitation. *J Am Coll Cardiol* 2010;**56**:570–8.
315. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. *Am J Cardiol* 2002;**90**:1284–9.
316. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR *et al*. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. *J Am Coll Cardiol* 2003;**42**:1199–205.
317. Appleton CP, Galloway JM, Gonzalez MS, Gaballa M, Basnight MA. Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and the difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. *J Am Coll Cardiol* 1993;**22**:1972–82.
318. Geske JB, Sorajja P, Nishimura RA, Ommen SR. The relationship of left atrial volume and left atrial pressure in patients with hypertrophic cardiomyopathy: an echocardiographic and cardiac catheterization study. *J Am Soc Echocardiogr* 2009;**22**:961–6.
319. Guron CW, Hartford M, Rosengren A, Thelle D, Wallentin I, Caidahl K. Usefulness of atrial size inequality as an indicator of abnormal left ventricular filling. *Am J Cardiol* 2005;**95**:1448–52.
320. Simek CL, Feldman MD, Haber HL, Wu CC, Jayaweera AR, Kaul S. Relationship between left ventricular wall thickness and left atrial size: comparison with other measures of diastolic function. *J Am Soc Echocardiogr* 1995;**8**:37–47.
321. Ersboll M, Andersen MJ, Valeur N, Mogensen UM, Waziri H, Møller JE *et al*. The prognostic value of left atrial peak reservoir strain in acute myocardial infarction is dependent on left ventricular longitudinal function and left atrial size. *Circ Cardiovasc Imaging* 2013;**6**:26–33.
322. Lonborg JT, Engstrom T, Møller JE, Ahtarovski KA, Kelbaek H, Holmvang L *et al*. Left atrial volume and function in patients following ST elevation myocardial infarction and the association with clinical outcome: a cardiovascular magnetic resonance study. *Eur Heart J Cardiovasc Imaging* 2013;**14**:118–27.
323. Barnes ME, Miyasaka Y, Seward JB, Gersh BJ, Rosales AG, Bailey KR *et al*. Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. *Mayo Clin Proc* 2004;**79**:1008–14.
324. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. *Circulation* 1995;**92**:835–41.
325. Bolca O, Akdemir O, Eren M, Dagdeviren B, Yildirim A, Tezel T. Left atrial maximum volume is a recurrence predictor in lone atrial fibrillation: an acoustic quantification study. *Jpn Heart J* 2002;**43**:241–8.
326. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. *Stroke* 1999;**30**:2019–24.

327. Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. *Am J Cardiol* 1995;**76**:355–8.
328. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. *J Cardiovasc Electrophysiol* 2012;**23**:797–9.
329. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. *Mayo Clin Proc* 2001;**76**:467–75.
330. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of non-rheumatic atrial fibrillation. The Framingham Heart Study. *Circulation* 1994;**89**:724–30.
331. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risks for atrial fibrillation and congestive heart failure in patients  $\geq 65$  years of age with abnormal left ventricular diastolic relaxation. *Am J Cardiol* 2004;**93**:54–8.
332. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. *J Am Coll Cardiol* 2002;**40**:1636–44.
333. Beinart R, Boyko V, Schwammenthal E, Kuperstein R, Sagie A, Hod H et al. Long-term prognostic significance of left atrial volume in acute myocardial infarction. *J Am Coll Cardiol* 2004;**44**:327–34.
334. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. *Circulation* 2003;**107**:2207–12.
335. Dini FL, Cortigiani L, Baldini U, Boni A, Nuti R, Barsotti L et al. Prognostic value of left atrial enlargement in patients with idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. *Am J Cardiol* 2002;**89**:518–23.
336. Kim H, Cho YK, Jun DH, Nam CW, Han SW, Hur SH et al. Prognostic implications of the NT-ProBNP level and left atrial size in non-ischemic dilated cardiomyopathy. *Circ J* 2008;**72**:1658–65.
337. Modena MG, Muia N, Sgura FA, Molinari R, Castella A, Rossi R. Left atrial size is the major predictor of cardiac death and overall clinical outcome in patients with dilated cardiomyopathy: a long-term follow-up study. *Clin Cardiol* 1997;**20**:553–60.
338. Quinones MA, Greenberg BH, Kopelen HA, Koilpillai C, Limacher MC, Shindler DM et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. *J Am Coll Cardiol* 2000;**35**:1237–44.
339. Sabharwal N, Cemin R, Rajan K, Hickman M, Lahiri A, Senior R. Usefulness of left atrial volume as a predictor of mortality in patients with ischemic cardiomyopathy. *Am J Cardiol* 2004;**94**:760–3.
340. Maddukuri PV, Vieira ML, DeCastro S, Maron MS, Kuvit JT, Patel AR et al. What is the best approach for the assessment of left atrial size? Comparison of various uni-dimensional and two-dimensional parameters with three-dimensional echocardiographically determined left atrial volume. *J Am Soc Echocardiogr* 2006;**19**:1026–32.
341. Wang Y, Gutman JM, Heilbron D, Wahr D, Schiller NB. Atrial volume in a normal adult population by two-dimensional echocardiography. *Chest* 1984;**86**:595–601.
342. Whitlock M, Garg A, Gelow J, Jacobson T, Broberg C. Comparison of left and right atrial volume by echocardiography versus cardiac magnetic resonance imaging using the area-length method. *Am J Cardiol* 2010;**106**:1345–50.
343. Aune E, Baekkevar M, Roislien J, Rodevand O, Otterstad JE. Normal reference ranges for left and right atrial volume indexes and ejection fractions obtained with real-time three-dimensional echocardiography. *Eur J Echocardiogr* 2009;**10**:738–44.
344. Peluso D, Badano LP, Muraru D, Dal Bianco L, Cucchini U, Kocabay G et al. Right atrial size and function assessed with three-dimensional and speckle-tracking echocardiography in 200 healthy volunteers. *Eur Heart J Cardiovasc Imaging* 2013;**14**:1106–14.
345. Poulsen MK, Dahl JS, Henriksen JE, Hey TM, Hoiland-Carlson PF, Beck-Nielsen H et al. Left atrial volume index: relation to long-term clinical outcome in type 2 diabetes. *J Am Coll Cardiol* 2013;**62**:2416–21.
346. Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M et al. EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. *Eur Heart J Cardiovasc Imaging* 2016;**17**:355–83.
347. Lang RM, Badano LP, Mor-Avi V, Afila J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015;**28**:1–39 e14.
348. Olshansky B, Heller EN, Mitchell LB, Chandler M, Slater W, Green M et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. *J Am Coll Cardiol* 2005;**45**:2026–33.
349. Rusinaru D, Tribouilloy C, Grigioni F, Avierinos JF, Suri RM, Barbieri A et al. Left atrial size is a potent predictor of mortality in mitral regurgitation due to flail leaflets: results from a large international multicenter study. *Circ Cardiovasc Imaging* 2011;**4**:473–81.
350. Wade MR, Chandraratna PA, Reid CL, Lin SL, Rahimtoola SH. Accuracy of non-directed and directed M-mode echocardiography as an estimate of left atrial size. *Am J Cardiol* 1987;**60**:1208–11.
351. Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. *Am J Cardiol* 1999;**84**:829–32.
352. Loperfido F, Pennestri F, Digaetano A, Scabbia E, Santarelli P, Mongiardo R et al. Assessment of left atrial dimensions by cross sectional echocardiography in patients with mitral valve disease. *Br Heart J* 1983;**50**:570–8.
353. Vyas H, Jackson K, Chenzbraun A. Switching to volumetric left atrial measurements: impact on routine echocardiographic practice. *Eur J Echocardiogr* 2011;**12**:107–11.
354. Gottdiener JS, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons  $\geq 65$  years of age (the cardiovascular health study). *Am J Cardiol* 2006;**97**:83–9.
355. Rossi A, Cicciola M, Zanolli L, Sandrini R, Golia G, Zardini P et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. *J Am Coll Cardiol* 2002;**40**:1425.
356. Takemoto Y, Barnes ME, Seward JB, Lester SJ, Appleton CA, Gersh BJ et al. Usefulness of left atrial volume in predicting first congestive heart failure in patients  $\geq 65$  years of age with well-preserved left ventricular systolic function. *Am J Cardiol* 2005;**96**:832–6.
357. Tani T, Tanabe K, Ono M, Yamaguchi K, Okada M, Sumida T et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. *J Am Soc Echocardiogr* 2004;**17**:644–8.
358. Tsang TS, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? *J Am Coll Cardiol* 2006;**47**:1018–23.
359. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. *J Am Coll Cardiol* 2003;**41**:1036–43.
360. Jenkins C, Bricknell K, Marwick TH. Use of real-time three-dimensional echocardiography to measure left atrial volume: comparison with other echocardiographic techniques. *J Am Soc Echocardiogr* 2005;**18**:991–7.
361. Maceira AM, Cosin-Sales J, Roughton M, Prasad SK, Pennell DJ. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2010;**12**:65.
362. Rodevan O, Bjornerheim R, Ljosland M, Maehle J, Smith HJ, Ihlen H. Left atrial volumes assessed by three- and two-dimensional echocardiography compared to MRI estimates. *Int J Card Imaging* 1999;**15**:397–410.
363. Stojanovska J, Cronin P, Patel S, Gross BH, Oral H, Chughtai K et al. Reference normal absolute and indexed values from ECG-gated MDCT: left atrial volume, function, and diameter. *AJR Am J Roentgenol* 2011;**197**:631–7.
364. Ujino K, Barnes ME, Cha SS, Langins AP, Bailey KR, Seward JB et al. Two-dimensional echocardiographic methods for assessment of left atrial volume. *Am J Cardiol* 2006;**98**:1185–8.
365. Aurigemma GP, Gottdiener JS, Arnold AM, Chinali M, Hill JC, Kitzman D. Left atrial volume and geometry in healthy aging: the Cardiovascular Health Study. *Circ Cardiovasc Imaging* 2009;**2**:282–9.
366. Thomas L, Levett K, Boyd A, Leung DY, Schiller NB, Ross DL. Compensatory changes in atrial volumes with normal aging: is atrial enlargement inevitable? *J Am Coll Cardiol* 2002;**40**:1630–5.
367. Yamaguchi K, Tanabe K, Tani T, Yagi T, Fujii Y, Konda T et al. Left atrial volume in normal Japanese adults. *Circ J* 2006;**70**:285–8.
368. Miyasaka Y, Tsujimoto S, Maeba H, Yuasa F, Takehana K, Dote K et al. Left atrial volume by real-time three-dimensional echocardiography: validation by 64-slice multidetector computed tomography. *J Am Soc Echocardiogr* 2011;**24**:680–6.
369. Rohner A, Brinkert M, Kawel N, Buechel RR, Leibundgut G, Grize L et al. Functional assessment of the left atrium by real-time three-dimensional echocardiography using a novel dedicated analysis tool: initial validation studies in comparison with computed tomography. *Eur J Echocardiogr* 2011;**12**:497–505.
370. Artang R, Migrino RQ, Harmann L, Bowers M, Woods TD. Left atrial volume measurement with automated border detection by 3-dimensional echocardiography: comparison with Magnetic Resonance Imaging. *Cardiovasc Ultrasound* 2009;**7**:16.
371. Mor-Avi V, Yodanis C, Jenkins C, Kuhl H, Nesser HJ, Marwick TH et al. Real-time 3D echocardiographic quantification of left atrial volume: multicenter study for validation with CMR. *JACC Cardiovasc Imaging* 2012;**5**:769–77.



372. Caselli S, Canali E, Foschi ML, Santini D, Di Angelantonio E, Pandian NG *et al*. Long-term prognostic significance of three-dimensional echocardiographic parameters of the left ventricle and left atrium. *Eur J Echocardiogr* 2010;**11**:250–6.
373. Suh IW, Song JM, Lee EY, Kang SH, Kim MJ, Kim JJ *et al*. Left atrial volume measured by real-time 3-dimensional echocardiography predicts clinical outcomes in patients with severe left ventricular dysfunction and in sinus rhythm. *J Am Soc Echocardiogr* 2008;**21**:439–45.
374. Vasan RS, Larson MG, Levy D, Galderisi M, Wolf PA, Benjamin EJ *et al*. Doppler transmitral flow indexes and risk of atrial fibrillation (the Framingham Heart Study). *Am J Cardiol* 2003;**91**:1079–83.
375. Mattioli AV, Tarabini Castellani E, Vivoli D, Molinari R, Mattioli G. Restoration of atrial function after atrial fibrillation of different etiological origins. *Cardiology* 1996;**87**:205–11.
376. Yuda S, Nakatani S, Isobe F, Kosakai Y, Miyatake K. Comparative efficacy of the maze procedure for restoration of atrial contraction in patients with and without giant left atrium associated with mitral valve disease. *J Am Coll Cardiol* 1998;**31**:1097–102.
377. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Nguyen TT, Botello G *et al*. Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. *Am J Cardiol* 2006;**98**:954–9.
378. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. *J Am Coll Cardiol* 1989;**13**:617–23.
379. Oki T, Fukuda N, Iuchi A, Tabata T, Tanimoto M, Manabe K *et al*. Left atrial systolic performance in the presence of elevated left ventricular end-diastolic pressure: evaluation by transesophageal pulsed Doppler echocardiography of left ventricular inflow and pulmonary venous flow velocities. *Echocardiography* 1997;**14**:23–32.
380. Oki T, Iuchi A, Tabata T, Yamada H, Manabe K, Kageji Y *et al*. Transesophageal pulsed Doppler echocardiographic evaluation of left atrial systolic performance in hypertrophic cardiomyopathy: combined analysis of transmitral and pulmonary venous flow velocities. *Clin Cardiol* 1997;**20**:47–54.
381. Sakai H, Kunichika H, Murata K, Seki K, Katayama K, Hiro T *et al*. Improvement of afterload mismatch of left atrial booster pump function with positive inotropic agent. *J Am Coll Cardiol* 2001;**37**:270–7.
382. Iuchi A, Oki T, Tabata T, Manabe K, Kageji Y, Sasaki M *et al*. [Changes in pulmonary venous and transmitral flow velocity patterns after cardioversion of atrial fibrillation]. *J Cardiol* 1995;**25**:317–24.
383. Thomas L, Levett K, Boyd A, Leung DY, Schiller NB, Ross DL. Changes in regional left atrial function with aging: evaluation by Doppler tissue imaging. *Eur J Echocardiogr* 2003;**4**:92–100.
384. Hesse B, Schuele SU, Thamilarasan M, Thomas J, Rodriguez L. A rapid method to quantify left atrial contractile function: Doppler tissue imaging of the mitral annulus during atrial systole. *Eur J Echocardiogr* 2004;**5**:86–92.
385. Inaba Y, Yuda S, Kobayashi N, Hashimoto A, Uno K, Nakata T *et al*. Strain rate imaging for noninvasive functional quantification of the left atrium: comparative studies in controls and patients with atrial fibrillation. *J Am Soc Echocardiogr* 2005;**18**:729–36.
386. Vianna-Pinton R, Moreno CA, Baxter CM, Lee KS, Tsang TS, Appleton CP. Two-dimensional speckle-tracking echocardiography of the left atrium: feasibility and regional contraction and relaxation differences in normal subjects. *J Am Soc Echocardiogr* 2009;**22**:299–305.
387. Kim DG, Lee KJ, Lee S, Jeong SY, Lee YS, Choi YJ *et al*. Feasibility of two-dimensional global longitudinal strain and strain rate imaging for the assessment of left atrial function: a study in subjects with a low probability of cardiovascular disease and normal exercise capacity. *Echocardiography* 2009;**26**:1179–87.
388. Cameli M, Caputo M, Mondillo S, Ballo P, Palmerini E, Lisi M *et al*. Feasibility and reference values of left atrial longitudinal strain imaging by two-dimensional speckle tracking. *Cardiovasc Ultrasound* 2009;**7**:6.
389. Cianciulli TF, Saccheri MC, Lax JA, Bermann AM, Ferreiro DE. Two-dimensional speckle tracking echocardiography for the assessment of atrial function. *World J Cardiol* 2010;**2**:163–70.
390. Cameli M, Lisi M, Focardi M, Reccia R, Natali BM, Sparta S *et al*. Left atrial deformation analysis by speckle tracking echocardiography for prediction of cardiovascular outcomes. *Am J Cardiol* 2012;**110**:264–9.
391. Thomas L, McKay T, Byth K, Marwick TH. Abnormalities of left atrial function after cardioversion: an atrial strain rate study. *Heart* 2007;**93**:89–95.
392. Wang T, Wang M, Fung JW, Yip GW, Zhang Y, Ho PP *et al*. Atrial strain rate echocardiography can predict success or failure of cardioversion for atrial fibrillation: a combined transthoracic tissue Doppler and transoesophageal imaging study. *Int J Cardiol* 2007;**114**:202–9.
393. Schneider C, Malisius R, Krause K, Lampe F, Bahlmann E, Boczor S *et al*. Strain rate imaging for functional quantification of the left atrium: atrial deformation predicts the maintenance of sinus rhythm after catheter ablation of atrial fibrillation. *Eur Heart J* 2008;**29**:1397–409.
394. Mirza M, Caracciolo G, Khan U, Mori N, Saha SK, Srivathsan K *et al*. Left atrial reservoir function predicts atrial fibrillation recurrence after catheter ablation: a two-dimensional speckle strain study. *J Interv Card Electrophysiol* 2011;**31**:197–206.
395. Saha SK, Anderson PL, Caracciolo G, Kiotsekoglou A, Wilansky S, Govind S *et al*. Global left atrial strain correlates with CHADS2 risk score in patients with atrial fibrillation. *J Am Soc Echocardiogr* 2011;**24**:506–12.
396. O'Connor K, Magne J, Rosca M, Pierard LA, Lancellotti P. Left atrial function and remodelling in aortic stenosis. *Eur J Echocardiogr* 2011;**12**:299–305.
397. O'Connor K, Magne J, Rosca M, Pierard LA, Lancellotti P. Impact of aortic valve stenosis on left atrial phasic function. *Am J Cardiol* 2010;**106**:1157–62.
398. Todaro MC, Choudhuri I, Belohlavek M, Jahangir A, Carerj S, Oretto L *et al*. New echocardiographic techniques for evaluation of left atrial mechanics. *Eur Heart J Cardiovasc Imaging* 2012;**13**:973–84.
399. Nikitin NP, Witte KK, Thackray SD, Goode LJ, Clark AL, Cleland JG. Effect of age and sex on left atrial morphology and function. *Eur J Echocardiogr* 2003;**4**:36–42.
400. Tsai WC, Lee CH, Lin CC, Liu YW, Huang YY, Li WT *et al*. Association of left atrial strain and strain rate assessed by speckle tracking echocardiography with paroxysmal atrial fibrillation. *Echocardiography* 2009;**26**:1188–94.
401. Wang Z, Tan H, Zhong M, Jiang G, Zhang Y, Zhang W. Strain rate imaging for non-invasive functional quantification of the left atrium in hypertensive patients with paroxysmal atrial fibrillation. *Cardiology* 2008;**109**:15–24.
402. Modesto KM, Dispenzieri A, Cauduro SA, Lacy M, Khandheria BK, Pellikka PA *et al*. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. *Eur Heart J* 2005;**26**:173–9.
403. Di Salvo G, Caso P, Lo Piccolo R, Fusco A, Martiniello AR, Russo MG *et al*. Atrial myocardial deformation properties predict maintenance of sinus rhythm after external cardioversion of recent-onset lone atrial fibrillation: a color Doppler myocardial imaging and transthoracic and transesophageal echocardiographic study. *Circulation* 2005;**112**:387–95.
404. D'Andrea A, Caso P, Romano S, Scarafile R, Cuomo S, Salerno G *et al*. Association between left atrial myocardial function and exercise capacity in patients with either idiopathic or ischemic dilated cardiomyopathy: a two-dimensional speckle strain study. *Int J Cardiol* 2009;**132**:354–63.
405. D'Andrea A, Caso P, Romano S, Scarafile R, Riegler L, Salerno G *et al*. Different effects of cardiac resynchronization therapy on left atrial function in patients with either idiopathic or ischemic dilated cardiomyopathy: a two-dimensional speckle strain study. *Eur Heart J* 2007;**28**:2738–48.
406. Kaplan JD, Evans GT Jr, Foster E, Lim D, Schiller NB. Evaluation of electrocardiographic criteria for right atrial enlargement by quantitative two-dimensional echocardiography. *J Am Coll Cardiol* 1994;**23**:747–52.
407. Quraini D, Pandian NG, Patel AR. Three-dimensional echocardiographic analysis of right atrial volume in normal and abnormal hearts: comparison of biplane and multiplane methods. *Echocardiography* 2012;**29**:608–13.
408. Nedijs S, Tang M, Roser M, Solowjowa N, Gerd-Li JH, Fleck E *et al*. Characteristic changes of volume and three-dimensional structure of the left atrium in different forms of atrial fibrillation: predictive value after ablative treatment. *J Interv Card Electrophysiol* 2011;**32**:87–94.
409. Kurotobi T, Iwakura K, Inoue K, Kimura R, Toyoshima Y, Ito N *et al*. The significance of the shape of the left atrial roof as a novel index for determining the electrophysiological and structural characteristics in patients with atrial fibrillation. *Europace* 2011;**13**:803–8.
410. Romero J, Husain SA, Kelesidis I, Sanz J, Medina HM, Garcia MJ. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. *Circ Cardiovasc Imaging* 2013;**6**:185–94.
411. Hamdan A, Charalampos K, Roettgen R, Wellenhofer E, Gebker R, Paetsch I *et al*. Magnetic resonance imaging versus computed tomography for characterization of pulmonary vein morphology before radiofrequency catheter ablation of atrial fibrillation. *Am J Cardiol* 2009;**104**:1540–6.
412. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN *et al*. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. *Circulation* 2009;**119**:1758–67.
413. Ling LH, McLellan AJ, Taylor AJ, Iles LM, Ellims AH, Kumar S *et al*. Magnetic resonance post-contrast T1 mapping in the human atrium: validation and impact on clinical outcome after catheter ablation for atrial fibrillation. *Heart Rhythm* 2014;**11**:1551–9.
414. Beinart R, Khurram IM, Liu S, Yarmohammadi H, Halperin HR, Bluemke DA *et al*. Cardiac magnetic resonance T1 mapping of left atrial myocardium. *Heart Rhythm* 2013;**10**:1325–31.
415. Harrison JL, Sohns C, Linton NW, Karim R, Williams SE, Rhode KS *et al*. Repeat left atrial catheter ablation: cardiac magnetic resonance prediction of endocardial voltage and gaps in ablation lesion sets. *Circ Arrhythm Electrophysiol* 2015;**8**:270–8.
416. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F *et al*. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA* 2014;**311**:498–506.



417. Akoum N, McGann C, Vergara G, Badger T, Ranjan R, Mahnkopf C et al. Atrial fibrosis quantified using late gadolinium enhancement MRI is associated with sinus node dysfunction requiring pacemaker implant. *J Cardiovasc Electrophysiol* 2012;**23**: 44–50.
418. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. *J Am Coll Cardiol* 2011;**57**:831–8.
419. Mahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. *Heart Rhythm* 2010;**7**:1475–81.
420. Bax JJ, Marsan NA, Delgado V. Non-invasive imaging in atrial fibrillation: focus on prognosis and catheter ablation. *Heart* 2015;**101**:94–100.
421. Bhagirath P, van der Graaf AW, Karim R, van Driel VJ, Ramanna H, Rhode KS et al. Multimodality imaging for patient evaluation and guidance of catheter ablation for atrial fibrillation—current status and future perspective. *Int J Cardiol* 2014;**175**: 400–8.
422. Peters DC, Wylie JV, Hauser TH, Nezafat R, Han Y, Woo JJ et al. Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. *JACC Cardiovasc Imaging* 2009;**2**:308–16.
423. McGann CJ, Kholmovski EG, Oakes RS, Blauer JJ, Daccarett M, Segerson N et al. New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. *J Am Coll Cardiol* 2008;**52**: 1263–71.
424. Peters DC, Wylie JV, Hauser TH, Kissinger KV, Botnar RM, Essebag V et al. Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. *Radiology* 2007;**243**:690–5.
425. Arujuna A, Karim R, Caulfield D, Knowles B, Rhode K, Schaeffter T et al. Acute pulmonary vein isolation is achieved by a combination of reversible and irreversible atrial injury after catheter ablation: evidence from magnetic resonance imaging. *Circ Arrhythm Electrophysiol* 2012;**5**:691–700.
426. Sohns C, Karim R, Harrison J, Arujuna A, Linton N, Sennett R et al. Quantitative magnetic resonance imaging analysis of the relationship between contact force and left atrial scar formation after catheter ablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 2014;**25**:138–45.
427. Bisbal F, Guiu E, Berrueto A, Cabanas P, Prat-Gonzales S, Garrido C et al. MRI guided approach to localize and ablate gaps in repeated AF ablation procedure: a pilot study. *J Am Coll Cardiol* 2013;**61**:E365.
428. Rajappan K, Kistler PM, Earley MJ, Thomas G, Izquierdo M, Sporton SC et al. Acute and chronic pulmonary vein reconnection after atrial fibrillation ablation: a prospective characterization of anatomical sites. *Pacing Clin Electrophysiol* 2008;**31**:1598–605.
429. Hunter RJ, Jones DA, Boubertakh R, Malcolm-Lawes LC, Kanagaratnam P, Juli CF et al. Diagnostic accuracy of cardiac magnetic resonance imaging in the detection and characterization of left atrial catheter ablation lesions: a multicenter experience. *J Cardiovasc Electrophysiol* 2013;**24**:396–403.
430. Piorkowski C, Hindricks G, Schreiber D, Tanner H, Weise W, Koch A et al. Electroanatomic reconstruction of the left atrium, pulmonary veins, and esophagus compared with the “true anatomy” on multislice computed tomography in patients undergoing catheter ablation of atrial fibrillation. *Heart Rhythm* 2006;**3**: 317–27.
431. Morton JB, Sanders P, Vohra JK, Sparks PB, Morgan JG, Spence SJ et al. Effect of chronic right atrial stretch on atrial electrical remodeling in patients with an atrial septal defect. *Circulation* 2003;**107**:1775–82.
432. Sanders P, Morton JB, Kistler PM, Spence SJ, Davidson NC, Hussin A et al. Electrophysiological and electroanatomic characterization of the atria in sinus node disease: evidence of diffuse atrial remodeling. *Circulation* 2004;**109**:1514–22.
433. Sanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. *Circulation* 2003;**108**:1461–8.
434. Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. *J Am Coll Cardiol* 2005;**45**:285–92.
435. Lo LW, Tai CT, Lin YJ, Chang SL, Wongcharoen W, Chang SH et al. Progressive remodeling of the atrial substrate—a novel finding from consecutive voltage mapping in patients with recurrence of atrial fibrillation after catheter ablation. *J Cardiovasc Electrophysiol* 2007;**18**:258–65.
436. Brooks AG, Stiles MK, Laborde J, Lau DH, Kuklik P, Shipp NJ et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. *Heart Rhythm* 2010;**7**:835–46.
437. Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M et al. Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction. *J Cardiovasc Electrophysiol* 2015;**26**:363–70.
438. Chao TF, Lin YJ, Tsao HM, Tsai CF, Lin WS, Chang SL et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. *J Am Coll Cardiol* 2011;**58**:2380–5.
439. Chao TF, Tsao HM, Lin YJ, Tsai CF, Lin WS, Chang SL et al. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up. *Circ Arrhythm Electrophysiol* 2012;**5**:14–20.
440. Combes S, Jacob S, Combes N, Karam N, Chaumeil A, Guy-Moyat B et al. Predicting favourable outcomes in the setting of radiofrequency catheter ablation of long-standing persistent atrial fibrillation: a pilot study assessing the value of left atrial appendage peak flow velocity. *Arch Cardiovasc Dis* 2013;**106**:36–43.
441. Cooper DH, Faddis MN. Catheter ablation of atrial fibrillation: long-term outcomes. *Expert Rev Cardiovasc Ther* 2011;**9**:567–70.
442. Hussein AA, Saliba WJ, Martin DO, Bhargava M, Sherman M, Magnelli-Reyes C et al. Natural history and long-term outcomes of ablated atrial fibrillation. *Circ Arrhythm Electrophysiol* 2011;**4**:271–8.
443. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. *Heart Rhythm* 2015;**12**:681–6.
444. Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D et al. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. *Circ Arrhythm Electrophysiol* 2014;**7**:281–7.
445. Kornej J, Hindricks G, Shoemaker MB, Husser D, Arya A, Sommer P et al. The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. *Clin Res Cardiol* 2015;**104**:871–6.
446. Kosiuk J, Breithardt OA, Bode K, Kornej J, Arya A, Piorkowski C et al. The predictive value of echocardiographic parameters associated with left ventricular diastolic dysfunction on short- and long-term outcomes of catheter ablation of atrial fibrillation. *Europace* 2014;**16**:1168–74.
447. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM et al. Lone atrial fibrillation: does it exist? *J Am Coll Cardiol* 2014;**63**:1715–23.
448. Chilukuri K, Dalal D, Gadrey S, Marine JE, Macpherson E, Henrikson CA et al. A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 2010;**21**:521–5.
449. Jongnarangsin K, Chugh A, Good E, Mukerji S, Dey S, Crawford T et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 2008;**19**:668–72.
450. Lemola K, Desjardins B, Sneider M, Case I, Chugh A, Good E et al. Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. *Heart Rhythm* 2005;**2**:923–8.
451. Steel KE, Roman-Gonzalez J, O'Bryan CL IV. Images in cardiovascular medicine. Severe left atrial edema and heart failure after atrial fibrillation ablation. *Circulation* 2006;**113**:e659.
452. Kumar S, Teh AW, Medi C, Kistler PM, Morton JB, Kalman JM. Atrial remodeling in varying clinical substrates within beating human hearts: relevance to atrial fibrillation. *Prog Biophys Mol Biol* 2012;**110**:278–94.
453. Teh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ et al. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. *J Cardiovasc Electrophysiol* 2012;**23**:232–8.
454. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K et al. Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. *Circ Arrhythm Electrophysiol* 2014;**7**:23–30.
455. Teh AW, Kalman JM, Lee G, Medi C, Heck PM, Ling LH et al. Electroanatomic remodelling of the pulmonary veins associated with age. *Europace* 2012;**14**:46–51.
456. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. *Pacing Clin Electrophysiol* 2010;**33**:146–52.
457. Kennedy R, Oral H. Catheter ablation of atrial fibrillation in the elderly: does the benefit outweigh the risk? *Expert Rev Cardiovasc Ther* 2013;**11**:697–704.
458. Kusumoto F, Prussak K, Wiesinger M, Pullen T, Lynady C. Radiofrequency catheter ablation of atrial fibrillation in older patients: outcomes and complications. *J Interv Card Electrophysiol* 2009;**25**:31–5.
459. Nademanee K, Amnueyapol M, Lee F, Drew CM, Suwannasri W, Schwab MC et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. *Heart Rhythm* 2015;**12**:44–51.
460. Santangeli P, Di Biase L, Mohanty P, Burkhardt JD, Horton R, Bai R et al. Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes. *J Cardiovasc Electrophysiol* 2012;**23**:687–93.
461. Spragg DD, Dalal D, Cheema A, Scherr D, Chilukuri K, Cheng A et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. *J Cardiovasc Electrophysiol* 2008;**19**:627–31.
462. Tuan TC, Chang SL, Tsao HM, Tai CT, Lin YJ, Hu YF et al. The impact of age on the electroanatomical characteristics and outcome of catheter ablation in patients with atrial fibrillation. *J Cardiovasc Electrophysiol* 2010;**21**:966–72.

463. Hao SC, Hunter TD, Gunnarsson C, March JL, White SA, Ladapo JA *et al.* Acute safety outcomes in younger and older patients with atrial fibrillation treated with catheter ablation. *J Interv Card Electrophysiol* 2012;**35**:173–82.
464. McLellan AJ, Schlaich MP, Taylor AJ, Prabhu S, Hering D, Hammond L *et al.* Reverse cardiac remodeling after renal denervation: atrial electrophysiologic and structural changes associated with blood pressure lowering. *Heart Rhythm* 2015;**12**:982–90.
465. Pokushalov E, Romanov A, Katritsis DG, Artyomenko S, Bayramova S, Losik D *et al.* Renal denervation for improving outcomes of catheter ablation in patients with atrial fibrillation and hypertension: early experience. *Heart Rhythm* 2014;**11**:1131–8.
466. Bortone A, Boveda S, Pasquie JL, Pujadas-Berthault P, Marijon E, Appetiti A *et al.* Sinus rhythm restoration by catheter ablation in patients with long-lasting atrial fibrillation and congestive heart failure: impact of the left ventricular ejection fraction improvement on the implantable cardioverter defibrillator insertion indication. *Europace* 2009;**11**:1018–23.
467. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F *et al.* Catheter ablation for atrial fibrillation in congestive heart failure. *N Engl J Med* 2004;**351**:2373–83.
468. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V *et al.* A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). *Circ Arrhythm Electrophysiol* 2014;**7**:31–8.
469. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL *et al.* A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. *J Am Coll Cardiol* 2013;**61**:1894–03.
470. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M *et al.* Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. *Heart* 2011;**97**:740–7.
471. Machino-Ohtsuka T, Seo Y, Ishizu T, Sugano A, Atsumi A, Yamamoto M *et al.* Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2013;**62**:1857–65.
472. O'Neill MD. Heart failure, atrial fibrillation, and catheter ablation: are we there yet? *J Am Coll Cardiol* 2013;**61**:1904–5.
473. Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. *J Am Coll Cardiol* 2014;**64**:710–21.
474. Ganesan AN, Nandal S, Lucker J, Pathak RK, Mahajan R, Twomey D *et al.* Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. *Heart Lung Circ* 2015;**24**:270–80.
475. Chang SL, Tuan TC, Tai CT, Lin YJ, Lo LW, Hu YF *et al.* Comparison of outcome in catheter ablation of atrial fibrillation in patients with versus without the metabolic syndrome. *Am J Cardiol* 2009;**103**:67–72.
476. Dinov B, Kosiuk J, Kircher S, Bollmann A, Acou WJ, Arya A *et al.* Impact of metabolic syndrome on left atrial electroanatomical remodeling and outcomes after radiofrequency ablation of nonvalvular atrial fibrillation. *Circ Arrhythm Electrophysiol* 2014;**7**:483–9.
477. Lin KJ, Cho SI, Tiwari N, Bergman M, Kizer JR, Palma EC *et al.* Impact of metabolic syndrome on the risk of atrial fibrillation recurrence after catheter ablation: systematic review and meta-analysis. *J Interv Card Electrophysiol* 2014;**39**:211–23.
478. Mohanty S, Mohanty P, Di Biase L, Bai R, Pump A, Santangeli P *et al.* Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. *J Am Coll Cardiol* 2012;**59**:1295–301.
479. Mohanty S, Mohanty P, Di Biase L, Bai R, Trivedi C, Santangeli P *et al.* Long-term outcome of catheter ablation in atrial fibrillation patients with coexistent metabolic syndrome and obstructive sleep apnea: impact of repeat procedures versus lifestyle changes. *J Cardiovasc Electrophysiol* 2014;**25**:930–8.
480. Wojcik M, Berkowitsch A, Kuniss M, Zaltsberg S, Pitschner HF, Hamm CW *et al.* Outcomes of atrial fibrillation ablation in patients with metabolic syndrome. *J Am Coll Cardiol* 2013;**61**:109–10.
481. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K *et al.* Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. *J Am Coll Cardiol* 2013;**62**:300–5.
482. D'Ascenzo F, Corleto A, Biondi-Zoccai G, Anselmino M, Ferraris F, di Biase L *et al.* Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. *Int J Cardiol* 2013;**167**:1984–9.
483. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. *Am J Cardiol* 2005;**95**:764–7.
484. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K *et al.* C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. *Heart Vessels* 2005;**20**:45–9.
485. Hak L, Mysliwska J, Wieckiewicz J, Szyndler K, Siebert J, Rogowski J. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). *J Interferon Cytokine Res* 2009;**29**:327–32.
486. Frustaci A, Caldarulo M, Buffon A, Bellocchi F, Fenici R, Melina D. Cardiac biopsy in patients with "primary" atrial fibrillation. Histologic evidence of occult myocardial diseases. *Chest* 1991;**100**:303–6.
487. Fuenmayor AJ, Fuenmayor AM, Carrasco H, Parada H, Fuenmayor C, Jugo D. Results of electrophysiologic studies in patients with acute Chagas myocarditis. *Clin Cardiol* 1997;**20**:1021–4.
488. Talwar KK, Radhakrishnan S, Chopra P. Myocarditis manifesting as persistent atrial standstill. *Int J Cardiol* 1988;**20**:283–6.
489. Abdelwahab A, Sapp JL, Parkash R, Basta M, Gardner M. Mapping and ablation of multiple atrial arrhythmias in a patient with persistent atrial standstill after remote viral myocarditis. *Pacing Clin Electrophysiol* 2009;**32**:275–7.
490. Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Kaoukis A *et al.* Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. *J Am Coll Cardiol* 2012;**60**:1790–6.
491. Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimbürger M *et al.* Myocardial cell death in fibrillating and dilated human right atria. *J Am Coll Cardiol* 1999;**34**:1577–86.
492. de Vos CB, Pisters R, Nieuwlaar R, Prins MH, Tieleman RG, Coelen RJ *et al.* Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. *J Am Coll Cardiol* 2010;**55**:725–31.
493. Reant P, Lafitte S, Jais P, Serri K, Weerasooriya R, Hocini M *et al.* Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. *Circulation* 2005;**112**:2896–03.
494. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T *et al.* The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. *Circulation* 2005;**112**:3697–706.
495. Allesie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. *Cardiovasc Res* 2002;**54**:230–46.
496. Everett TH IV, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE. Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. *Am J Physiol Heart Circ Physiol* 2006;**291**:H2911–23.
497. Lu Z, Scherlag BJ, Lin J, Niu G, Fung KM, Zhao L *et al.* Atrial fibrillation begets atrial fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. *Circ Arrhythm Electrophysiol* 2008;**1**:184–92.
498. Jais P, Hocini M, Macle L, Choi KJ, Deisenhofer I, Weerasooriya R *et al.* Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation. *Circulation* 2002;**106**:2479–85.
499. Hof IE, Velthuis BK, Chaldoupi SM, Wittkamp FH, van Driel VJ, van der Heijden JF *et al.* Pulmonary vein antrum isolation leads to a significant decrease of left atrial size. *Europace* 2011;**13**:371–5.
500. Pump A, Di Biase L, Price J, Mohanty P, Bai R, Santangeli P *et al.* Efficacy of catheter ablation in nonparoxysmal atrial fibrillation patients with severe enlarged left atrium and its impact on left atrial structural remodeling. *J Cardiovasc Electrophysiol* 2013;**24**:1224–31.
501. Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL *et al.* Early management of atrial fibrillation to prevent cardiovascular complications. *Eur Heart J* 2014;**35**:1448–56.
502. Aliot E, Brandes A, Eckardt L, Elvan A, Gulizia M, Heidbuchel H *et al.* The EAST study: redefining the role of rhythm control therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. *Eur Heart J* 2015;**36**:255–6.
503. Bukowska A, Lendeckel U, Hirte D, Wolke C, Striggow F, Rohnert P *et al.* Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. *Cell Mol Life Sci* 2006;**63**:333–42.
504. Goette A, Lendeckel U, Kuchenbecker A, Bukowska A, Peters B, Klein HU *et al.* Cigarette smoking induces atrial fibrosis in humans via nicotine. *Heart* 2007;**93**:1056–63.
505. Gramley F, Lorenzen J, Knackstedt C, Rana OR, Saygili E, Frechen D *et al.* Age-related atrial fibrosis. *Age* 2009;**31**:27–38.
506. Goette A, Juenemann G, Peters B, Klein HU, Roessner A, Huth C *et al.* Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. *Cardiovasc Res* 2002;**54**:390–6.
507. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. *Stroke* 1990;**21**:47–51.
508. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. *J Am Coll Cardiol* 1990;**16**:377–80.

509. Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotani C *et al*. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. *Blood Coagul Fibrinolysis* 1992;**3**:469–73.
510. Sahara H, Miyahara K. Effect of atrial fibrillation on the fibrino-coagulation system—study in patients with paroxysmal atrial fibrillation. *Jpn Circ J* 1994;**58**: 821–6.
511. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. *Br Heart J* 1995;**73**:527–33.
512. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD *et al*. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. *Circulation* 1996;**94**:425–31.
513. Kahn SR, Solymoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. *CMAJ* 1997;**157**:673–81.
514. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. *Heart* 1997;**77**:407–11.
515. Shinohara H, Fukuda N, Soeki T, Takeichi N, Yui Y, Tamura Y *et al*. Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation. *Jpn Heart J* 1998;**39**:721–30.
516. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY *et al*. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. *Stroke* 1999;**30**:2547–53.
517. Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R *et al*. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. *Int J Cardiol* 2000;**75**:227–32.
518. Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K *et al*. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. *J Am Coll Cardiol* 2001;**37**:1436–42.
519. Kamath S, Blann AD, Chin BS, Lanza F, Aleil B, Cazenave JP *et al*. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. *Eur Heart J* 2002;**23**:1788–95.
520. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. *Thromb Haemost* 2003;**90**:1163–72.
521. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T *et al*. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. *Thromb Res* 2003;**111**:137–42.
522. Kamath S, Blann AD, Chin BS, Lip GY. Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. *Heart* 2003;**89**:1093–5.
523. Sakurai K, Hirai T, Nakagawa K, Kameyama T, Nozawa T, Asanoi H *et al*. Prolonged activation of hemostatic markers following conversion of atrial flutter to sinus rhythm. *Circ J* 2004;**68**:1041–4.
524. Inoue H, Nozawa T, Okumura K, Jong-Dae L, Shimizu A, Yano K. Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism. *Chest* 2004;**126**:687–92.
525. Kumagai K, Fukuchi M, Ohta J, Baba S, Oda K, Akimoto H *et al*. Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling. *Circ J* 2004;**68**:321–7.
526. Marin F, Roldan V, Climent VE, Ibanez A, Garcia A, Marco P *et al*. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. *Heart* 2004;**90**:1162–6.
527. Nozawa T, Inoue H, Iwasa A, Okumura K, Jong-dae L, Shimizu A *et al*. Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. *Circ J* 2004;**68**:29–34.
528. Freestone B, Chong AY, Lim HS, Blann A, Lip GY. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? *Ann Med* 2005;**37**:365–72.